[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fmQQDZbk6fRJi-4d-FNao6uSYxQ-sOL4acNOm01gnA7o":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"University College, London",[4],633,false,152,56,33177880,84,438,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Stroke",25,{"name":18,"count":19},"Prostate Cancer",23,{"name":21,"count":22},"Heart Failure",18,{"name":24,"count":25},"Dementia",16,{"name":27,"count":28},"Lymphoma",14,{"name":30,"count":31},"Lung Cancer",12,{"name":33,"count":34},"Obesity",10,{"name":36,"count":34},"Peripheral Arterial Disease",[38,43,48,53,57,62,67,72,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02315716","Carfilzomib\u002FCyclophosphamide\u002FDexamethasone with Maintenance Carfilzomib in Multiple Myeloma","2019-11","Consolidation with 4 cycles of CarCyDex",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03061539","Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature","2022-06-20","Nivolumab & Ipilimumab",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03385226","A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)\u002FSezary Syndrome (SS)","2023-09-01","Pembrolizumab",{"nctId":54,"briefTitle":55,"date":56,"intervention":52},"NCT03813836","Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC","2024-01-10",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT03288532","Renal Adjuvant MultiPle Arm Randomised Trial","2024-07-01","Durvalumab",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT02935257","Immunotherapy for High Risk\u002FRelapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)\u002F Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19","2024-08-15","CD19CAT-41BBZ CAR T-cells",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT05391490","Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies","2024-11","KCAT19 T cells",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04443829","Immunotherapy Using CAR T-cells to Target CD19 for Relapsed\u002FRefractory CD19+ Primary CNS Lymphoma","2024-12","CD19CAR T-cells",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT05073835","Semaglutide 2.4 mg in Patients With Poor Weight-loss","2025-03","Semaglutide 3 mg",{"nctId":83,"briefTitle":84,"date":85,"intervention":61},"NCT04106115","DURvalumab in Combination With S-488210\u002FS-488211 vAccine in Non-muscle Invasive Bladder CancEr","2025-05-31",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,173,237,263,289,315,365,398,488,525,556,608,634,652,670,688,706,735,753,771,789,807,825,843,870,888,911,937,963,981,1079,1205,1235,1257,1279,1317,1343,1371,1389,1407,1425,1450,1473,1494,1517,1540,1558,1576,1594,1612,1630,1648,1676,1704,1722,1740,1758,1782,1804,1829,1847,1865,1883,1901,1919,1937,1964,1982,2016,2050,2077,2095,2113,2134,2161,2184,2205,2232,2257,2275,2296,2320,2346,2364,2393,2418,2443,2470,2494,2520,2538,2567,2585,2610,2634,2652,2697,2732,2762,2792,2823,2867,2889,2911,2939,2961,2988,3015,3033,3058,3076,3105,3123,3141,3159,3185,3203,3228,3246,3271,3289,3315,3339,3367,3385,3410,3428,3446,3464,3487,3510,3534,3561,3579,3604,3622,3647,3665,3683,3711,3729,3747,3765,3783,3808,3826,3844,3862,3880,3917,3948,3976,4011,4041,4071,4107,4136,4164,4190,4214,4232,4250,4268,4293,4311,4334,4352,4374,4392,4418,4436,4454,4472,4490,4508,4526,4549,4567,4585,4611,4635,4653,4678,4703,4727,4752,4770,4793,4820,4843,4869,4887,4905,4923,4941,4959,4977,4995,5019,5042,5066,5090,5115,5139,5164,5189,5213,5241,5268,5286,5304,5322,5346,5371,5395,5419,5446,5464,5482,5508,5526,5544,5562,5586,5610,5628,5657,5675,5699,5721,5747,5770,5788,5806,5831,5854,5882,5904,5927,5951,5969,5994,6021,6043,6061,6079,6102,6127,6154,6172,6223,6253,6283,6309,6331,6356,6380,6412,6430,6453,6477,6501,6525,6551,6578,6601,6627,6645,6663,6681,6699,6717,6735,6753,6771,6798,6824,6852,6881,6905],{"intervention":95,"totalTrials":96,"cells":97},"Carboplatin",4,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":138,"PHASE4":169,"NA":171},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":137,"soonestReadout":110},[105,123],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":122},"NCT05080556","Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer","RECRUITING",[89],"2026-11-01","2027-11-01","2023-05-24",80,[115,116,117,118,119,120,121],"Ovarian Cancer","Relapsed Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Cancer","Endometrioid Carcinoma","High Grade Serous Carcinoma","Ovary Cancer",[95],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":133},"NCT02722369","STUDY 15 - Comparing Gemcitabine\u002FCarboplatin and Hydroxychloroquine Versus Carboplatin\u002FEtoposide Therapy Alone in Small Cell Lung Cancer (SCLC)","TERMINATED",[89],"2021-03-12","2017-03-14",72,[132],"Small Cell Lung Cancer",[134,95,135,136],"Gemcitabine","Etoposide","Hydroxychloroquine",1,{"trials":139,"activeCount":137,"soonestReadout":145},[140,154],{"nctId":141,"briefTitle":142,"status":143,"phases":144,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":151},"NCT01566240","Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer","ACTIVE_NOT_RECRUITING",[90],"2026-02","2026-12","2012-11-08",500,[150],"Cervical Cancer",[152,95,153],"Paclitaxel","Cisplatin",{"nctId":155,"briefTitle":156,"status":157,"phases":158,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":164},"NCT00433498","Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer","COMPLETED",[90],"2012-01","2013-11","2007-01",846,[30],[165,166,167,168],"carboplatin","cisplatin","etoposide phosphate","pravastatin sodium",{"trials":170,"activeCount":100},[],{"trials":172,"activeCount":100},[],{"intervention":174,"totalTrials":175,"cells":176},"Isoniazid",3,{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":206,"PHASE4":233,"NA":235},{"trials":178,"activeCount":100},[],{"trials":180,"activeCount":100},[],{"trials":182,"activeCount":137,"soonestReadout":187},[183],{"nctId":184,"briefTitle":185,"status":108,"phases":186,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NCT06114628","Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB",[89],"2027-02-24","2027-08-11","2024-01-09",2500,[192],"Pulmonary Tuberculosis",[194,195,196,197,198,199,200,201,202,174,203,204,205],"Ganfeborole","BTZ-043","Bedaquiline","Delamanid","Pretomanid","Moxifloxacin","Linezolid","Pyrazinamide","Rifampicin","Ethambutol","Delpazolid","Quabodepistat",{"trials":207,"activeCount":137,"soonestReadout":213},[208,220],{"nctId":209,"briefTitle":210,"status":211,"phases":212,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":219},"NCT07163143","Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)","NOT_YET_RECRUITING",[90],"2028-11","2029-04","2025-11",784,[218],"Tuberculosis (TB)",[174,202,201,203],{"nctId":221,"briefTitle":222,"status":157,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":229},"NCT03474198","Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis",[89,90],"2022-01-20","2018-03-21",675,[228],"Tuberculosis, Pulmonary",[202,174,201,203,200,230,231,232,196,202],"Clofazimine","Rifapentine","Levofloxacin",{"trials":234,"activeCount":100},[],{"trials":236,"activeCount":100},[],{"intervention":202,"totalTrials":175,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":249,"PHASE4":259,"NA":261},{"trials":240,"activeCount":100},[],{"trials":242,"activeCount":100},[],{"trials":244,"activeCount":137,"soonestReadout":187},[245],{"nctId":184,"briefTitle":185,"status":108,"phases":246,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":247,"interventions":248},[89],[192],[194,195,196,197,198,199,200,201,202,174,203,204,205],{"trials":250,"activeCount":137,"soonestReadout":213},[251,255],{"nctId":209,"briefTitle":210,"status":211,"phases":252,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":253,"interventions":254},[90],[218],[174,202,201,203],{"nctId":221,"briefTitle":222,"status":157,"phases":256,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":257,"interventions":258},[89,90],[228],[202,174,201,203,200,230,231,232,196,202],{"trials":260,"activeCount":100},[],{"trials":262,"activeCount":100},[],{"intervention":201,"totalTrials":175,"cells":264},{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":275,"PHASE4":285,"NA":287},{"trials":266,"activeCount":100},[],{"trials":268,"activeCount":100},[],{"trials":270,"activeCount":137,"soonestReadout":187},[271],{"nctId":184,"briefTitle":185,"status":108,"phases":272,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":273,"interventions":274},[89],[192],[194,195,196,197,198,199,200,201,202,174,203,204,205],{"trials":276,"activeCount":137,"soonestReadout":213},[277,281],{"nctId":209,"briefTitle":210,"status":211,"phases":278,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":279,"interventions":280},[90],[218],[174,202,201,203],{"nctId":221,"briefTitle":222,"status":157,"phases":282,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":283,"interventions":284},[89,90],[228],[202,174,201,203,200,230,231,232,196,202],{"trials":286,"activeCount":100},[],{"trials":288,"activeCount":100},[],{"intervention":203,"totalTrials":175,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":301,"PHASE4":311,"NA":313},{"trials":292,"activeCount":100},[],{"trials":294,"activeCount":100},[],{"trials":296,"activeCount":137,"soonestReadout":187},[297],{"nctId":184,"briefTitle":185,"status":108,"phases":298,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":299,"interventions":300},[89],[192],[194,195,196,197,198,199,200,201,202,174,203,204,205],{"trials":302,"activeCount":137,"soonestReadout":213},[303,307],{"nctId":209,"briefTitle":210,"status":211,"phases":304,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":305,"interventions":306},[90],[218],[174,202,201,203],{"nctId":221,"briefTitle":222,"status":157,"phases":308,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":309,"interventions":310},[89,90],[228],[202,174,201,203,200,230,231,232,196,202],{"trials":312,"activeCount":100},[],{"trials":314,"activeCount":100},[],{"intervention":316,"totalTrials":175,"cells":317},"Dexamethasone",{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":348,"PHASE4":361,"NA":363},{"trials":319,"activeCount":100},[],{"trials":321,"activeCount":100},[],{"trials":323,"activeCount":137,"soonestReadout":328},[324,336],{"nctId":325,"briefTitle":326,"status":108,"phases":327,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":333},"NCT06762769","Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma",[89],"2032-11","2025-06-02",63,[332],"Smouldering Myeloma",[334,335,316],"Isatuximab","Iberdomide",{"nctId":337,"briefTitle":338,"status":157,"phases":339,"primaryCompletion":340,"completion":341,"start":342,"enrollment":34,"conditions":343,"interventions":345},"NCT02545907","A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis",[88,89],"2019-09-26","2019-10-21","2017-09-14",[344],"Amyloidosis",[346,347,316],"Carfilzomib","Thalidomide",{"trials":349,"activeCount":137,"soonestReadout":354},[350],{"nctId":351,"briefTitle":352,"status":143,"phases":353,"primaryCompletion":354,"completion":146,"start":355,"enrollment":356,"conditions":357,"interventions":359},"NCT02544308","Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma",[90],"2026-04","2017-03-10",36,[358],"Plasmacytoma",[360,316],"Lenalidomide",{"trials":362,"activeCount":100},[],{"trials":364,"activeCount":100},[],{"intervention":61,"totalTrials":366,"cells":367},2,{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":383,"PHASE4":394,"NA":396},{"trials":369,"activeCount":100},[],{"trials":371,"activeCount":100},[],{"trials":373,"activeCount":137,"soonestReadout":85},[374],{"nctId":83,"briefTitle":84,"status":108,"phases":375,"primaryCompletion":85,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":381},[88,89],"2029-05-31","2022-03-25",64,[380],"Bladder Cancer",[61,382],"S-488210\u002FS-488211",{"trials":384,"activeCount":137,"soonestReadout":60},[385],{"nctId":58,"briefTitle":59,"status":108,"phases":386,"primaryCompletion":60,"completion":387,"start":388,"enrollment":389,"conditions":390,"interventions":392},[90],"2034-12-01","2018-07-19",1750,[391],"Renal Cell Carcinoma",[61,393],"Tremelimumab",{"trials":395,"activeCount":100},[],{"trials":397,"activeCount":100},[],{"intervention":166,"totalTrials":399,"cells":400},8,{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":440,"PHASE3":451,"PHASE4":484,"NA":486},{"trials":402,"activeCount":100},[],{"trials":404,"activeCount":100},[405,416,431],{"nctId":406,"briefTitle":407,"status":157,"phases":408,"primaryCompletion":409,"completion":410,"start":411,"enrollment":25,"conditions":412,"interventions":414},"NCT02308072","Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer",[88],"2020-06","2026-04-24","2015-09",[413],"Head and Neck Cancer",[415,153],"Olaparib",{"nctId":417,"briefTitle":418,"status":157,"phases":419,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":428},"NCT01242605","ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer",[88],"2013-03","2016-05","2012-02",13,[425,426,427],"Biliary Tract Neoplasms","Cholangiocarcinoma","Gallbladder Neoplasms",[429,430,166],"selumetinib","gemcitabine",{"nctId":432,"briefTitle":433,"status":434,"phases":435,"enrollment":100,"conditions":436,"interventions":438},"NCT01491139","Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck","WITHDRAWN",[88],[437],"Carcinoma, Squamous Cell",[439,166],"olaparib",{"trials":441,"activeCount":100},[442],{"nctId":443,"briefTitle":444,"status":434,"phases":445,"enrollment":100,"conditions":446,"interventions":448},"NCT01353482","A Phase I\u002FII Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma",[88,89],[447],"Malignant Pleural Mesothelioma",[153,449,450],"Pemetrexed","Vorinostat",{"trials":452,"activeCount":137,"soonestReadout":145},[453,465,469,480],{"nctId":454,"briefTitle":455,"status":157,"phases":456,"primaryCompletion":457,"start":458,"enrollment":459,"conditions":460,"interventions":463},"NCT00262769","Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors",[90],"2008-08","2005-05",324,[461,462],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer",[166,464],"gemcitabine hydrochloride",{"nctId":141,"briefTitle":142,"status":143,"phases":466,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":467,"interventions":468},[90],[150],[152,95,153],{"nctId":470,"briefTitle":471,"status":157,"phases":472,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":478},"NCT00939848","Cediranib Versus Placebo Plus Cisplatin\u002FGemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers",[89,90],"2012-09","2014-09","2011-04",124,[425],[430,166,166,479,430],"cediranib",{"nctId":155,"briefTitle":156,"status":157,"phases":481,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":482,"interventions":483},[90],[30],[165,166,167,168],{"trials":485,"activeCount":100},[],{"trials":487,"activeCount":100},[],{"intervention":489,"totalTrials":366,"cells":490},"Docetaxel",{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":506,"PHASE4":521,"NA":523},{"trials":492,"activeCount":100},[],{"trials":494,"activeCount":100},[],{"trials":496,"activeCount":100},[497],{"nctId":498,"briefTitle":499,"status":126,"phases":500,"primaryCompletion":475,"completion":475,"start":501,"enrollment":96,"conditions":502,"interventions":503},"NCT01313390","Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer",[88,89],"2009-06",[413],[504,505],"docetaxel","everolimus",{"trials":507,"activeCount":137,"soonestReadout":512},[508],{"nctId":509,"briefTitle":510,"status":108,"phases":511,"primaryCompletion":512,"completion":513,"start":514,"enrollment":515,"conditions":516,"interventions":518},"NCT06320067","A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer",[90],"2031-04","2032-03","2024-06-11",3360,[517],"Prostate Cancer Metastatic",[519,520,489],"Androgen Deprivation Therapy","Androgen Receptor Signalling Inhibitor",{"trials":522,"activeCount":100},[],{"trials":524,"activeCount":100},[],{"intervention":152,"totalTrials":366,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":552,"NA":554},{"trials":528,"activeCount":100},[],{"trials":530,"activeCount":100},[],{"trials":532,"activeCount":100},[],{"trials":534,"activeCount":137,"soonestReadout":145},[535,548],{"nctId":536,"briefTitle":537,"status":157,"phases":538,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":545},"NCT01196741","Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer",[89,90],"2012-11","2014-01","2011-03",107,[115,117,544],"Primary Peritoneal Cancer",[152,546,547],"Saracatinib","Matched placebo",{"nctId":141,"briefTitle":142,"status":143,"phases":549,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":550,"interventions":551},[90],[150],[152,95,153],{"trials":553,"activeCount":100},[],{"trials":555,"activeCount":100},[],{"intervention":557,"totalTrials":366,"cells":558},"Dacarbazine",{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":565,"PHASE4":604,"NA":606},{"trials":560,"activeCount":100},[],{"trials":562,"activeCount":100},[],{"trials":564,"activeCount":100},[],{"trials":566,"activeCount":137,"soonestReadout":571},[567,583],{"nctId":568,"briefTitle":569,"status":108,"phases":570,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":577},"NCT04685616","Brentuximab Vedotin in Early Stage Hodgkin Lymphoma",[90],"2030-09","2032-09","2022-04-14",1042,[576],"Hodgkin Lymphoma",[578,579,580,581,557,582],"Doxorubicin","Bleomycin","Brentuximab vedotin","Vinblastine","Haematopoietic growth factor",{"nctId":584,"briefTitle":585,"status":157,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":592},"NCT00678327","Fludeoxyglucose F 18-PET\u002FCT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma",[90],"2016-01-31","2024-05-01","2008-08-29",1202,[27],[593,594,595,596,597,598,599,600,601,602,603],"bleomycin sulfate","filgrastim","pegfilgrastim","cyclophosphamide","dacarbazine","doxorubicin hydrochloride","etoposide","prednisolone","procarbazine hydrochloride","vinblastine sulfate","vincristine sulfate",{"trials":605,"activeCount":100},[],{"trials":607,"activeCount":100},[],{"intervention":609,"totalTrials":137,"cells":610},"Ambroxol Hydrochloride",{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":617,"PHASE4":630,"NA":632},{"trials":612,"activeCount":100},[],{"trials":614,"activeCount":100},[],{"trials":616,"activeCount":100},[],{"trials":618,"activeCount":137,"soonestReadout":623},[619],{"nctId":620,"briefTitle":621,"status":108,"phases":622,"primaryCompletion":623,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":629},"NCT05778617","Ambroxol to Slow Progression in Parkinson Disease",[90],"2029-02","2029-09","2025-02-25",330,[628],"Parkinson Disease",[609],{"trials":631,"activeCount":100},[],{"trials":633,"activeCount":100},[],{"intervention":393,"totalTrials":137,"cells":635},{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":642,"PHASE4":648,"NA":650},{"trials":637,"activeCount":100},[],{"trials":639,"activeCount":100},[],{"trials":641,"activeCount":100},[],{"trials":643,"activeCount":137,"soonestReadout":60},[644],{"nctId":58,"briefTitle":59,"status":108,"phases":645,"primaryCompletion":60,"completion":387,"start":388,"enrollment":389,"conditions":646,"interventions":647},[90],[391],[61,393],{"trials":649,"activeCount":100},[],{"trials":651,"activeCount":100},[],{"intervention":519,"totalTrials":137,"cells":653},{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":660,"PHASE4":666,"NA":668},{"trials":655,"activeCount":100},[],{"trials":657,"activeCount":100},[],{"trials":659,"activeCount":100},[],{"trials":661,"activeCount":137,"soonestReadout":512},[662],{"nctId":509,"briefTitle":510,"status":108,"phases":663,"primaryCompletion":512,"completion":513,"start":514,"enrollment":515,"conditions":664,"interventions":665},[90],[517],[519,520,489],{"trials":667,"activeCount":100},[],{"trials":669,"activeCount":100},[],{"intervention":520,"totalTrials":137,"cells":671},{"EARLY_PHASE1":672,"PHASE1":674,"PHASE2":676,"PHASE3":678,"PHASE4":684,"NA":686},{"trials":673,"activeCount":100},[],{"trials":675,"activeCount":100},[],{"trials":677,"activeCount":100},[],{"trials":679,"activeCount":137,"soonestReadout":512},[680],{"nctId":509,"briefTitle":510,"status":108,"phases":681,"primaryCompletion":512,"completion":513,"start":514,"enrollment":515,"conditions":682,"interventions":683},[90],[517],[519,520,489],{"trials":685,"activeCount":100},[],{"trials":687,"activeCount":100},[],{"intervention":360,"totalTrials":137,"cells":689},{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":696,"PHASE4":702,"NA":704},{"trials":691,"activeCount":100},[],{"trials":693,"activeCount":100},[],{"trials":695,"activeCount":100},[],{"trials":697,"activeCount":137,"soonestReadout":354},[698],{"nctId":351,"briefTitle":352,"status":143,"phases":699,"primaryCompletion":354,"completion":146,"start":355,"enrollment":356,"conditions":700,"interventions":701},[90],[358],[360,316],{"trials":703,"activeCount":100},[],{"trials":705,"activeCount":100},[],{"intervention":707,"totalTrials":137,"cells":708},"Aspirin 100mg",{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":715,"PHASE4":731,"NA":733},{"trials":710,"activeCount":100},[],{"trials":712,"activeCount":100},[],{"trials":714,"activeCount":100},[],{"trials":716,"activeCount":137,"soonestReadout":721},[717],{"nctId":718,"briefTitle":719,"status":143,"phases":720,"primaryCompletion":721,"completion":721,"start":722,"enrollment":723,"conditions":724,"interventions":729},"NCT02804815","Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours",[90],"2026-10","2015-10",11000,[725,726,18,727,728],"Cancer","Breast Cancer","Colorectal Cancer","Gastro-oesophageal Cancer",[707,730],"Aspirin 300mg",{"trials":732,"activeCount":100},[],{"trials":734,"activeCount":100},[],{"intervention":730,"totalTrials":137,"cells":736},{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":749,"NA":751},{"trials":738,"activeCount":100},[],{"trials":740,"activeCount":100},[],{"trials":742,"activeCount":100},[],{"trials":744,"activeCount":137,"soonestReadout":721},[745],{"nctId":718,"briefTitle":719,"status":143,"phases":746,"primaryCompletion":721,"completion":721,"start":722,"enrollment":723,"conditions":747,"interventions":748},[90],[725,726,18,727,728],[707,730],{"trials":750,"activeCount":100},[],{"trials":752,"activeCount":100},[],{"intervention":578,"totalTrials":137,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":761,"PHASE4":767,"NA":769},{"trials":756,"activeCount":100},[],{"trials":758,"activeCount":100},[],{"trials":760,"activeCount":100},[],{"trials":762,"activeCount":137,"soonestReadout":571},[763],{"nctId":568,"briefTitle":569,"status":108,"phases":764,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":765,"interventions":766},[90],[576],[578,579,580,581,557,582],{"trials":768,"activeCount":100},[],{"trials":770,"activeCount":100},[],{"intervention":579,"totalTrials":137,"cells":772},{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":779,"PHASE4":785,"NA":787},{"trials":774,"activeCount":100},[],{"trials":776,"activeCount":100},[],{"trials":778,"activeCount":100},[],{"trials":780,"activeCount":137,"soonestReadout":571},[781],{"nctId":568,"briefTitle":569,"status":108,"phases":782,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":783,"interventions":784},[90],[576],[578,579,580,581,557,582],{"trials":786,"activeCount":100},[],{"trials":788,"activeCount":100},[],{"intervention":580,"totalTrials":137,"cells":790},{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":795,"PHASE3":797,"PHASE4":803,"NA":805},{"trials":792,"activeCount":100},[],{"trials":794,"activeCount":100},[],{"trials":796,"activeCount":100},[],{"trials":798,"activeCount":137,"soonestReadout":571},[799],{"nctId":568,"briefTitle":569,"status":108,"phases":800,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":801,"interventions":802},[90],[576],[578,579,580,581,557,582],{"trials":804,"activeCount":100},[],{"trials":806,"activeCount":100},[],{"intervention":581,"totalTrials":137,"cells":808},{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":815,"PHASE4":821,"NA":823},{"trials":810,"activeCount":100},[],{"trials":812,"activeCount":100},[],{"trials":814,"activeCount":100},[],{"trials":816,"activeCount":137,"soonestReadout":571},[817],{"nctId":568,"briefTitle":569,"status":108,"phases":818,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":819,"interventions":820},[90],[576],[578,579,580,581,557,582],{"trials":822,"activeCount":100},[],{"trials":824,"activeCount":100},[],{"intervention":582,"totalTrials":137,"cells":826},{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":833,"PHASE4":839,"NA":841},{"trials":828,"activeCount":100},[],{"trials":830,"activeCount":100},[],{"trials":832,"activeCount":100},[],{"trials":834,"activeCount":137,"soonestReadout":571},[835],{"nctId":568,"briefTitle":569,"status":108,"phases":836,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":837,"interventions":838},[90],[576],[578,579,580,581,557,582],{"trials":840,"activeCount":100},[],{"trials":842,"activeCount":100},[],{"intervention":844,"totalTrials":137,"cells":845},"Telmisartan",{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":866,"NA":868},{"trials":847,"activeCount":100},[],{"trials":849,"activeCount":100},[],{"trials":851,"activeCount":100},[],{"trials":853,"activeCount":137,"soonestReadout":858},[854],{"nctId":855,"briefTitle":856,"status":108,"phases":857,"primaryCompletion":858,"completion":859,"start":860,"enrollment":861,"conditions":862,"interventions":864},"NCT07207057","Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial",[90],"2031-05","2031-07-31","2025-09-12",1200,[863],"Parkinsons Disease (PD)",[844,865],"Terazosin",{"trials":867,"activeCount":100},[],{"trials":869,"activeCount":100},[],{"intervention":865,"totalTrials":137,"cells":871},{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":884,"NA":886},{"trials":873,"activeCount":100},[],{"trials":875,"activeCount":100},[],{"trials":877,"activeCount":100},[],{"trials":879,"activeCount":137,"soonestReadout":858},[880],{"nctId":855,"briefTitle":856,"status":108,"phases":881,"primaryCompletion":858,"completion":859,"start":860,"enrollment":861,"conditions":882,"interventions":883},[90],[863],[844,865],{"trials":885,"activeCount":100},[],{"trials":887,"activeCount":100},[],{"intervention":81,"totalTrials":137,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":907,"NA":909},{"trials":891,"activeCount":100},[],{"trials":893,"activeCount":100},[],{"trials":895,"activeCount":100},[],{"trials":897,"activeCount":137,"soonestReadout":80},[898],{"nctId":78,"briefTitle":79,"status":143,"phases":899,"primaryCompletion":80,"completion":900,"start":901,"enrollment":902,"conditions":903,"interventions":906},[90],"2025-09","2022-11-01",70,[33,904,905],"Diabetes","Metabolic Syndrome",[81],{"trials":908,"activeCount":100},[],{"trials":910,"activeCount":100},[],{"intervention":912,"totalTrials":137,"cells":913},"Nicotinomide",{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":920,"PHASE4":933,"NA":935},{"trials":915,"activeCount":100},[],{"trials":917,"activeCount":100},[],{"trials":919,"activeCount":100},[],{"trials":921,"activeCount":137,"soonestReadout":926},[922],{"nctId":923,"briefTitle":924,"status":108,"phases":925,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":932},"NCT05405868","Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial",[90],"2027-04-30","2027-06-30","2024-01-18",496,[931],"Glaucoma, Open-Angle",[912],{"trials":934,"activeCount":100},[],{"trials":936,"activeCount":100},[],{"intervention":938,"totalTrials":137,"cells":939},"Dexamethasone, cyclophosphamide, rituximab",{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":946,"PHASE4":959,"NA":961},{"trials":941,"activeCount":100},[],{"trials":943,"activeCount":100},[],{"trials":945,"activeCount":100},[],{"trials":947,"activeCount":137,"soonestReadout":952},[948],{"nctId":949,"briefTitle":950,"status":108,"phases":951,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":955,"interventions":957},"NCT04061512","Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia",[89,90],"2030-03","2020-02-03",148,[956],"Waldenstrom Macroglobulinemia",[938,958],"Rituximab, ibrutinib",{"trials":960,"activeCount":100},[],{"trials":962,"activeCount":100},[],{"intervention":958,"totalTrials":137,"cells":964},{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":969,"PHASE3":971,"PHASE4":977,"NA":979},{"trials":966,"activeCount":100},[],{"trials":968,"activeCount":100},[],{"trials":970,"activeCount":100},[],{"trials":972,"activeCount":137,"soonestReadout":952},[973],{"nctId":949,"briefTitle":950,"status":108,"phases":974,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":975,"interventions":976},[89,90],[956],[938,958],{"trials":978,"activeCount":100},[],{"trials":980,"activeCount":100},[],{"intervention":52,"totalTrials":399,"cells":982},{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":1073,"PHASE4":1075,"NA":1077},{"trials":984,"activeCount":100},[],{"trials":986,"activeCount":100},[],{"trials":988,"activeCount":96,"soonestReadout":51},[989,998,1006,1018,1029,1037,1050,1062],{"nctId":990,"briefTitle":991,"status":157,"phases":992,"primaryCompletion":993,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":997},"NCT03430700","Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer",[89],"2025-12-03","2019-05-16",20,[115,117,118],[52],{"nctId":54,"briefTitle":55,"status":143,"phases":999,"primaryCompletion":56,"completion":1000,"start":1001,"enrollment":330,"conditions":1002,"interventions":1005},[89],"2026-01-31","2019-07-05",[1003,1004],"Metastatic Head and Neck Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma",[52],{"nctId":1007,"briefTitle":1008,"status":1009,"phases":1010,"primaryCompletion":1011,"completion":1011,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1016},"NCT04913025","REduced Frequency ImmuNE Checkpoint Inhibition in Cancers","UNKNOWN",[89],"2025-04","2022-05-26",160,[391,1015],"Melanoma",[1017,52],"Nivolumab",{"nctId":1019,"briefTitle":1020,"status":157,"phases":1021,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":1025,"conditions":1026,"interventions":1027},"NCT03630042","Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed\u002FRefractory Waldenström's Macroglobulinaemia",[89],"2021-09-21","2024-02-14","2019-09-06",17,[956],[52,1028],"Rituximab",{"nctId":49,"briefTitle":50,"status":143,"phases":1030,"primaryCompletion":51,"completion":900,"start":1031,"enrollment":1032,"conditions":1033,"interventions":1036},[89],"2019-01-15",46,[1034,1035],"Cutaneous T Cell Lymphoma","Mycosis Fungoides\u002FSezary Syndrome",[52],{"nctId":1038,"briefTitle":1039,"status":108,"phases":1040,"primaryCompletion":1041,"completion":1042,"start":1043,"enrollment":1044,"conditions":1045,"interventions":1047},"NCT05185739","Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)",[89],"2028-07","2030-07","2022-08-25",60,[1046],"Hepatocellular Carcinoma",[52,1048,1049],"Lenvatinib","Pembrolizumab and Lenvatinib",{"nctId":1051,"briefTitle":1052,"status":1009,"phases":1053,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1061},"NCT03425565","A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer",[89],"2024-09","2019-02-18",48,[1058,1059,1060],"Clear Cell Tumor","Gynecologic Cancer","Advanced Cancer",[52],{"nctId":1063,"briefTitle":1064,"status":108,"phases":1065,"primaryCompletion":1066,"completion":1067,"start":1068,"enrollment":1069,"conditions":1070,"interventions":1072},"NCT05197322","NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer",[89],"2026-07-31","2029-07-31","2022-07-20",88,[1071],"Adenocarcinoma of the Colon",[52,52],{"trials":1074,"activeCount":100},[],{"trials":1076,"activeCount":100},[],{"trials":1078,"activeCount":100},[],{"intervention":1028,"totalTrials":34,"cells":1080},{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1158,"PHASE4":1180,"NA":1182},{"trials":1082,"activeCount":100},[],{"trials":1084,"activeCount":100},[],{"trials":1086,"activeCount":366,"soonestReadout":1133},[1087,1091,1106,1118,1129,1139,1149],{"nctId":1019,"briefTitle":1020,"status":157,"phases":1088,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":1025,"conditions":1089,"interventions":1090},[89],[956],[52,1028],{"nctId":1092,"briefTitle":1093,"status":157,"phases":1094,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":1098,"conditions":1099,"interventions":1101},"NCT01679119","Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy",[89],"2019-03","2022-03","2013-10",129,[1100],"Diffuse Large B Cell Lymphoma",[1102,1103,1104,1028,1105,134],"Cyclophosphamide","Vincristine","Prednisolone","Inotuzumab Ozogamicin",{"nctId":1107,"briefTitle":1108,"status":157,"phases":1109,"primaryCompletion":1110,"completion":1111,"start":1112,"enrollment":1044,"conditions":1113,"interventions":1115},"NCT01592981","Randomised Trial in Waldenstrom's Macroglobulinaemia",[89],"2017-03","2020-08-02","2013-01",[1114],"Waldenstrom's Macroglobulinaemia",[1116,1102,1028,1117],"Bortezomib","Fludarabine",{"nctId":1119,"briefTitle":1120,"status":108,"phases":1121,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":1125,"interventions":1127},"NCT05635162","Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma",[89],"2028-10","2024-05-17",50,[1126],"Mantle Cell Lymphoma",[1128,1028],"Zanubrutinib",{"nctId":1130,"briefTitle":1131,"status":108,"phases":1132,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":1056,"conditions":1136,"interventions":1137},"NCT05004064","Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma",[89],"2026-11-30","2028-12-01","2023-11-30",[1126],[1138,1028],"Acalabrutinib",{"nctId":1140,"briefTitle":1141,"status":157,"phases":1142,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":1145,"conditions":1146,"interventions":1147},"NCT00971763","Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma",[89],"2011-07","2006-03",62,[27],[1148,596,464,600,603],"rituximab",{"nctId":1150,"briefTitle":1151,"status":157,"phases":1152,"primaryCompletion":1153,"completion":1153,"start":1144,"enrollment":1154,"conditions":1155,"interventions":1157},"NCT00937131","The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)",[89],"2010-06",40,[1156],"Thrombotic Thrombocytopenic Purpura (TTP)",[1028],{"trials":1159,"activeCount":100},[1160,1170],{"nctId":1161,"briefTitle":1162,"status":157,"phases":1163,"primaryCompletion":1164,"completion":1165,"start":1166,"enrollment":1167,"conditions":1168,"interventions":1169},"NCT00641095","Phase III, Multicentre, Randomised Study of Fludarabine\u002FCyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma",[89,90],"2011-11-23","2015-05-22","2006-12-07",370,[27],[1148,1102,1117],{"nctId":1171,"briefTitle":1172,"status":157,"phases":1173,"primaryCompletion":1174,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1179},"NCT00112931","Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma",[90],"2014-03","2023-09-14","2004-09",462,[27],[1148],{"trials":1181,"activeCount":100},[],{"trials":1183,"activeCount":100},[1184],{"nctId":1185,"briefTitle":1186,"status":157,"phases":1187,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":1190,"interventions":1194},"NCT01085617","Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia",[],"2025-02-24","2010-12",[1191,1192,1193],"Leukemia","Mucositis","Oral Complications",[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],"palifermin","cytarabine","daunorubicin hydrochloride","fludarabine phosphate","imatinib mesylate","melphalan","mercaptopurine","methotrexate","nelarabine","pegaspargase",{"intervention":199,"totalTrials":366,"cells":1206},{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1217,"PHASE4":1231,"NA":1233},{"trials":1208,"activeCount":100},[],{"trials":1210,"activeCount":100},[],{"trials":1212,"activeCount":137,"soonestReadout":187},[1213],{"nctId":184,"briefTitle":185,"status":108,"phases":1214,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":1215,"interventions":1216},[89],[192],[194,195,196,197,198,199,200,201,202,174,203,204,205],{"trials":1218,"activeCount":100},[1219],{"nctId":1220,"briefTitle":1221,"status":1009,"phases":1222,"primaryCompletion":1112,"completion":1223,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1228},"NCT01398072","Development of an Optimal Antibiotic Regime for Long-term Therapy in Stable Chronic Obstructive Pulmonary Disease (COPD)",[90],"2013-04","2011-12",200,[1227],"Chronic Obstructive Pulmonary Disease (COPD).",[199,1229,1230],"Azithromycin","Doxycycline",{"trials":1232,"activeCount":100},[],{"trials":1234,"activeCount":100},[],{"intervention":196,"totalTrials":366,"cells":1236},{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1247,"PHASE4":1253,"NA":1255},{"trials":1238,"activeCount":100},[],{"trials":1240,"activeCount":100},[],{"trials":1242,"activeCount":137,"soonestReadout":187},[1243],{"nctId":184,"briefTitle":185,"status":108,"phases":1244,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":1245,"interventions":1246},[89],[192],[194,195,196,197,198,199,200,201,202,174,203,204,205],{"trials":1248,"activeCount":100},[1249],{"nctId":221,"briefTitle":222,"status":157,"phases":1250,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":1251,"interventions":1252},[89,90],[228],[202,174,201,203,200,230,231,232,196,202],{"trials":1254,"activeCount":100},[],{"trials":1256,"activeCount":100},[],{"intervention":200,"totalTrials":366,"cells":1258},{"EARLY_PHASE1":1259,"PHASE1":1261,"PHASE2":1263,"PHASE3":1269,"PHASE4":1275,"NA":1277},{"trials":1260,"activeCount":100},[],{"trials":1262,"activeCount":100},[],{"trials":1264,"activeCount":137,"soonestReadout":187},[1265],{"nctId":184,"briefTitle":185,"status":108,"phases":1266,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":1267,"interventions":1268},[89],[192],[194,195,196,197,198,199,200,201,202,174,203,204,205],{"trials":1270,"activeCount":100},[1271],{"nctId":221,"briefTitle":222,"status":157,"phases":1272,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":1273,"interventions":1274},[89,90],[228],[202,174,201,203,200,230,231,232,196,202],{"trials":1276,"activeCount":100},[],{"trials":1278,"activeCount":100},[],{"intervention":1280,"totalTrials":366,"cells":1281},"5-ALA",{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1311,"PHASE4":1313,"NA":1315},{"trials":1283,"activeCount":100},[],{"trials":1285,"activeCount":100},[],{"trials":1287,"activeCount":137,"soonestReadout":1305},[1288,1301],{"nctId":1289,"briefTitle":1290,"status":157,"phases":1291,"primaryCompletion":1292,"completion":1292,"start":1293,"enrollment":1294,"conditions":1295,"interventions":1297},"NCT01310868","Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma",[89],"2015-03","2011-05",59,[1296],"Glioblastoma",[1280,1298,1299,1300],"Gliadel wafers","Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist","Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist",{"nctId":1302,"briefTitle":1303,"status":211,"phases":1304,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":113,"conditions":1308,"interventions":1310},"NCT06678867","The Use of 5-ALA in Paediatric Patients With High Grade Brain Tumours",[89],"2026-06-30","2026-12-30","2025-03-25",[1309],"Brain Tumor",[1280],{"trials":1312,"activeCount":100},[],{"trials":1314,"activeCount":100},[],{"trials":1316,"activeCount":100},[],{"intervention":1318,"totalTrials":137,"cells":1319},"Actinium (225Ac) rhPSMA-10.1",{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1337,"PHASE4":1339,"NA":1341},{"trials":1321,"activeCount":100},[],{"trials":1323,"activeCount":100},[],{"trials":1325,"activeCount":137,"soonestReadout":1330},[1326],{"nctId":1327,"briefTitle":1328,"status":108,"phases":1329,"primaryCompletion":1330,"completion":1331,"start":1332,"enrollment":1044,"conditions":1333,"interventions":1336},"NCT07414940","ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium",[88,89],"2031-03-30","2031-12-30","2026-04-13",[1334,1335,18],"Metastatic Castration-resistant Prostate Cancer","Metastatic Prostate Cancer",[1318],{"trials":1338,"activeCount":100},[],{"trials":1340,"activeCount":100},[],{"trials":1342,"activeCount":100},[],{"intervention":1344,"totalTrials":137,"cells":1345},"Dapagliflozin",{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1365,"PHASE4":1367,"NA":1369},{"trials":1347,"activeCount":100},[],{"trials":1349,"activeCount":100},[],{"trials":1351,"activeCount":137,"soonestReadout":1356},[1352],{"nctId":1353,"briefTitle":1354,"status":211,"phases":1355,"primaryCompletion":1356,"completion":1357,"start":146,"enrollment":1358,"conditions":1359,"interventions":1361},"NCT07539259","To Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement, Result in Better Left Ventricular Mass Regression, Myocardial Health and Patient Reported Outcomes",[89],"2029-08","2030-02-28",445,[1360],"Aortic Stenosis",[1344,1362,1363,1364],"Spironolactone","Spironolactone + Dapagliflozin","Epleronone",{"trials":1366,"activeCount":100},[],{"trials":1368,"activeCount":100},[],{"trials":1370,"activeCount":100},[],{"intervention":1362,"totalTrials":137,"cells":1372},{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1383,"PHASE4":1385,"NA":1387},{"trials":1374,"activeCount":100},[],{"trials":1376,"activeCount":100},[],{"trials":1378,"activeCount":137,"soonestReadout":1356},[1379],{"nctId":1353,"briefTitle":1354,"status":211,"phases":1380,"primaryCompletion":1356,"completion":1357,"start":146,"enrollment":1358,"conditions":1381,"interventions":1382},[89],[1360],[1344,1362,1363,1364],{"trials":1384,"activeCount":100},[],{"trials":1386,"activeCount":100},[],{"trials":1388,"activeCount":100},[],{"intervention":1363,"totalTrials":137,"cells":1390},{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1401,"PHASE4":1403,"NA":1405},{"trials":1392,"activeCount":100},[],{"trials":1394,"activeCount":100},[],{"trials":1396,"activeCount":137,"soonestReadout":1356},[1397],{"nctId":1353,"briefTitle":1354,"status":211,"phases":1398,"primaryCompletion":1356,"completion":1357,"start":146,"enrollment":1358,"conditions":1399,"interventions":1400},[89],[1360],[1344,1362,1363,1364],{"trials":1402,"activeCount":100},[],{"trials":1404,"activeCount":100},[],{"trials":1406,"activeCount":100},[],{"intervention":1364,"totalTrials":137,"cells":1408},{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1419,"PHASE4":1421,"NA":1423},{"trials":1410,"activeCount":100},[],{"trials":1412,"activeCount":100},[],{"trials":1414,"activeCount":137,"soonestReadout":1356},[1415],{"nctId":1353,"briefTitle":1354,"status":211,"phases":1416,"primaryCompletion":1356,"completion":1357,"start":146,"enrollment":1358,"conditions":1417,"interventions":1418},[89],[1360],[1344,1362,1363,1364],{"trials":1420,"activeCount":100},[],{"trials":1422,"activeCount":100},[],{"trials":1424,"activeCount":100},[],{"intervention":1426,"totalTrials":137,"cells":1427},"AAV2\u002F8-HLP-FVIII-V3",{"EARLY_PHASE1":1428,"PHASE1":1430,"PHASE2":1432,"PHASE3":1444,"PHASE4":1446,"NA":1448},{"trials":1429,"activeCount":100},[],{"trials":1431,"activeCount":100},[],{"trials":1433,"activeCount":137,"soonestReadout":1438},[1434],{"nctId":1435,"briefTitle":1436,"status":143,"phases":1437,"primaryCompletion":1438,"completion":1439,"start":1440,"enrollment":28,"conditions":1441,"interventions":1443},"NCT03001830","Gene Therapy for Haemophilia A.",[88,89],"2029-01","2029-12","2017-06-14",[1442],"Hemophilia A",[1426],{"trials":1445,"activeCount":100},[],{"trials":1447,"activeCount":100},[],{"trials":1449,"activeCount":100},[],{"intervention":1451,"totalTrials":137,"cells":1452},"Tislelizumab, AVD, Radiotherapy",{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1457,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1454,"activeCount":100},[],{"trials":1456,"activeCount":100},[],{"trials":1458,"activeCount":137,"soonestReadout":1463},[1459],{"nctId":1460,"briefTitle":1461,"status":211,"phases":1462,"primaryCompletion":1463,"completion":1463,"start":1464,"enrollment":113,"conditions":1465,"interventions":1466},"NCT05627115","Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma",[89],"2028-10-01","2024-03-01",[576],[1451],{"trials":1468,"activeCount":100},[],{"trials":1470,"activeCount":100},[],{"trials":1472,"activeCount":100},[],{"intervention":47,"totalTrials":137,"cells":1474},{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1479,"PHASE3":1488,"PHASE4":1490,"NA":1492},{"trials":1476,"activeCount":100},[],{"trials":1478,"activeCount":100},[],{"trials":1480,"activeCount":137,"soonestReadout":46},[1481],{"nctId":44,"briefTitle":45,"status":143,"phases":1482,"primaryCompletion":46,"completion":1483,"start":1484,"enrollment":1485,"conditions":1486,"interventions":1487},[89],"2027-06","2018-02-06",380,[18],[47],{"trials":1489,"activeCount":100},[],{"trials":1491,"activeCount":100},[],{"trials":1493,"activeCount":100},[],{"intervention":1495,"totalTrials":137,"cells":1496},"AAVLK03hOTC",{"EARLY_PHASE1":1497,"PHASE1":1499,"PHASE2":1501,"PHASE3":1511,"PHASE4":1513,"NA":1515},{"trials":1498,"activeCount":100},[],{"trials":1500,"activeCount":100},[],{"trials":1502,"activeCount":137,"soonestReadout":1305},[1503],{"nctId":1504,"briefTitle":1505,"status":108,"phases":1506,"primaryCompletion":1305,"completion":927,"start":1507,"enrollment":31,"conditions":1508,"interventions":1510},"NCT05092685","Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn",[88,89],"2023-11-01",[1509],"Ornithine Transcarbamylase Deficiency",[1495],{"trials":1512,"activeCount":100},[],{"trials":1514,"activeCount":100},[],{"trials":1516,"activeCount":100},[],{"intervention":1518,"totalTrials":137,"cells":1519},"lentiviral gene therapy",{"EARLY_PHASE1":1520,"PHASE1":1522,"PHASE2":1524,"PHASE3":1534,"PHASE4":1536,"NA":1538},{"trials":1521,"activeCount":100},[],{"trials":1523,"activeCount":100},[],{"trials":1525,"activeCount":137,"soonestReadout":1530},[1526],{"nctId":1527,"briefTitle":1528,"status":211,"phases":1529,"primaryCompletion":1530,"completion":572,"start":1054,"enrollment":34,"conditions":1531,"interventions":1533},"NCT04601974","Lentiviral Gene Therapy for Epilepsy",[88,89],"2028-09",[1532],"Drug Resistant Epilepsy",[1518],{"trials":1535,"activeCount":100},[],{"trials":1537,"activeCount":100},[],{"trials":1539,"activeCount":100},[],{"intervention":1048,"totalTrials":137,"cells":1541},{"EARLY_PHASE1":1542,"PHASE1":1544,"PHASE2":1546,"PHASE3":1552,"PHASE4":1554,"NA":1556},{"trials":1543,"activeCount":100},[],{"trials":1545,"activeCount":100},[],{"trials":1547,"activeCount":137,"soonestReadout":1041},[1548],{"nctId":1038,"briefTitle":1039,"status":108,"phases":1549,"primaryCompletion":1041,"completion":1042,"start":1043,"enrollment":1044,"conditions":1550,"interventions":1551},[89],[1046],[52,1048,1049],{"trials":1553,"activeCount":100},[],{"trials":1555,"activeCount":100},[],{"trials":1557,"activeCount":100},[],{"intervention":1049,"totalTrials":137,"cells":1559},{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1570,"PHASE4":1572,"NA":1574},{"trials":1561,"activeCount":100},[],{"trials":1563,"activeCount":100},[],{"trials":1565,"activeCount":137,"soonestReadout":1041},[1566],{"nctId":1038,"briefTitle":1039,"status":108,"phases":1567,"primaryCompletion":1041,"completion":1042,"start":1043,"enrollment":1044,"conditions":1568,"interventions":1569},[89],[1046],[52,1048,1049],{"trials":1571,"activeCount":100},[],{"trials":1573,"activeCount":100},[],{"trials":1575,"activeCount":100},[],{"intervention":382,"totalTrials":137,"cells":1577},{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1582,"PHASE3":1588,"PHASE4":1590,"NA":1592},{"trials":1579,"activeCount":100},[],{"trials":1581,"activeCount":100},[],{"trials":1583,"activeCount":137,"soonestReadout":85},[1584],{"nctId":83,"briefTitle":84,"status":108,"phases":1585,"primaryCompletion":85,"completion":376,"start":377,"enrollment":378,"conditions":1586,"interventions":1587},[88,89],[380],[61,382],{"trials":1589,"activeCount":100},[],{"trials":1591,"activeCount":100},[],{"trials":1593,"activeCount":100},[],{"intervention":334,"totalTrials":137,"cells":1595},{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1600,"PHASE3":1606,"PHASE4":1608,"NA":1610},{"trials":1597,"activeCount":100},[],{"trials":1599,"activeCount":100},[],{"trials":1601,"activeCount":137,"soonestReadout":328},[1602],{"nctId":325,"briefTitle":326,"status":108,"phases":1603,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":1604,"interventions":1605},[89],[332],[334,335,316],{"trials":1607,"activeCount":100},[],{"trials":1609,"activeCount":100},[],{"trials":1611,"activeCount":100},[],{"intervention":335,"totalTrials":137,"cells":1613},{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1618,"PHASE3":1624,"PHASE4":1626,"NA":1628},{"trials":1615,"activeCount":100},[],{"trials":1617,"activeCount":100},[],{"trials":1619,"activeCount":137,"soonestReadout":328},[1620],{"nctId":325,"briefTitle":326,"status":108,"phases":1621,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":1622,"interventions":1623},[89],[332],[334,335,316],{"trials":1625,"activeCount":100},[],{"trials":1627,"activeCount":100},[],{"trials":1629,"activeCount":100},[],{"intervention":1128,"totalTrials":137,"cells":1631},{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1642,"PHASE4":1644,"NA":1646},{"trials":1633,"activeCount":100},[],{"trials":1635,"activeCount":100},[],{"trials":1637,"activeCount":137,"soonestReadout":1122},[1638],{"nctId":1119,"briefTitle":1120,"status":108,"phases":1639,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":1640,"interventions":1641},[89],[1126],[1128,1028],{"trials":1643,"activeCount":100},[],{"trials":1645,"activeCount":100},[],{"trials":1647,"activeCount":100},[],{"intervention":1649,"totalTrials":137,"cells":1650},"Lu-177 DOTATATE",{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1655,"PHASE3":1670,"PHASE4":1672,"NA":1674},{"trials":1652,"activeCount":100},[],{"trials":1654,"activeCount":100},[],{"trials":1656,"activeCount":137,"soonestReadout":1661},[1657],{"nctId":1658,"briefTitle":1659,"status":211,"phases":1660,"primaryCompletion":1661,"completion":1661,"start":1662,"enrollment":1663,"conditions":1664,"interventions":1669},"NCT06121271","Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications",[89],"2027-11-06","2023-12-18",110,[1665,1666,1667,1668],"Bronchial and Thymic Neuroendocrine Tumour","Paraganglioma\u002F Phaeochromocytoma","Medullary Thyroid Carcinoma","Those Requiring Repeat Peptide Receptor Radionuclide Therapy",[1649],{"trials":1671,"activeCount":100},[],{"trials":1673,"activeCount":100},[],{"trials":1675,"activeCount":100},[],{"intervention":1677,"totalTrials":137,"cells":1678},"Glofitamab",{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1683,"PHASE3":1698,"PHASE4":1700,"NA":1702},{"trials":1680,"activeCount":100},[],{"trials":1682,"activeCount":100},[],{"trials":1684,"activeCount":137,"soonestReadout":1689},[1685],{"nctId":1686,"briefTitle":1687,"status":108,"phases":1688,"primaryCompletion":1689,"completion":1690,"start":1691,"enrollment":1692,"conditions":1693,"interventions":1695},"NCT06071871","A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma",[89],"2027-07-30","2028-07-30","2024-08-16",99,[1694],"Large B-cell Lymphoma",[1677,1696,1697],"Polatuzumab vedotin","Obinutuzumab",{"trials":1699,"activeCount":100},[],{"trials":1701,"activeCount":100},[],{"trials":1703,"activeCount":100},[],{"intervention":1696,"totalTrials":137,"cells":1705},{"EARLY_PHASE1":1706,"PHASE1":1708,"PHASE2":1710,"PHASE3":1716,"PHASE4":1718,"NA":1720},{"trials":1707,"activeCount":100},[],{"trials":1709,"activeCount":100},[],{"trials":1711,"activeCount":137,"soonestReadout":1689},[1712],{"nctId":1686,"briefTitle":1687,"status":108,"phases":1713,"primaryCompletion":1689,"completion":1690,"start":1691,"enrollment":1692,"conditions":1714,"interventions":1715},[89],[1694],[1677,1696,1697],{"trials":1717,"activeCount":100},[],{"trials":1719,"activeCount":100},[],{"trials":1721,"activeCount":100},[],{"intervention":1697,"totalTrials":137,"cells":1723},{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1734,"PHASE4":1736,"NA":1738},{"trials":1725,"activeCount":100},[],{"trials":1727,"activeCount":100},[],{"trials":1729,"activeCount":137,"soonestReadout":1689},[1730],{"nctId":1686,"briefTitle":1687,"status":108,"phases":1731,"primaryCompletion":1689,"completion":1690,"start":1691,"enrollment":1692,"conditions":1732,"interventions":1733},[89],[1694],[1677,1696,1697],{"trials":1735,"activeCount":100},[],{"trials":1737,"activeCount":100},[],{"trials":1739,"activeCount":100},[],{"intervention":1138,"totalTrials":137,"cells":1741},{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1743,"activeCount":100},[],{"trials":1745,"activeCount":100},[],{"trials":1747,"activeCount":137,"soonestReadout":1133},[1748],{"nctId":1130,"briefTitle":1131,"status":108,"phases":1749,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":1056,"conditions":1750,"interventions":1751},[89],[1126],[1138,1028],{"trials":1753,"activeCount":100},[],{"trials":1755,"activeCount":100},[],{"trials":1757,"activeCount":100},[],{"intervention":1759,"totalTrials":137,"cells":1760},"Letermovir",{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1776,"PHASE4":1778,"NA":1780},{"trials":1762,"activeCount":100},[],{"trials":1764,"activeCount":100},[],{"trials":1766,"activeCount":137,"soonestReadout":1771},[1767],{"nctId":1768,"briefTitle":1769,"status":211,"phases":1770,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":356,"conditions":1773,"interventions":1775},"NCT06626555","Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection",[89],"2026-03","2024-10",[1774],"HIV",[1759],{"trials":1777,"activeCount":100},[],{"trials":1779,"activeCount":100},[],{"trials":1781,"activeCount":100},[],{"intervention":42,"totalTrials":137,"cells":1783},{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1798,"PHASE4":1800,"NA":1802},{"trials":1785,"activeCount":100},[],{"trials":1787,"activeCount":100},[],{"trials":1789,"activeCount":137,"soonestReadout":41},[1790],{"nctId":39,"briefTitle":40,"status":143,"phases":1791,"primaryCompletion":41,"completion":1792,"start":1793,"enrollment":1794,"conditions":1795,"interventions":1797},[89],"2029-11","2015-06-16",281,[1796],"Multiple Myeloma",[42],{"trials":1799,"activeCount":100},[],{"trials":1801,"activeCount":100},[],{"trials":1803,"activeCount":100},[],{"intervention":1805,"totalTrials":137,"cells":1806},"Dostarlimab",{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1811,"PHASE3":1823,"PHASE4":1825,"NA":1827},{"trials":1808,"activeCount":100},[],{"trials":1810,"activeCount":100},[],{"trials":1812,"activeCount":137,"soonestReadout":1817},[1813],{"nctId":1814,"briefTitle":1815,"status":211,"phases":1816,"primaryCompletion":1817,"completion":1818,"start":1819,"enrollment":1154,"conditions":1820,"interventions":1822},"NCT07115927","pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer",[89],"2030-04-30","2031-01-31","2025-09-30",[1821],"Endometrial Cancer",[1805],{"trials":1824,"activeCount":100},[],{"trials":1826,"activeCount":100},[],{"trials":1828,"activeCount":100},[],{"intervention":194,"totalTrials":137,"cells":1830},{"EARLY_PHASE1":1831,"PHASE1":1833,"PHASE2":1835,"PHASE3":1841,"PHASE4":1843,"NA":1845},{"trials":1832,"activeCount":100},[],{"trials":1834,"activeCount":100},[],{"trials":1836,"activeCount":137,"soonestReadout":187},[1837],{"nctId":184,"briefTitle":185,"status":108,"phases":1838,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":1839,"interventions":1840},[89],[192],[194,195,196,197,198,199,200,201,202,174,203,204,205],{"trials":1842,"activeCount":100},[],{"trials":1844,"activeCount":100},[],{"trials":1846,"activeCount":100},[],{"intervention":195,"totalTrials":137,"cells":1848},{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1859,"PHASE4":1861,"NA":1863},{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[],{"trials":1854,"activeCount":137,"soonestReadout":187},[1855],{"nctId":184,"briefTitle":185,"status":108,"phases":1856,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":1857,"interventions":1858},[89],[192],[194,195,196,197,198,199,200,201,202,174,203,204,205],{"trials":1860,"activeCount":100},[],{"trials":1862,"activeCount":100},[],{"trials":1864,"activeCount":100},[],{"intervention":197,"totalTrials":137,"cells":1866},{"EARLY_PHASE1":1867,"PHASE1":1869,"PHASE2":1871,"PHASE3":1877,"PHASE4":1879,"NA":1881},{"trials":1868,"activeCount":100},[],{"trials":1870,"activeCount":100},[],{"trials":1872,"activeCount":137,"soonestReadout":187},[1873],{"nctId":184,"briefTitle":185,"status":108,"phases":1874,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":1875,"interventions":1876},[89],[192],[194,195,196,197,198,199,200,201,202,174,203,204,205],{"trials":1878,"activeCount":100},[],{"trials":1880,"activeCount":100},[],{"trials":1882,"activeCount":100},[],{"intervention":198,"totalTrials":137,"cells":1884},{"EARLY_PHASE1":1885,"PHASE1":1887,"PHASE2":1889,"PHASE3":1895,"PHASE4":1897,"NA":1899},{"trials":1886,"activeCount":100},[],{"trials":1888,"activeCount":100},[],{"trials":1890,"activeCount":137,"soonestReadout":187},[1891],{"nctId":184,"briefTitle":185,"status":108,"phases":1892,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":1893,"interventions":1894},[89],[192],[194,195,196,197,198,199,200,201,202,174,203,204,205],{"trials":1896,"activeCount":100},[],{"trials":1898,"activeCount":100},[],{"trials":1900,"activeCount":100},[],{"intervention":204,"totalTrials":137,"cells":1902},{"EARLY_PHASE1":1903,"PHASE1":1905,"PHASE2":1907,"PHASE3":1913,"PHASE4":1915,"NA":1917},{"trials":1904,"activeCount":100},[],{"trials":1906,"activeCount":100},[],{"trials":1908,"activeCount":137,"soonestReadout":187},[1909],{"nctId":184,"briefTitle":185,"status":108,"phases":1910,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":1911,"interventions":1912},[89],[192],[194,195,196,197,198,199,200,201,202,174,203,204,205],{"trials":1914,"activeCount":100},[],{"trials":1916,"activeCount":100},[],{"trials":1918,"activeCount":100},[],{"intervention":205,"totalTrials":137,"cells":1920},{"EARLY_PHASE1":1921,"PHASE1":1923,"PHASE2":1925,"PHASE3":1931,"PHASE4":1933,"NA":1935},{"trials":1922,"activeCount":100},[],{"trials":1924,"activeCount":100},[],{"trials":1926,"activeCount":137,"soonestReadout":187},[1927],{"nctId":184,"briefTitle":185,"status":108,"phases":1928,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":1929,"interventions":1930},[89],[192],[194,195,196,197,198,199,200,201,202,174,203,204,205],{"trials":1932,"activeCount":100},[],{"trials":1934,"activeCount":100},[],{"trials":1936,"activeCount":100},[],{"intervention":1938,"totalTrials":137,"cells":1939},"Treatment dose antibiotic in combination with methenamine hippurate",{"EARLY_PHASE1":1940,"PHASE1":1942,"PHASE2":1944,"PHASE3":1958,"PHASE4":1960,"NA":1962},{"trials":1941,"activeCount":100},[],{"trials":1943,"activeCount":100},[],{"trials":1945,"activeCount":137,"soonestReadout":1950},[1946],{"nctId":1947,"briefTitle":1948,"status":108,"phases":1949,"primaryCompletion":1950,"completion":1951,"start":1952,"enrollment":1953,"conditions":1954,"interventions":1956},"NCT07202949","A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection",[89],"2027-10","2027-11","2026-02-26",192,[1955],"Chronic Urinary Tract Infection",[1938,1957],"Prophylactic dose antibiotic or methenamine hippurate monotherapy",{"trials":1959,"activeCount":100},[],{"trials":1961,"activeCount":100},[],{"trials":1963,"activeCount":100},[],{"intervention":1957,"totalTrials":137,"cells":1965},{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1967,"activeCount":100},[],{"trials":1969,"activeCount":100},[],{"trials":1971,"activeCount":137,"soonestReadout":1950},[1972],{"nctId":1947,"briefTitle":1948,"status":108,"phases":1973,"primaryCompletion":1950,"completion":1951,"start":1952,"enrollment":1953,"conditions":1974,"interventions":1975},[89],[1955],[1938,1957],{"trials":1977,"activeCount":100},[],{"trials":1979,"activeCount":100},[],{"trials":1981,"activeCount":100},[],{"intervention":1983,"totalTrials":366,"cells":1984},"GD2 CAR T cells",{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":2008,"PHASE3":2010,"PHASE4":2012,"NA":2014},{"trials":1986,"activeCount":100},[],{"trials":1988,"activeCount":366,"soonestReadout":2002},[1989,1998],{"nctId":1990,"briefTitle":1991,"status":143,"phases":1992,"primaryCompletion":146,"completion":1993,"start":1994,"enrollment":31,"conditions":1995,"interventions":1997},"NCT05990751","Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma",[88],"2041-12","2024-04-19",[1996],"Neuroblastoma",[1983],{"nctId":1999,"briefTitle":2000,"status":108,"phases":2001,"primaryCompletion":2002,"completion":2003,"start":2004,"enrollment":31,"conditions":2005,"interventions":2007},"NCT05544526","CAR T Cells to Target GD2 for DMG",[88],"2025-12","2039-12","2023-08-15",[2006],"Diffuse Midline Glioma, H3 K27M-Mutant",[1983],{"trials":2009,"activeCount":100},[],{"trials":2011,"activeCount":100},[],{"trials":2013,"activeCount":100},[],{"trials":2015,"activeCount":100},[],{"intervention":2017,"totalTrials":366,"cells":2018},"Ipilimumab",{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2034,"PHASE3":2044,"PHASE4":2046,"NA":2048},{"trials":2020,"activeCount":100},[],{"trials":2022,"activeCount":137,"soonestReadout":2027},[2023],{"nctId":2024,"briefTitle":2025,"status":108,"phases":2026,"primaryCompletion":2027,"completion":2028,"start":2029,"enrollment":25,"conditions":2030,"interventions":2033},"NCT07134842","A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.",[88],"2027-01-01","2028-01-01","2025-07-10",[1296,2031,2032],"Gliosarcoma, Adult","Glioblastoma - Category",[2017],{"trials":2035,"activeCount":100},[2036],{"nctId":2037,"briefTitle":2038,"status":126,"phases":2039,"primaryCompletion":2040,"completion":2040,"start":2041,"enrollment":137,"conditions":2042,"interventions":2043},"NCT05074992","A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma",[89],"2023-05-02","2022-08-24",[1296],[2017],{"trials":2045,"activeCount":100},[],{"trials":2047,"activeCount":100},[],{"trials":2049,"activeCount":100},[],{"intervention":2051,"totalTrials":137,"cells":2052},"Lymphodepletion with Fludarabine",{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2069,"PHASE3":2071,"PHASE4":2073,"NA":2075},{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":137,"soonestReadout":2061},[2057],{"nctId":2058,"briefTitle":2059,"status":108,"phases":2060,"primaryCompletion":2061,"completion":2062,"start":2063,"enrollment":1124,"conditions":2064,"interventions":2066},"NCT02443831","CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia",[88],"2026-12-31","2041-12-31","2016-04",[2065],"Acute Lymphoblastic Leukemia",[2051,2067,2068],"Lymphodepletion with Cyclophosphamide","CD19+CD22 CAR T-cells",{"trials":2070,"activeCount":100},[],{"trials":2072,"activeCount":100},[],{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[],{"intervention":2067,"totalTrials":137,"cells":2078},{"EARLY_PHASE1":2079,"PHASE1":2081,"PHASE2":2087,"PHASE3":2089,"PHASE4":2091,"NA":2093},{"trials":2080,"activeCount":100},[],{"trials":2082,"activeCount":137,"soonestReadout":2061},[2083],{"nctId":2058,"briefTitle":2059,"status":108,"phases":2084,"primaryCompletion":2061,"completion":2062,"start":2063,"enrollment":1124,"conditions":2085,"interventions":2086},[88],[2065],[2051,2067,2068],{"trials":2088,"activeCount":100},[],{"trials":2090,"activeCount":100},[],{"trials":2092,"activeCount":100},[],{"trials":2094,"activeCount":100},[],{"intervention":2068,"totalTrials":137,"cells":2096},{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2105,"PHASE3":2107,"PHASE4":2109,"NA":2111},{"trials":2098,"activeCount":100},[],{"trials":2100,"activeCount":137,"soonestReadout":2061},[2101],{"nctId":2058,"briefTitle":2059,"status":108,"phases":2102,"primaryCompletion":2061,"completion":2062,"start":2063,"enrollment":1124,"conditions":2103,"interventions":2104},[88],[2065],[2051,2067,2068],{"trials":2106,"activeCount":100},[],{"trials":2108,"activeCount":100},[],{"trials":2110,"activeCount":100},[],{"trials":2112,"activeCount":100},[],{"intervention":71,"totalTrials":137,"cells":2114},{"EARLY_PHASE1":2115,"PHASE1":2117,"PHASE2":2126,"PHASE3":2128,"PHASE4":2130,"NA":2132},{"trials":2116,"activeCount":100},[],{"trials":2118,"activeCount":137,"soonestReadout":70},[2119],{"nctId":68,"briefTitle":69,"status":211,"phases":2120,"primaryCompletion":70,"completion":2121,"start":2122,"enrollment":31,"conditions":2123,"interventions":2125},[88],"2034-11","2022-10",[2124],"Blood Cancer",[71],{"trials":2127,"activeCount":100},[],{"trials":2129,"activeCount":100},[],{"trials":2131,"activeCount":100},[],{"trials":2133,"activeCount":100},[],{"intervention":2135,"totalTrials":137,"cells":2136},"NIO752",{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2153,"PHASE3":2155,"PHASE4":2157,"NA":2159},{"trials":2138,"activeCount":100},[],{"trials":2140,"activeCount":137,"soonestReadout":2145},[2141],{"nctId":2142,"briefTitle":2143,"status":108,"phases":2144,"primaryCompletion":2145,"completion":2145,"start":2146,"enrollment":34,"conditions":2147,"interventions":2152},"NCT06372821","A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK",[88],"2026-07","2024-11-18",[2148,2149,2150,2151],"Alzheimer Disease","Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)","Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder)","Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)",[2135],{"trials":2154,"activeCount":100},[],{"trials":2156,"activeCount":100},[],{"trials":2158,"activeCount":100},[],{"trials":2160,"activeCount":100},[],{"intervention":2162,"totalTrials":137,"cells":2163},"Psilocybin 25mg",{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2176,"PHASE3":2178,"PHASE4":2180,"NA":2182},{"trials":2165,"activeCount":100},[],{"trials":2167,"activeCount":137,"soonestReadout":1771},[2168],{"nctId":2169,"briefTitle":2170,"status":108,"phases":2171,"primaryCompletion":1771,"completion":146,"start":2172,"enrollment":1154,"conditions":2173,"interventions":2175},"NCT06815653","Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs",[88],"2025-03-01",[2174],"Healthy",[2162],{"trials":2177,"activeCount":100},[],{"trials":2179,"activeCount":100},[],{"trials":2181,"activeCount":100},[],{"trials":2183,"activeCount":100},[],{"intervention":76,"totalTrials":137,"cells":2185},{"EARLY_PHASE1":2186,"PHASE1":2188,"PHASE2":2197,"PHASE3":2199,"PHASE4":2201,"NA":2203},{"trials":2187,"activeCount":100},[],{"trials":2189,"activeCount":137,"soonestReadout":75},[2190],{"nctId":73,"briefTitle":74,"status":143,"phases":2191,"primaryCompletion":75,"completion":2192,"start":2193,"enrollment":31,"conditions":2194,"interventions":2196},[88],"2032-12","2021-03-23",[2195],"Primary CNS Lymphoma",[76],{"trials":2198,"activeCount":100},[],{"trials":2200,"activeCount":100},[],{"trials":2202,"activeCount":100},[],{"trials":2204,"activeCount":100},[],{"intervention":2206,"totalTrials":137,"cells":2207},"CARCCR9 T cells",{"EARLY_PHASE1":2208,"PHASE1":2210,"PHASE2":2224,"PHASE3":2226,"PHASE4":2228,"NA":2230},{"trials":2209,"activeCount":100},[],{"trials":2211,"activeCount":137,"soonestReadout":2216},[2212],{"nctId":2213,"briefTitle":2214,"status":108,"phases":2215,"primaryCompletion":2216,"completion":2217,"start":2218,"enrollment":2219,"conditions":2220,"interventions":2223},"NCT07300683","Anti-CCR9 CAR T Cells for T Cell Leukaemia\u002FLymphoma",[88],"2027-12","2042-12","2025-11-11",24,[2221,2222],"T Cell Acute Lymphoblastic Leukemia","T Cell Lymphoblastic Lymphoma",[2206],{"trials":2225,"activeCount":100},[],{"trials":2227,"activeCount":100},[],{"trials":2229,"activeCount":100},[],{"trials":2231,"activeCount":100},[],{"intervention":2233,"totalTrials":137,"cells":2234},"BCMA CAR T cells",{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2249,"PHASE3":2251,"PHASE4":2253,"NA":2255},{"trials":2236,"activeCount":100},[],{"trials":2238,"activeCount":137,"soonestReadout":2243},[2239],{"nctId":2240,"briefTitle":2241,"status":108,"phases":2242,"primaryCompletion":2243,"completion":2243,"start":2244,"enrollment":2245,"conditions":2246,"interventions":2247},"NCT04795882","A New Study Evaluating the Activity of Modular CAR T for mYeloma",[88],"2029-03-31","2022-04-22",27,[1796],[2233,2248],"BCMA\u002FCD19 CAR T cells",{"trials":2250,"activeCount":100},[],{"trials":2252,"activeCount":100},[],{"trials":2254,"activeCount":100},[],{"trials":2256,"activeCount":100},[],{"intervention":2248,"totalTrials":137,"cells":2258},{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2267,"PHASE3":2269,"PHASE4":2271,"NA":2273},{"trials":2260,"activeCount":100},[],{"trials":2262,"activeCount":137,"soonestReadout":2243},[2263],{"nctId":2240,"briefTitle":2241,"status":108,"phases":2264,"primaryCompletion":2243,"completion":2243,"start":2244,"enrollment":2245,"conditions":2265,"interventions":2266},[88],[1796],[2233,2248],{"trials":2268,"activeCount":100},[],{"trials":2270,"activeCount":100},[],{"trials":2272,"activeCount":100},[],{"trials":2274,"activeCount":100},[],{"intervention":66,"totalTrials":137,"cells":2276},{"EARLY_PHASE1":2277,"PHASE1":2279,"PHASE2":2288,"PHASE3":2290,"PHASE4":2292,"NA":2294},{"trials":2278,"activeCount":100},[],{"trials":2280,"activeCount":137,"soonestReadout":65},[2281],{"nctId":63,"briefTitle":64,"status":143,"phases":2282,"primaryCompletion":65,"completion":2283,"start":2284,"enrollment":130,"conditions":2285,"interventions":2287},[88],"2033-12","2017-09-29",[2286],"Leukemia, Lymphoblastic, Acute, Lymphoma",[66],{"trials":2289,"activeCount":100},[],{"trials":2291,"activeCount":100},[],{"trials":2293,"activeCount":100},[],{"trials":2295,"activeCount":100},[],{"intervention":2297,"totalTrials":137,"cells":2298},"Luteinising Hormone-Releasing Factor Analogue",{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2305,"PHASE4":2307,"NA":2309},{"trials":2300,"activeCount":100},[],{"trials":2302,"activeCount":100},[],{"trials":2304,"activeCount":100},[],{"trials":2306,"activeCount":100},[],{"trials":2308,"activeCount":100},[],{"trials":2310,"activeCount":137,"soonestReadout":2315},[2311],{"nctId":2312,"briefTitle":2313,"status":211,"phases":2314,"primaryCompletion":2315,"completion":2315,"start":2316,"enrollment":2317,"conditions":2318,"interventions":2319},"NCT06145958","Radiotherapy and Androgen Deprivation In Combination After Local Surgery (RADICALS) Translational Study",[],"2028-08-30","2024-01-01",2585,[18],[2297],{"intervention":2321,"totalTrials":137,"cells":2322},"Ciprofloxacin",{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2327,"PHASE3":2329,"PHASE4":2331,"NA":2333},{"trials":2324,"activeCount":100},[],{"trials":2326,"activeCount":100},[],{"trials":2328,"activeCount":100},[],{"trials":2330,"activeCount":100},[],{"trials":2332,"activeCount":100},[],{"trials":2334,"activeCount":137,"soonestReadout":2028},[2335],{"nctId":2336,"briefTitle":2337,"status":143,"phases":2338,"primaryCompletion":2028,"completion":2339,"start":2340,"enrollment":2341,"conditions":2342,"interventions":2344},"NCT04678869","CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia)",[92],"2028-06-01","2022-06-29",313,[2343],"Acute Lymphoblastic Leukaemia - Category",[2321,2345],"Antibiotic",{"intervention":2345,"totalTrials":137,"cells":2347},{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2352,"PHASE3":2354,"PHASE4":2356,"NA":2358},{"trials":2349,"activeCount":100},[],{"trials":2351,"activeCount":100},[],{"trials":2353,"activeCount":100},[],{"trials":2355,"activeCount":100},[],{"trials":2357,"activeCount":100},[],{"trials":2359,"activeCount":137,"soonestReadout":2028},[2360],{"nctId":2336,"briefTitle":2337,"status":143,"phases":2361,"primaryCompletion":2028,"completion":2339,"start":2340,"enrollment":2341,"conditions":2362,"interventions":2363},[92],[2343],[2321,2345],{"intervention":2365,"totalTrials":137,"cells":2366},"CTG18.1 Expansion Status Genotyping",{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2373,"PHASE4":2375,"NA":2377},{"trials":2368,"activeCount":100},[],{"trials":2370,"activeCount":100},[],{"trials":2372,"activeCount":100},[],{"trials":2374,"activeCount":100},[],{"trials":2376,"activeCount":100},[],{"trials":2378,"activeCount":137,"soonestReadout":2383},[2379],{"nctId":2380,"briefTitle":2381,"status":108,"phases":2382,"primaryCompletion":2383,"completion":2384,"start":2385,"enrollment":148,"conditions":2386,"interventions":2392},"NCT06881771","FECD-TRACE: Fuchs' Endothelial Corneal Dystrophy TRAjectory and Correlation With Genotype in the United Kingdom",[],"2026-02-01","2027-02-01","2024-02-01",[2387,2388,2389,2390,2391],"Fuchs Dystrophy","Fuchs' Endothelial Dystrophy","Fuchs' Endothelial Corneal Dystrophy of Bilateral Eyes","Corneal Dystrophy Fuchs","Corneal Dystrophy",[2365],{"intervention":2394,"totalTrials":137,"cells":2395},"Antiepileptic drug therapy",{"EARLY_PHASE1":2396,"PHASE1":2398,"PHASE2":2400,"PHASE3":2402,"PHASE4":2404,"NA":2416},{"trials":2397,"activeCount":100},[],{"trials":2399,"activeCount":100},[],{"trials":2401,"activeCount":100},[],{"trials":2403,"activeCount":100},[],{"trials":2405,"activeCount":100},[2406],{"nctId":2407,"briefTitle":2408,"status":1009,"phases":2409,"primaryCompletion":2410,"completion":2411,"start":2412,"enrollment":1013,"conditions":2413,"interventions":2415},"NCT02205931","Ketogenic Diet in Infants With Epilepsy (KIWE)",[91],"2018-06","2019-06","2015-01",[2414],"Epilepsy",[2394],{"trials":2417,"activeCount":100},[],{"intervention":2419,"totalTrials":137,"cells":2420},"GnRH analogue downregulation",{"EARLY_PHASE1":2421,"PHASE1":2423,"PHASE2":2425,"PHASE3":2427,"PHASE4":2429,"NA":2441},{"trials":2422,"activeCount":100},[],{"trials":2424,"activeCount":100},[],{"trials":2426,"activeCount":100},[],{"trials":2428,"activeCount":100},[],{"trials":2430,"activeCount":100},[2431],{"nctId":2432,"briefTitle":2433,"status":1009,"phases":2434,"primaryCompletion":2435,"completion":1123,"start":2436,"enrollment":2437,"conditions":2438,"interventions":2440},"NCT03946722","Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer.",[91],"2023-08-17","2020-08-17",162,[2439],"Adenomyosis",[2419],{"trials":2442,"activeCount":100},[],{"intervention":2444,"totalTrials":137,"cells":2445},"Magnesium",{"EARLY_PHASE1":2446,"PHASE1":2448,"PHASE2":2450,"PHASE3":2452,"PHASE4":2454,"NA":2468},{"trials":2447,"activeCount":100},[],{"trials":2449,"activeCount":100},[],{"trials":2451,"activeCount":100},[],{"trials":2453,"activeCount":100},[],{"trials":2455,"activeCount":100},[2456],{"nctId":2457,"briefTitle":2458,"status":1009,"phases":2459,"primaryCompletion":2460,"completion":2461,"start":2462,"enrollment":2463,"conditions":2464,"interventions":2467},"NCT05149820","Point of Care RandOmisation Systems for Performing Embedded Comparative Effectiveness Trials Of Routine Treatments",[91],"2023-02","2023-08","2022-03-22",100,[2465,2466],"Atrial Fibrillation New Onset","Magnesium Deficiency",[2444],{"trials":2469,"activeCount":100},[],{"intervention":2471,"totalTrials":137,"cells":2472},"Liraglutide Pen Injector [Saxenda]",{"EARLY_PHASE1":2473,"PHASE1":2475,"PHASE2":2477,"PHASE3":2479,"PHASE4":2481,"NA":2492},{"trials":2474,"activeCount":100},[],{"trials":2476,"activeCount":100},[],{"trials":2478,"activeCount":100},[],{"trials":2480,"activeCount":100},[],{"trials":2482,"activeCount":100},[2483],{"nctId":2484,"briefTitle":2485,"status":157,"phases":2486,"primaryCompletion":2487,"completion":2488,"start":2489,"enrollment":902,"conditions":2490,"interventions":2491},"NCT03341429","Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response",[91],"2019-11-28","2020-06-11","2018-08-22",[33],[2471],{"trials":2493,"activeCount":100},[],{"intervention":2495,"totalTrials":137,"cells":2496},"ganciclovir",{"EARLY_PHASE1":2497,"PHASE1":2499,"PHASE2":2501,"PHASE3":2503,"PHASE4":2505,"NA":2518},{"trials":2498,"activeCount":100},[],{"trials":2500,"activeCount":100},[],{"trials":2502,"activeCount":100},[],{"trials":2504,"activeCount":100},[],{"trials":2506,"activeCount":100},[2507],{"nctId":2508,"briefTitle":2509,"status":157,"phases":2510,"primaryCompletion":1224,"completion":2511,"start":2512,"enrollment":2513,"conditions":2514,"interventions":2516},"NCT00947141","Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)",[91],"2013-02","2003-02",165,[2515],"Viraemia",[2495,2517],"Stop treatment when 2 levels CMV PCR \u003C3,000 copies \u002F ml",{"trials":2519,"activeCount":100},[],{"intervention":2517,"totalTrials":137,"cells":2521},{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2530,"NA":2536},{"trials":2523,"activeCount":100},[],{"trials":2525,"activeCount":100},[],{"trials":2527,"activeCount":100},[],{"trials":2529,"activeCount":100},[],{"trials":2531,"activeCount":100},[2532],{"nctId":2508,"briefTitle":2509,"status":157,"phases":2533,"primaryCompletion":1224,"completion":2511,"start":2512,"enrollment":2513,"conditions":2534,"interventions":2535},[91],[2515],[2495,2517],{"trials":2537,"activeCount":100},[],{"intervention":2539,"totalTrials":137,"cells":2540},"Antipsychotic Reduction",{"EARLY_PHASE1":2541,"PHASE1":2543,"PHASE2":2545,"PHASE3":2547,"PHASE4":2549,"NA":2565},{"trials":2542,"activeCount":100},[],{"trials":2544,"activeCount":100},[],{"trials":2546,"activeCount":100},[],{"trials":2548,"activeCount":100},[],{"trials":2550,"activeCount":100},[2551],{"nctId":2552,"briefTitle":2553,"status":157,"phases":2554,"primaryCompletion":2555,"completion":2555,"start":2556,"enrollment":2557,"conditions":2558,"interventions":2563},"NCT03559426","Research Into Antipsychotic Discontinuation and Reduction Trial",[91],"2022-03-10","2016-03-24",253,[2559,2560,2561,2562],"Schizophrenia","Schizoaffective Disorder","Delusional Disorder","Schizophreniform Disorders",[2539,2564],"Antipsychotic Maintenance",{"trials":2566,"activeCount":100},[],{"intervention":2564,"totalTrials":137,"cells":2568},{"EARLY_PHASE1":2569,"PHASE1":2571,"PHASE2":2573,"PHASE3":2575,"PHASE4":2577,"NA":2583},{"trials":2570,"activeCount":100},[],{"trials":2572,"activeCount":100},[],{"trials":2574,"activeCount":100},[],{"trials":2576,"activeCount":100},[],{"trials":2578,"activeCount":100},[2579],{"nctId":2552,"briefTitle":2553,"status":157,"phases":2580,"primaryCompletion":2555,"completion":2555,"start":2556,"enrollment":2557,"conditions":2581,"interventions":2582},[91],[2559,2560,2561,2562],[2539,2564],{"trials":2584,"activeCount":100},[],{"intervention":2586,"totalTrials":137,"cells":2587},"Sertraline",{"EARLY_PHASE1":2588,"PHASE1":2590,"PHASE2":2592,"PHASE3":2594,"PHASE4":2596,"NA":2608},{"trials":2589,"activeCount":100},[],{"trials":2591,"activeCount":100},[],{"trials":2593,"activeCount":100},[],{"trials":2595,"activeCount":100},[],{"trials":2597,"activeCount":100},[2598],{"nctId":2599,"briefTitle":2600,"status":126,"phases":2601,"primaryCompletion":2602,"completion":2602,"start":2603,"enrollment":2604,"conditions":2605,"interventions":2607},"NCT02347033","Trial of Sertraline Versus Cognitive Behaviour Therapy for Generalised Anxiety",[91],"2016-02","2014-08",5,[2606],"Generalised Anxiety Disorder",[2586],{"trials":2609,"activeCount":100},[],{"intervention":2611,"totalTrials":137,"cells":2612},"Heliox21",{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2617,"PHASE3":2619,"PHASE4":2621,"NA":2632},{"trials":2614,"activeCount":100},[],{"trials":2616,"activeCount":100},[],{"trials":2618,"activeCount":100},[],{"trials":2620,"activeCount":100},[],{"trials":2622,"activeCount":100},[2623],{"nctId":2624,"briefTitle":2625,"status":1009,"phases":2626,"primaryCompletion":1112,"completion":1223,"start":159,"enrollment":2627,"conditions":2628,"interventions":2630},"NCT01498432","Physiological Response to Heliox21 and Air O2",[91],38,[2629],"Respiratory Insufficiency",[2611,2631],"Air O2",{"trials":2633,"activeCount":100},[],{"intervention":2631,"totalTrials":137,"cells":2635},{"EARLY_PHASE1":2636,"PHASE1":2638,"PHASE2":2640,"PHASE3":2642,"PHASE4":2644,"NA":2650},{"trials":2637,"activeCount":100},[],{"trials":2639,"activeCount":100},[],{"trials":2641,"activeCount":100},[],{"trials":2643,"activeCount":100},[],{"trials":2645,"activeCount":100},[2646],{"nctId":2624,"briefTitle":2625,"status":1009,"phases":2647,"primaryCompletion":1112,"completion":1223,"start":159,"enrollment":2627,"conditions":2648,"interventions":2649},[91],[2629],[2611,2631],{"trials":2651,"activeCount":100},[],{"intervention":1117,"totalTrials":96,"cells":2653},{"EARLY_PHASE1":2654,"PHASE1":2656,"PHASE2":2669,"PHASE3":2687,"PHASE4":2693,"NA":2695},{"trials":2655,"activeCount":100},[],{"trials":2657,"activeCount":100},[2658],{"nctId":2659,"briefTitle":2660,"status":157,"phases":2661,"primaryCompletion":2662,"completion":2663,"start":2664,"enrollment":34,"conditions":2665,"interventions":2667},"NCT02431988","Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation",[88],"2020-02-02","2022-03-21","2016-06",[2666],"Diffuse Large B-Cell Lymphoma",[1102,1117,2668],"CAR19 T-Cells",{"trials":2670,"activeCount":100},[2671,2683],{"nctId":2672,"briefTitle":2673,"status":126,"phases":2674,"primaryCompletion":2675,"completion":2675,"start":1143,"enrollment":2676,"conditions":2677,"interventions":2680},"NCT02310997","Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)",[89],"2015-05",11,[2678,27,2679],"Leukaemia","Other Haematological Diseases",[1102,2681,2682,1117],"Busulfan","Melphalan",{"nctId":1107,"briefTitle":1108,"status":157,"phases":2684,"primaryCompletion":1110,"completion":1111,"start":1112,"enrollment":1044,"conditions":2685,"interventions":2686},[89],[1114],[1116,1102,1028,1117],{"trials":2688,"activeCount":100},[2689],{"nctId":1161,"briefTitle":1162,"status":157,"phases":2690,"primaryCompletion":1164,"completion":1165,"start":1166,"enrollment":1167,"conditions":2691,"interventions":2692},[89,90],[27],[1148,1102,1117],{"trials":2694,"activeCount":100},[],{"trials":2696,"activeCount":100},[],{"intervention":600,"totalTrials":96,"cells":2698},{"EARLY_PHASE1":2699,"PHASE1":2701,"PHASE2":2703,"PHASE3":2722,"PHASE4":2728,"NA":2730},{"trials":2700,"activeCount":100},[],{"trials":2702,"activeCount":100},[],{"trials":2704,"activeCount":100},[2705,2714,2718],{"nctId":2706,"briefTitle":2707,"status":157,"phases":2708,"primaryCompletion":473,"completion":473,"start":2709,"enrollment":2710,"conditions":2711,"interventions":2713},"NCT00666484","Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma",[89],"2008-03",47,[27,2712],"Neurotoxicity",[596,598,599,600,601,603],{"nctId":1092,"briefTitle":1093,"status":157,"phases":2715,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":1098,"conditions":2716,"interventions":2717},[89],[1100],[1102,1103,1104,1028,1105,134],{"nctId":1140,"briefTitle":1141,"status":157,"phases":2719,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":1145,"conditions":2720,"interventions":2721},[89],[27],[1148,596,464,600,603],{"trials":2723,"activeCount":100},[2724],{"nctId":584,"briefTitle":585,"status":157,"phases":2725,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":2726,"interventions":2727},[90],[27],[593,594,595,596,597,598,599,600,601,602,603],{"trials":2729,"activeCount":100},[],{"trials":2731,"activeCount":100},[],{"intervention":134,"totalTrials":96,"cells":2733},{"EARLY_PHASE1":2734,"PHASE1":2736,"PHASE2":2742,"PHASE3":2752,"PHASE4":2758,"NA":2760},{"trials":2735,"activeCount":100},[],{"trials":2737,"activeCount":100},[2738],{"nctId":417,"briefTitle":418,"status":157,"phases":2739,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":2740,"interventions":2741},[88],[425,426,427],[429,430,166],{"trials":2743,"activeCount":100},[2744,2748],{"nctId":1092,"briefTitle":1093,"status":157,"phases":2745,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":1098,"conditions":2746,"interventions":2747},[89],[1100],[1102,1103,1104,1028,1105,134],{"nctId":124,"briefTitle":125,"status":126,"phases":2749,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":2750,"interventions":2751},[89],[132],[134,95,135,136],{"trials":2753,"activeCount":100},[2754],{"nctId":470,"briefTitle":471,"status":157,"phases":2755,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":2756,"interventions":2757},[89,90],[425],[430,166,166,479,430],{"trials":2759,"activeCount":100},[],{"trials":2761,"activeCount":100},[],{"intervention":464,"totalTrials":175,"cells":2763},{"EARLY_PHASE1":2764,"PHASE1":2766,"PHASE2":2768,"PHASE3":2782,"PHASE4":2788,"NA":2790},{"trials":2765,"activeCount":100},[],{"trials":2767,"activeCount":100},[],{"trials":2769,"activeCount":100},[2770,2778],{"nctId":2771,"briefTitle":2772,"status":157,"phases":2773,"primaryCompletion":2774,"completion":540,"start":2709,"enrollment":356,"conditions":2775,"interventions":2776},"NCT00660231","Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma",[89],"2011-09",[27],[2777,464],"bexarotene",{"nctId":1140,"briefTitle":1141,"status":157,"phases":2779,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":1145,"conditions":2780,"interventions":2781},[89],[27],[1148,596,464,600,603],{"trials":2783,"activeCount":100},[2784],{"nctId":454,"briefTitle":455,"status":157,"phases":2785,"primaryCompletion":457,"start":458,"enrollment":459,"conditions":2786,"interventions":2787},[90],[461,462],[166,464],{"trials":2789,"activeCount":100},[],{"trials":2791,"activeCount":100},[],{"intervention":415,"totalTrials":175,"cells":2793},{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2806,"PHASE3":2808,"PHASE4":2819,"NA":2821},{"trials":2795,"activeCount":100},[],{"trials":2797,"activeCount":100},[2798,2802],{"nctId":406,"briefTitle":407,"status":157,"phases":2799,"primaryCompletion":409,"completion":410,"start":411,"enrollment":25,"conditions":2800,"interventions":2801},[88],[413],[415,153],{"nctId":432,"briefTitle":433,"status":434,"phases":2803,"enrollment":100,"conditions":2804,"interventions":2805},[88],[437],[439,166],{"trials":2807,"activeCount":100},[],{"trials":2809,"activeCount":100},[2810],{"nctId":2811,"briefTitle":2812,"status":1009,"phases":2813,"primaryCompletion":2814,"completion":2814,"start":2815,"enrollment":626,"conditions":2816,"interventions":2817},"NCT03278717","Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients",[90],"2023-12","2018-06-15",[115],[415,2818],"Cediranib",{"trials":2820,"activeCount":100},[],{"trials":2822,"activeCount":100},[],{"intervention":2824,"totalTrials":175,"cells":2825},"Simvastatin",{"EARLY_PHASE1":2826,"PHASE1":2828,"PHASE2":2830,"PHASE3":2841,"PHASE4":2863,"NA":2865},{"trials":2827,"activeCount":100},[],{"trials":2829,"activeCount":100},[],{"trials":2831,"activeCount":100},[2832],{"nctId":2833,"briefTitle":2834,"status":157,"phases":2835,"primaryCompletion":2836,"completion":2837,"start":994,"enrollment":1154,"conditions":2838,"interventions":2840},"NCT03896217","Simvastatin in Secondary Progressive Multiple Sclerosis",[89],"2022-09-13","2023-06-15",[2839],"Secondary Progressive Multiple Sclerosis",[2824],{"trials":2842,"activeCount":100},[2843,2852],{"nctId":2844,"briefTitle":2845,"status":1009,"phases":2846,"primaryCompletion":2847,"completion":2848,"start":411,"enrollment":1124,"conditions":2849,"interventions":2851},"NCT02252328","Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients",[89,90],"2018-08","2019-08",[2850],"Uveitis",[2824],{"nctId":2853,"briefTitle":2854,"status":157,"phases":2855,"primaryCompletion":2856,"completion":2857,"start":2858,"enrollment":2859,"conditions":2860,"interventions":2862},"NCT03387670","Multiple Sclerosis-Simvastatin Trial 2",[90],"2024-07-26","2024-08-25","2018-03-28",964,[2861],"Secondary Progressive Multiple Sclerosis (SPMS)",[2824],{"trials":2864,"activeCount":100},[],{"trials":2866,"activeCount":100},[],{"intervention":598,"totalTrials":366,"cells":2868},{"EARLY_PHASE1":2869,"PHASE1":2871,"PHASE2":2873,"PHASE3":2879,"PHASE4":2885,"NA":2887},{"trials":2870,"activeCount":100},[],{"trials":2872,"activeCount":100},[],{"trials":2874,"activeCount":100},[2875],{"nctId":2706,"briefTitle":2707,"status":157,"phases":2876,"primaryCompletion":473,"completion":473,"start":2709,"enrollment":2710,"conditions":2877,"interventions":2878},[89],[27,2712],[596,598,599,600,601,603],{"trials":2880,"activeCount":100},[2881],{"nctId":584,"briefTitle":585,"status":157,"phases":2882,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":2883,"interventions":2884},[90],[27],[593,594,595,596,597,598,599,600,601,602,603],{"trials":2886,"activeCount":100},[],{"trials":2888,"activeCount":100},[],{"intervention":601,"totalTrials":366,"cells":2890},{"EARLY_PHASE1":2891,"PHASE1":2893,"PHASE2":2895,"PHASE3":2901,"PHASE4":2907,"NA":2909},{"trials":2892,"activeCount":100},[],{"trials":2894,"activeCount":100},[],{"trials":2896,"activeCount":100},[2897],{"nctId":2706,"briefTitle":2707,"status":157,"phases":2898,"primaryCompletion":473,"completion":473,"start":2709,"enrollment":2710,"conditions":2899,"interventions":2900},[89],[27,2712],[596,598,599,600,601,603],{"trials":2902,"activeCount":100},[2903],{"nctId":584,"briefTitle":585,"status":157,"phases":2904,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":2905,"interventions":2906},[90],[27],[593,594,595,596,597,598,599,600,601,602,603],{"trials":2908,"activeCount":100},[],{"trials":2910,"activeCount":100},[],{"intervention":547,"totalTrials":366,"cells":2912},{"EARLY_PHASE1":2913,"PHASE1":2915,"PHASE2":2917,"PHASE3":2919,"PHASE4":2935,"NA":2937},{"trials":2914,"activeCount":100},[],{"trials":2916,"activeCount":100},[],{"trials":2918,"activeCount":100},[],{"trials":2920,"activeCount":100},[2921,2925],{"nctId":536,"briefTitle":537,"status":157,"phases":2922,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":2923,"interventions":2924},[89,90],[115,117,544],[152,546,547],{"nctId":2926,"briefTitle":2927,"status":157,"phases":2928,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":2931,"conditions":2932,"interventions":2933},"NCT00275132","Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",[90],"2009-04","2005-04",670,[30],[2934,547],"erlotinib hydrochloride",{"trials":2936,"activeCount":100},[],{"trials":2938,"activeCount":100},[],{"intervention":479,"totalTrials":366,"cells":2940},{"EARLY_PHASE1":2941,"PHASE1":2943,"PHASE2":2945,"PHASE3":2947,"PHASE4":2957,"NA":2959},{"trials":2942,"activeCount":100},[],{"trials":2944,"activeCount":100},[],{"trials":2946,"activeCount":100},[],{"trials":2948,"activeCount":100},[2949,2953],{"nctId":470,"briefTitle":471,"status":157,"phases":2950,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":2951,"interventions":2952},[89,90],[425],[430,166,166,479,430],{"nctId":2811,"briefTitle":2812,"status":1009,"phases":2954,"primaryCompletion":2814,"completion":2814,"start":2815,"enrollment":626,"conditions":2955,"interventions":2956},[90],[115],[415,2818],{"trials":2958,"activeCount":100},[],{"trials":2960,"activeCount":100},[],{"intervention":2934,"totalTrials":366,"cells":2962},{"EARLY_PHASE1":2963,"PHASE1":2965,"PHASE2":2967,"PHASE3":2978,"PHASE4":2984,"NA":2986},{"trials":2964,"activeCount":100},[],{"trials":2966,"activeCount":100},[],{"trials":2968,"activeCount":100},[2969],{"nctId":2970,"briefTitle":2971,"status":126,"phases":2972,"primaryCompletion":2973,"completion":2973,"start":2974,"enrollment":113,"conditions":2975,"interventions":2977},"NCT00554775","WBRT & Erlotinib in Advanced NSCLC and Brain Metastases",[89],"2010-11","2008-01",[30,2976],"Metastatic Cancer",[2934],{"trials":2979,"activeCount":100},[2980],{"nctId":2926,"briefTitle":2927,"status":157,"phases":2981,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":2931,"conditions":2982,"interventions":2983},[90],[30],[2934,547],{"trials":2985,"activeCount":100},[],{"trials":2987,"activeCount":100},[],{"intervention":2989,"totalTrials":137,"cells":2990},"Nortriptyline",{"EARLY_PHASE1":2991,"PHASE1":2993,"PHASE2":2995,"PHASE3":2997,"PHASE4":3011,"NA":3013},{"trials":2992,"activeCount":100},[],{"trials":2994,"activeCount":100},[],{"trials":2996,"activeCount":100},[],{"trials":2998,"activeCount":100},[2999],{"nctId":3000,"briefTitle":3001,"status":157,"phases":3002,"primaryCompletion":3003,"completion":3004,"start":3005,"enrollment":3006,"conditions":3007,"interventions":3009},"NCT03652870","Antidepressants Trial in Parkinson's Disease",[90],"2023-01-23","2023-04-30","2021-03-05",52,[3008,628],"Depression",[2989,3010],"Escitalopram",{"trials":3012,"activeCount":100},[],{"trials":3014,"activeCount":100},[],{"intervention":3010,"totalTrials":137,"cells":3016},{"EARLY_PHASE1":3017,"PHASE1":3019,"PHASE2":3021,"PHASE3":3023,"PHASE4":3029,"NA":3031},{"trials":3018,"activeCount":100},[],{"trials":3020,"activeCount":100},[],{"trials":3022,"activeCount":100},[],{"trials":3024,"activeCount":100},[3025],{"nctId":3000,"briefTitle":3001,"status":157,"phases":3026,"primaryCompletion":3003,"completion":3004,"start":3005,"enrollment":3006,"conditions":3027,"interventions":3028},[90],[3008,628],[2989,3010],{"trials":3030,"activeCount":100},[],{"trials":3032,"activeCount":100},[],{"intervention":3034,"totalTrials":137,"cells":3035},"doxorubicin-eluting beads",{"EARLY_PHASE1":3036,"PHASE1":3038,"PHASE2":3040,"PHASE3":3042,"PHASE4":3054,"NA":3056},{"trials":3037,"activeCount":100},[],{"trials":3039,"activeCount":100},[],{"trials":3041,"activeCount":100},[],{"trials":3043,"activeCount":100},[3044],{"nctId":3045,"briefTitle":3046,"status":1009,"phases":3047,"primaryCompletion":3048,"start":2973,"enrollment":3049,"conditions":3050,"interventions":3052},"NCT01324076","Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery",[90],"2014-11",412,[3051],"Liver Cancer",[3034,3053],"sorafenib tosylate",{"trials":3055,"activeCount":100},[],{"trials":3057,"activeCount":100},[],{"intervention":3053,"totalTrials":137,"cells":3059},{"EARLY_PHASE1":3060,"PHASE1":3062,"PHASE2":3064,"PHASE3":3066,"PHASE4":3072,"NA":3074},{"trials":3061,"activeCount":100},[],{"trials":3063,"activeCount":100},[],{"trials":3065,"activeCount":100},[],{"trials":3067,"activeCount":100},[3068],{"nctId":3045,"briefTitle":3046,"status":1009,"phases":3069,"primaryCompletion":3048,"start":2973,"enrollment":3049,"conditions":3070,"interventions":3071},[90],[3051],[3034,3053],{"trials":3073,"activeCount":100},[],{"trials":3075,"activeCount":100},[],{"intervention":3077,"totalTrials":137,"cells":3078},"bicalutamide",{"EARLY_PHASE1":3079,"PHASE1":3081,"PHASE2":3083,"PHASE3":3085,"PHASE4":3101,"NA":3103},{"trials":3080,"activeCount":100},[],{"trials":3082,"activeCount":100},[],{"trials":3084,"activeCount":100},[],{"trials":3086,"activeCount":100},[3087],{"nctId":3088,"briefTitle":3089,"status":157,"phases":3090,"primaryCompletion":3091,"completion":3091,"start":3092,"enrollment":3093,"conditions":3094,"interventions":3098},"NCT00541047","RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery",[90],"2022-07-27","2007-11",4236,[3095,18,3096,3097],"Gastrointestinal Complications","Sexual Dysfunction","Urinary Complications",[3077,3099,3100],"goserelin acetate","leuprolide acetate",{"trials":3102,"activeCount":100},[],{"trials":3104,"activeCount":100},[],{"intervention":3099,"totalTrials":137,"cells":3106},{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3113,"PHASE4":3119,"NA":3121},{"trials":3108,"activeCount":100},[],{"trials":3110,"activeCount":100},[],{"trials":3112,"activeCount":100},[],{"trials":3114,"activeCount":100},[3115],{"nctId":3088,"briefTitle":3089,"status":157,"phases":3116,"primaryCompletion":3091,"completion":3091,"start":3092,"enrollment":3093,"conditions":3117,"interventions":3118},[90],[3095,18,3096,3097],[3077,3099,3100],{"trials":3120,"activeCount":100},[],{"trials":3122,"activeCount":100},[],{"intervention":3100,"totalTrials":137,"cells":3124},{"EARLY_PHASE1":3125,"PHASE1":3127,"PHASE2":3129,"PHASE3":3131,"PHASE4":3137,"NA":3139},{"trials":3126,"activeCount":100},[],{"trials":3128,"activeCount":100},[],{"trials":3130,"activeCount":100},[],{"trials":3132,"activeCount":100},[3133],{"nctId":3088,"briefTitle":3089,"status":157,"phases":3134,"primaryCompletion":3091,"completion":3091,"start":3092,"enrollment":3093,"conditions":3135,"interventions":3136},[90],[3095,18,3096,3097],[3077,3099,3100],{"trials":3138,"activeCount":100},[],{"trials":3140,"activeCount":100},[],{"intervention":546,"totalTrials":137,"cells":3142},{"EARLY_PHASE1":3143,"PHASE1":3145,"PHASE2":3147,"PHASE3":3149,"PHASE4":3155,"NA":3157},{"trials":3144,"activeCount":100},[],{"trials":3146,"activeCount":100},[],{"trials":3148,"activeCount":100},[],{"trials":3150,"activeCount":100},[3151],{"nctId":536,"briefTitle":537,"status":157,"phases":3152,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":3153,"interventions":3154},[89,90],[115,117,544],[152,546,547],{"trials":3156,"activeCount":100},[],{"trials":3158,"activeCount":100},[],{"intervention":3160,"totalTrials":137,"cells":3161},"Carboplatin, etoposide & thalidomide",{"EARLY_PHASE1":3162,"PHASE1":3164,"PHASE2":3166,"PHASE3":3168,"PHASE4":3181,"NA":3183},{"trials":3163,"activeCount":100},[],{"trials":3165,"activeCount":100},[],{"trials":3167,"activeCount":100},[],{"trials":3169,"activeCount":100},[3170],{"nctId":3171,"briefTitle":3172,"status":157,"phases":3173,"primaryCompletion":3174,"completion":3175,"start":3176,"enrollment":3177,"conditions":3178,"interventions":3179},"NCT00061919","Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer",[90],"2007-02","2007-07","2003-04",724,[30],[3160,3180],"Carboplatin, etoposide & placebo",{"trials":3182,"activeCount":100},[],{"trials":3184,"activeCount":100},[],{"intervention":3180,"totalTrials":137,"cells":3186},{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3193,"PHASE4":3199,"NA":3201},{"trials":3188,"activeCount":100},[],{"trials":3190,"activeCount":100},[],{"trials":3192,"activeCount":100},[],{"trials":3194,"activeCount":100},[3195],{"nctId":3171,"briefTitle":3172,"status":157,"phases":3196,"primaryCompletion":3174,"completion":3175,"start":3176,"enrollment":3177,"conditions":3197,"interventions":3198},[90],[30],[3160,3180],{"trials":3200,"activeCount":100},[],{"trials":3202,"activeCount":100},[],{"intervention":3204,"totalTrials":137,"cells":3205},"Control arm (SEQ):",{"EARLY_PHASE1":3206,"PHASE1":3208,"PHASE2":3210,"PHASE3":3212,"PHASE4":3224,"NA":3226},{"trials":3207,"activeCount":100},[],{"trials":3209,"activeCount":100},[],{"trials":3211,"activeCount":100},[],{"trials":3213,"activeCount":100},[3214],{"nctId":3215,"briefTitle":3216,"status":157,"phases":3217,"primaryCompletion":3218,"completion":422,"start":3219,"enrollment":3220,"conditions":3221,"interventions":3222},"NCT00309972","Cisplatin, Vinorelbine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery",[90],"2011-02","2005-12",130,[30],[3204,3223],"Experimental arm (CON):",{"trials":3225,"activeCount":100},[],{"trials":3227,"activeCount":100},[],{"intervention":3223,"totalTrials":137,"cells":3229},{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3236,"PHASE4":3242,"NA":3244},{"trials":3231,"activeCount":100},[],{"trials":3233,"activeCount":100},[],{"trials":3235,"activeCount":100},[],{"trials":3237,"activeCount":100},[3238],{"nctId":3215,"briefTitle":3216,"status":157,"phases":3239,"primaryCompletion":3218,"completion":422,"start":3219,"enrollment":3220,"conditions":3240,"interventions":3241},[90],[30],[3204,3223],{"trials":3243,"activeCount":100},[],{"trials":3245,"activeCount":100},[],{"intervention":3247,"totalTrials":137,"cells":3248},"Mexiletine",{"EARLY_PHASE1":3249,"PHASE1":3251,"PHASE2":3253,"PHASE3":3255,"PHASE4":3267,"NA":3269},{"trials":3250,"activeCount":100},[],{"trials":3252,"activeCount":100},[],{"trials":3254,"activeCount":100},[],{"trials":3256,"activeCount":100},[3257],{"nctId":3258,"briefTitle":3259,"status":1009,"phases":3260,"primaryCompletion":2461,"completion":3261,"start":3262,"enrollment":1044,"conditions":3263,"interventions":3265},"NCT05017155","MExiletine Versus Lamotrigine in Non-Dystrophic Myotonias",[90],"2024-04-02","2021-08-12",[3264],"Non-Dystrophic Myotonia",[3247,3266],"Lamotrigine 25Mg Oral Tablet, Extended Release",{"trials":3268,"activeCount":100},[],{"trials":3270,"activeCount":100},[],{"intervention":3266,"totalTrials":137,"cells":3272},{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3277,"PHASE3":3279,"PHASE4":3285,"NA":3287},{"trials":3274,"activeCount":100},[],{"trials":3276,"activeCount":100},[],{"trials":3278,"activeCount":100},[],{"trials":3280,"activeCount":100},[3281],{"nctId":3258,"briefTitle":3259,"status":1009,"phases":3282,"primaryCompletion":2461,"completion":3261,"start":3262,"enrollment":1044,"conditions":3283,"interventions":3284},[90],[3264],[3247,3266],{"trials":3286,"activeCount":100},[],{"trials":3288,"activeCount":100},[],{"intervention":3290,"totalTrials":137,"cells":3291},"Exenatide extended release 2mg",{"EARLY_PHASE1":3292,"PHASE1":3294,"PHASE2":3296,"PHASE3":3298,"PHASE4":3311,"NA":3313},{"trials":3293,"activeCount":100},[],{"trials":3295,"activeCount":100},[],{"trials":3297,"activeCount":100},[],{"trials":3299,"activeCount":100},[3300],{"nctId":3301,"briefTitle":3302,"status":157,"phases":3303,"primaryCompletion":3304,"completion":3305,"start":3306,"enrollment":3307,"conditions":3308,"interventions":3310},"NCT04232969","Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease",[90],"2024-02-24","2024-07-31","2020-01-20",194,[3309],"Parkinson's Disease",[3290],{"trials":3312,"activeCount":100},[],{"trials":3314,"activeCount":100},[],{"intervention":3316,"totalTrials":137,"cells":3317},"recombinant thyroid-stimulating hormone",{"EARLY_PHASE1":3318,"PHASE1":3320,"PHASE2":3322,"PHASE3":3324,"PHASE4":3335,"NA":3337},{"trials":3319,"activeCount":100},[],{"trials":3321,"activeCount":100},[],{"trials":3323,"activeCount":100},[],{"trials":3325,"activeCount":100},[3326],{"nctId":3327,"briefTitle":3328,"status":1009,"phases":3329,"primaryCompletion":3330,"completion":3331,"start":3332,"enrollment":12,"conditions":3333,"interventions":3334},"NCT00415233","High Dose vs Low Dose I 131 +\u002F- rhTSH for Differentiated Thyroid Cancer",[90],"2011-06","2025-07","2006-11",[413],[3316],{"trials":3336,"activeCount":100},[],{"trials":3338,"activeCount":100},[],{"intervention":3340,"totalTrials":137,"cells":3341},"Cabotegravir, Rilpivirine Drug Combination",{"EARLY_PHASE1":3342,"PHASE1":3344,"PHASE2":3346,"PHASE3":3348,"PHASE4":3363,"NA":3365},{"trials":3343,"activeCount":100},[],{"trials":3345,"activeCount":100},[],{"trials":3347,"activeCount":100},[],{"trials":3349,"activeCount":100},[3350],{"nctId":3351,"briefTitle":3352,"status":1009,"phases":3353,"primaryCompletion":80,"completion":1771,"start":3354,"enrollment":3355,"conditions":3356,"interventions":3361},"NCT05154747","Long-Acting Treatment in Adolescents (LATA)",[90],"2023-06-22",476,[3357,3358,3359,3360],"Hiv","HIV Infections","HIV-1-infection","Paediatric Human Immunodeficiency Virus Infection",[3340,3362],"TLD",{"trials":3364,"activeCount":100},[],{"trials":3366,"activeCount":100},[],{"intervention":3362,"totalTrials":137,"cells":3368},{"EARLY_PHASE1":3369,"PHASE1":3371,"PHASE2":3373,"PHASE3":3375,"PHASE4":3381,"NA":3383},{"trials":3370,"activeCount":100},[],{"trials":3372,"activeCount":100},[],{"trials":3374,"activeCount":100},[],{"trials":3376,"activeCount":100},[3377],{"nctId":3351,"briefTitle":3352,"status":1009,"phases":3378,"primaryCompletion":80,"completion":1771,"start":3354,"enrollment":3355,"conditions":3379,"interventions":3380},[90],[3357,3358,3359,3360],[3340,3362],{"trials":3382,"activeCount":100},[],{"trials":3384,"activeCount":100},[],{"intervention":3386,"totalTrials":137,"cells":3387},"Ferric carboxymaltose",{"EARLY_PHASE1":3388,"PHASE1":3390,"PHASE2":3392,"PHASE3":3394,"PHASE4":3406,"NA":3408},{"trials":3389,"activeCount":100},[],{"trials":3391,"activeCount":100},[],{"trials":3393,"activeCount":100},[],{"trials":3395,"activeCount":100},[3396],{"nctId":3397,"briefTitle":3398,"status":157,"phases":3399,"primaryCompletion":3400,"completion":3400,"start":540,"enrollment":3401,"conditions":3402,"interventions":3404},"NCT01692418","Preoperative Intravenous Iron to Treat Anaemia in Major Surgery",[90],"2019-05",487,[3403],"Anaemia",[3386,3405],"Normal saline",{"trials":3407,"activeCount":100},[],{"trials":3409,"activeCount":100},[],{"intervention":3405,"totalTrials":137,"cells":3411},{"EARLY_PHASE1":3412,"PHASE1":3414,"PHASE2":3416,"PHASE3":3418,"PHASE4":3424,"NA":3426},{"trials":3413,"activeCount":100},[],{"trials":3415,"activeCount":100},[],{"trials":3417,"activeCount":100},[],{"trials":3419,"activeCount":100},[3420],{"nctId":3397,"briefTitle":3398,"status":157,"phases":3421,"primaryCompletion":3400,"completion":3400,"start":540,"enrollment":3401,"conditions":3422,"interventions":3423},[90],[3403],[3386,3405],{"trials":3425,"activeCount":100},[],{"trials":3427,"activeCount":100},[],{"intervention":1229,"totalTrials":137,"cells":3429},{"EARLY_PHASE1":3430,"PHASE1":3432,"PHASE2":3434,"PHASE3":3436,"PHASE4":3442,"NA":3444},{"trials":3431,"activeCount":100},[],{"trials":3433,"activeCount":100},[],{"trials":3435,"activeCount":100},[],{"trials":3437,"activeCount":100},[3438],{"nctId":1220,"briefTitle":1221,"status":1009,"phases":3439,"primaryCompletion":1112,"completion":1223,"start":1224,"enrollment":1225,"conditions":3440,"interventions":3441},[90],[1227],[199,1229,1230],{"trials":3443,"activeCount":100},[],{"trials":3445,"activeCount":100},[],{"intervention":1230,"totalTrials":137,"cells":3447},{"EARLY_PHASE1":3448,"PHASE1":3450,"PHASE2":3452,"PHASE3":3454,"PHASE4":3460,"NA":3462},{"trials":3449,"activeCount":100},[],{"trials":3451,"activeCount":100},[],{"trials":3453,"activeCount":100},[],{"trials":3455,"activeCount":100},[3456],{"nctId":1220,"briefTitle":1221,"status":1009,"phases":3457,"primaryCompletion":1112,"completion":1223,"start":1224,"enrollment":1225,"conditions":3458,"interventions":3459},[90],[1227],[199,1229,1230],{"trials":3461,"activeCount":100},[],{"trials":3463,"activeCount":100},[],{"intervention":3465,"totalTrials":137,"cells":3466},"Mineralocorticoid receptor antagonist potassium-canrenoate",{"EARLY_PHASE1":3467,"PHASE1":3469,"PHASE2":3471,"PHASE3":3473,"PHASE4":3483,"NA":3485},{"trials":3468,"activeCount":100},[],{"trials":3470,"activeCount":100},[],{"trials":3472,"activeCount":100},[],{"trials":3474,"activeCount":100},[3475],{"nctId":3476,"briefTitle":3477,"status":157,"phases":3478,"primaryCompletion":421,"completion":421,"start":160,"enrollment":3479,"conditions":3480,"interventions":3482},"NCT01882179","Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size",[90],61,[3481],"ST-elevation Myocardial Infarction",[3465],{"trials":3484,"activeCount":100},[],{"trials":3486,"activeCount":100},[],{"intervention":3488,"totalTrials":137,"cells":3489},"porfimer sodium",{"EARLY_PHASE1":3490,"PHASE1":3492,"PHASE2":3494,"PHASE3":3496,"PHASE4":3506,"NA":3508},{"trials":3491,"activeCount":100},[],{"trials":3493,"activeCount":100},[],{"trials":3495,"activeCount":100},[],{"trials":3497,"activeCount":100},[3498],{"nctId":3499,"briefTitle":3500,"status":157,"phases":3501,"primaryCompletion":3502,"start":3175,"enrollment":3503,"conditions":3504,"interventions":3505},"NCT00513539","Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery",[90],"2009-12",92,[461,462],[3488],{"trials":3507,"activeCount":100},[],{"trials":3509,"activeCount":100},[],{"intervention":3511,"totalTrials":137,"cells":3512},"Cisplatin, Paclitaxel",{"EARLY_PHASE1":3513,"PHASE1":3515,"PHASE2":3517,"PHASE3":3519,"PHASE4":3530,"NA":3532},{"trials":3514,"activeCount":100},[],{"trials":3516,"activeCount":100},[],{"trials":3518,"activeCount":100},[],{"trials":3520,"activeCount":100},[3521],{"nctId":3522,"briefTitle":3523,"status":126,"phases":3524,"primaryCompletion":3525,"start":3526,"enrollment":3527,"conditions":3528,"interventions":3529},"NCT00801736","ERCC1 Targeted Trial",[90],"2013-07","2009-10",648,[30],[3511],{"trials":3531,"activeCount":100},[],{"trials":3533,"activeCount":100},[],{"intervention":3535,"totalTrials":137,"cells":3536},"Maraviroc",{"EARLY_PHASE1":3537,"PHASE1":3539,"PHASE2":3541,"PHASE3":3543,"PHASE4":3557,"NA":3559},{"trials":3538,"activeCount":100},[],{"trials":3540,"activeCount":100},[],{"trials":3542,"activeCount":100},[],{"trials":3544,"activeCount":100},[3545],{"nctId":3546,"briefTitle":3547,"status":157,"phases":3548,"primaryCompletion":3549,"completion":3550,"start":3551,"enrollment":3552,"conditions":3553,"interventions":3555},"NCT03129113","Adding MAraViroc &\u002For METformin for Hepatic Steatosis in People Living With HIV",[89,90],"2020-11-05","2020-11-06","2017-03-01",90,[3554,3359],"Hepatic Steatosis",[3535,3556],"Metformin",{"trials":3558,"activeCount":100},[],{"trials":3560,"activeCount":100},[],{"intervention":3556,"totalTrials":137,"cells":3562},{"EARLY_PHASE1":3563,"PHASE1":3565,"PHASE2":3567,"PHASE3":3569,"PHASE4":3575,"NA":3577},{"trials":3564,"activeCount":100},[],{"trials":3566,"activeCount":100},[],{"trials":3568,"activeCount":100},[],{"trials":3570,"activeCount":100},[3571],{"nctId":3546,"briefTitle":3547,"status":157,"phases":3572,"primaryCompletion":3549,"completion":3550,"start":3551,"enrollment":3552,"conditions":3573,"interventions":3574},[89,90],[3554,3359],[3535,3556],{"trials":3576,"activeCount":100},[],{"trials":3578,"activeCount":100},[],{"intervention":3580,"totalTrials":137,"cells":3581},"IV Normal saline",{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3586,"PHASE3":3588,"PHASE4":3600,"NA":3602},{"trials":3583,"activeCount":100},[],{"trials":3585,"activeCount":100},[],{"trials":3587,"activeCount":100},[],{"trials":3589,"activeCount":100},[3590],{"nctId":3591,"briefTitle":3592,"status":157,"phases":3593,"primaryCompletion":3594,"completion":3595,"start":540,"enrollment":1953,"conditions":3596,"interventions":3598},"NCT01864252","Investigation Into the Role of GTN & RIPC in Cardiac Surgery",[90],"2018-10","2019-02",[3597],"Myocardial Reperfusion Injury",[3580,3599],"IV Glyceryl trinitrate 2-5ml\u002Fh",{"trials":3601,"activeCount":100},[],{"trials":3603,"activeCount":100},[],{"intervention":3599,"totalTrials":137,"cells":3605},{"EARLY_PHASE1":3606,"PHASE1":3608,"PHASE2":3610,"PHASE3":3612,"PHASE4":3618,"NA":3620},{"trials":3607,"activeCount":100},[],{"trials":3609,"activeCount":100},[],{"trials":3611,"activeCount":100},[],{"trials":3613,"activeCount":100},[3614],{"nctId":3591,"briefTitle":3592,"status":157,"phases":3615,"primaryCompletion":3594,"completion":3595,"start":540,"enrollment":1953,"conditions":3616,"interventions":3617},[90],[3597],[3580,3599],{"trials":3619,"activeCount":100},[],{"trials":3621,"activeCount":100},[],{"intervention":3623,"totalTrials":137,"cells":3624},"Co-Trimoxazole 960Mg Dispersible",{"EARLY_PHASE1":3625,"PHASE1":3627,"PHASE2":3629,"PHASE3":3631,"PHASE4":3643,"NA":3645},{"trials":3626,"activeCount":100},[],{"trials":3628,"activeCount":100},[],{"trials":3630,"activeCount":100},[],{"trials":3632,"activeCount":100},[3633],{"nctId":3634,"briefTitle":3635,"status":1009,"phases":3636,"primaryCompletion":3637,"completion":3637,"start":3638,"enrollment":3639,"conditions":3640,"interventions":3642},"NCT04395365","Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis",[90],"2025-10","2019-06-30",442,[3641],"Spontaneous Bacterial Peritonitis",[3623],{"trials":3644,"activeCount":100},[],{"trials":3646,"activeCount":100},[],{"intervention":167,"totalTrials":137,"cells":3648},{"EARLY_PHASE1":3649,"PHASE1":3651,"PHASE2":3653,"PHASE3":3655,"PHASE4":3661,"NA":3663},{"trials":3650,"activeCount":100},[],{"trials":3652,"activeCount":100},[],{"trials":3654,"activeCount":100},[],{"trials":3656,"activeCount":100},[3657],{"nctId":155,"briefTitle":156,"status":157,"phases":3658,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":3659,"interventions":3660},[90],[30],[165,166,167,168],{"trials":3662,"activeCount":100},[],{"trials":3664,"activeCount":100},[],{"intervention":168,"totalTrials":137,"cells":3666},{"EARLY_PHASE1":3667,"PHASE1":3669,"PHASE2":3671,"PHASE3":3673,"PHASE4":3679,"NA":3681},{"trials":3668,"activeCount":100},[],{"trials":3670,"activeCount":100},[],{"trials":3672,"activeCount":100},[],{"trials":3674,"activeCount":100},[3675],{"nctId":155,"briefTitle":156,"status":157,"phases":3676,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":3677,"interventions":3678},[90],[30],[165,166,167,168],{"trials":3680,"activeCount":100},[],{"trials":3682,"activeCount":100},[],{"intervention":3684,"totalTrials":137,"cells":3685},"Goserelin",{"EARLY_PHASE1":3686,"PHASE1":3688,"PHASE2":3690,"PHASE3":3692,"PHASE4":3707,"NA":3709},{"trials":3687,"activeCount":100},[],{"trials":3689,"activeCount":100},[],{"trials":3691,"activeCount":100},[],{"trials":3693,"activeCount":100},[3694],{"nctId":3695,"briefTitle":3696,"status":1009,"phases":3697,"primaryCompletion":3698,"completion":3698,"start":1144,"enrollment":3699,"conditions":3700,"interventions":3705},"NCT00303784","Prostate Adenocarcinoma TransCutaneous Hormones",[90],"2021-08",2200,[3701,3702,3703,3704,18],"Anemia","Cardiovascular Complications","Hot Flashes","Osteoporosis",[3684,3706],"Estradiol",{"trials":3708,"activeCount":100},[],{"trials":3710,"activeCount":100},[],{"intervention":3706,"totalTrials":137,"cells":3712},{"EARLY_PHASE1":3713,"PHASE1":3715,"PHASE2":3717,"PHASE3":3719,"PHASE4":3725,"NA":3727},{"trials":3714,"activeCount":100},[],{"trials":3716,"activeCount":100},[],{"trials":3718,"activeCount":100},[],{"trials":3720,"activeCount":100},[3721],{"nctId":3695,"briefTitle":3696,"status":1009,"phases":3722,"primaryCompletion":3698,"completion":3698,"start":1144,"enrollment":3699,"conditions":3723,"interventions":3724},[90],[3701,3702,3703,3704,18],[3684,3706],{"trials":3726,"activeCount":100},[],{"trials":3728,"activeCount":100},[],{"intervention":230,"totalTrials":137,"cells":3730},{"EARLY_PHASE1":3731,"PHASE1":3733,"PHASE2":3735,"PHASE3":3737,"PHASE4":3743,"NA":3745},{"trials":3732,"activeCount":100},[],{"trials":3734,"activeCount":100},[],{"trials":3736,"activeCount":100},[],{"trials":3738,"activeCount":100},[3739],{"nctId":221,"briefTitle":222,"status":157,"phases":3740,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":3741,"interventions":3742},[89,90],[228],[202,174,201,203,200,230,231,232,196,202],{"trials":3744,"activeCount":100},[],{"trials":3746,"activeCount":100},[],{"intervention":231,"totalTrials":137,"cells":3748},{"EARLY_PHASE1":3749,"PHASE1":3751,"PHASE2":3753,"PHASE3":3755,"PHASE4":3761,"NA":3763},{"trials":3750,"activeCount":100},[],{"trials":3752,"activeCount":100},[],{"trials":3754,"activeCount":100},[],{"trials":3756,"activeCount":100},[3757],{"nctId":221,"briefTitle":222,"status":157,"phases":3758,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":3759,"interventions":3760},[89,90],[228],[202,174,201,203,200,230,231,232,196,202],{"trials":3762,"activeCount":100},[],{"trials":3764,"activeCount":100},[],{"intervention":232,"totalTrials":137,"cells":3766},{"EARLY_PHASE1":3767,"PHASE1":3769,"PHASE2":3771,"PHASE3":3773,"PHASE4":3779,"NA":3781},{"trials":3768,"activeCount":100},[],{"trials":3770,"activeCount":100},[],{"trials":3772,"activeCount":100},[],{"trials":3774,"activeCount":100},[3775],{"nctId":221,"briefTitle":222,"status":157,"phases":3776,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":3777,"interventions":3778},[89,90],[228],[202,174,201,203,200,230,231,232,196,202],{"trials":3780,"activeCount":100},[],{"trials":3782,"activeCount":100},[],{"intervention":3784,"totalTrials":137,"cells":3785},"onabotulinumtoxinA",{"EARLY_PHASE1":3786,"PHASE1":3788,"PHASE2":3790,"PHASE3":3792,"PHASE4":3804,"NA":3806},{"trials":3787,"activeCount":100},[],{"trials":3789,"activeCount":100},[],{"trials":3791,"activeCount":100},[],{"trials":3793,"activeCount":100},[3794],{"nctId":3795,"briefTitle":3796,"status":157,"phases":3797,"primaryCompletion":3798,"start":3799,"enrollment":34,"conditions":3800,"interventions":3803},"NCT02428881","Botulinum Toxin A Injections in Patients With Fowler's Syndrome",[89,90],"2012-07","2009-11",[3801,3802],"Urinary Retention","Fowler's Syndrome",[3784],{"trials":3805,"activeCount":100},[],{"trials":3807,"activeCount":100},[],{"intervention":593,"totalTrials":137,"cells":3809},{"EARLY_PHASE1":3810,"PHASE1":3812,"PHASE2":3814,"PHASE3":3816,"PHASE4":3822,"NA":3824},{"trials":3811,"activeCount":100},[],{"trials":3813,"activeCount":100},[],{"trials":3815,"activeCount":100},[],{"trials":3817,"activeCount":100},[3818],{"nctId":584,"briefTitle":585,"status":157,"phases":3819,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":3820,"interventions":3821},[90],[27],[593,594,595,596,597,598,599,600,601,602,603],{"trials":3823,"activeCount":100},[],{"trials":3825,"activeCount":100},[],{"intervention":594,"totalTrials":137,"cells":3827},{"EARLY_PHASE1":3828,"PHASE1":3830,"PHASE2":3832,"PHASE3":3834,"PHASE4":3840,"NA":3842},{"trials":3829,"activeCount":100},[],{"trials":3831,"activeCount":100},[],{"trials":3833,"activeCount":100},[],{"trials":3835,"activeCount":100},[3836],{"nctId":584,"briefTitle":585,"status":157,"phases":3837,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":3838,"interventions":3839},[90],[27],[593,594,595,596,597,598,599,600,601,602,603],{"trials":3841,"activeCount":100},[],{"trials":3843,"activeCount":100},[],{"intervention":595,"totalTrials":137,"cells":3845},{"EARLY_PHASE1":3846,"PHASE1":3848,"PHASE2":3850,"PHASE3":3852,"PHASE4":3858,"NA":3860},{"trials":3847,"activeCount":100},[],{"trials":3849,"activeCount":100},[],{"trials":3851,"activeCount":100},[],{"trials":3853,"activeCount":100},[3854],{"nctId":584,"briefTitle":585,"status":157,"phases":3855,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":3856,"interventions":3857},[90],[27],[593,594,595,596,597,598,599,600,601,602,603],{"trials":3859,"activeCount":100},[],{"trials":3861,"activeCount":100},[],{"intervention":602,"totalTrials":137,"cells":3863},{"EARLY_PHASE1":3864,"PHASE1":3866,"PHASE2":3868,"PHASE3":3870,"PHASE4":3876,"NA":3878},{"trials":3865,"activeCount":100},[],{"trials":3867,"activeCount":100},[],{"trials":3869,"activeCount":100},[],{"trials":3871,"activeCount":100},[3872],{"nctId":584,"briefTitle":585,"status":157,"phases":3873,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":3874,"interventions":3875},[90],[27],[593,594,595,596,597,598,599,600,601,602,603],{"trials":3877,"activeCount":100},[],{"trials":3879,"activeCount":100},[],{"intervention":3881,"totalTrials":366,"cells":3882},"Glucarpidase",{"EARLY_PHASE1":3883,"PHASE1":3885,"PHASE2":3887,"PHASE3":3911,"PHASE4":3913,"NA":3915},{"trials":3884,"activeCount":100},[],{"trials":3886,"activeCount":100},[],{"trials":3888,"activeCount":100},[3889,3901],{"nctId":3890,"briefTitle":3891,"status":126,"phases":3892,"primaryCompletion":3893,"completion":3893,"start":3175,"enrollment":3894,"conditions":3895,"interventions":3898},"NCT02022358","Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?",[89],"2015-06",34,[3896,3897],"Osteosarcoma","Spindle Cell Sarcoma of Bone",[3881,3899,3900],"Methotrexate","Folinic Acid",{"nctId":3902,"briefTitle":3903,"status":157,"phases":3904,"primaryCompletion":1143,"completion":1143,"start":3905,"enrollment":96,"conditions":3906,"interventions":3908},"NCT00727831","Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma",[88,89],"2008-07",[3907,27,1192,2712],"Chemotherapeutic Agent Toxicity",[3909,3910,1202],"glucarpidase","leucovorin calcium",{"trials":3912,"activeCount":100},[],{"trials":3914,"activeCount":100},[],{"trials":3916,"activeCount":100},[],{"intervention":3900,"totalTrials":366,"cells":3918},{"EARLY_PHASE1":3919,"PHASE1":3921,"PHASE2":3923,"PHASE3":3942,"PHASE4":3944,"NA":3946},{"trials":3920,"activeCount":100},[],{"trials":3922,"activeCount":100},[],{"trials":3924,"activeCount":100},[3925,3929],{"nctId":3890,"briefTitle":3891,"status":126,"phases":3926,"primaryCompletion":3893,"completion":3893,"start":3175,"enrollment":3894,"conditions":3927,"interventions":3928},[89],[3896,3897],[3881,3899,3900],{"nctId":3930,"briefTitle":3931,"status":157,"phases":3932,"primaryCompletion":3933,"completion":3933,"start":3934,"enrollment":2219,"conditions":3935,"interventions":3938},"NCT01862003","Phase I\u002FII Trial of Antagonism of HER in GI Cancer",[89],"2019-08-02","2014-05",[3936,3937],"Metastatic Colorectal Cancer","Recurrent Colorectal Cancer",[3939,3940,3900,3941,3941],"AZD8931","Irinotecan","Fluorouracil",{"trials":3943,"activeCount":100},[],{"trials":3945,"activeCount":100},[],{"trials":3947,"activeCount":100},[],{"intervention":1017,"totalTrials":366,"cells":3949},{"EARLY_PHASE1":3950,"PHASE1":3952,"PHASE2":3954,"PHASE3":3970,"PHASE4":3972,"NA":3974},{"trials":3951,"activeCount":100},[],{"trials":3953,"activeCount":100},[],{"trials":3955,"activeCount":100},[3956,3960],{"nctId":1007,"briefTitle":1008,"status":1009,"phases":3957,"primaryCompletion":1011,"completion":1011,"start":1012,"enrollment":1013,"conditions":3958,"interventions":3959},[89],[391,1015],[1017,52],{"nctId":3961,"briefTitle":3962,"status":1009,"phases":3963,"primaryCompletion":3964,"completion":3965,"start":3966,"enrollment":3967,"conditions":3968,"interventions":3969},"NCT03337919","ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed\u002FRefractory Hodgkin Lymphoma",[89],"2023-03-01","2026-02-28","2018-12-03",78,[576],[1017],{"trials":3971,"activeCount":100},[],{"trials":3973,"activeCount":100},[],{"trials":3975,"activeCount":100},[],{"intervention":3977,"totalTrials":366,"cells":3978},"Afatinib",{"EARLY_PHASE1":3979,"PHASE1":3981,"PHASE2":3983,"PHASE3":4005,"PHASE4":4007,"NA":4009},{"trials":3980,"activeCount":100},[],{"trials":3982,"activeCount":100},[],{"trials":3984,"activeCount":100},[3985,3994],{"nctId":3986,"briefTitle":3987,"status":157,"phases":3988,"primaryCompletion":3989,"completion":3989,"start":3990,"enrollment":31,"conditions":3991,"interventions":3993},"NCT02183883","Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity",[89],"2023-03-22","2016-12-16",[3992],"Non-small Cell Lung Cancer",[3977],{"nctId":3995,"briefTitle":3996,"status":157,"phases":3997,"primaryCompletion":3998,"completion":3999,"start":4000,"enrollment":4001,"conditions":4002,"interventions":4004},"NCT01415011","Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients",[89],"2015-08","2018-11-30","2012-12",39,[4003],"Carcinoma, Non-Small-Cell Lung",[3977],{"trials":4006,"activeCount":100},[],{"trials":4008,"activeCount":100},[],{"trials":4010,"activeCount":100},[],{"intervention":3940,"totalTrials":366,"cells":4012},{"EARLY_PHASE1":4013,"PHASE1":4015,"PHASE2":4017,"PHASE3":4035,"PHASE4":4037,"NA":4039},{"trials":4014,"activeCount":100},[],{"trials":4016,"activeCount":100},[],{"trials":4018,"activeCount":100},[4019,4031],{"nctId":4020,"briefTitle":4021,"status":157,"phases":4022,"primaryCompletion":4023,"completion":4024,"start":1223,"enrollment":995,"conditions":4025,"interventions":4027},"NCT01650428","Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery",[89],"2018-01-10","2019-02-14",[4026],"Rectal Cancer",[4028,3940,4029,4030],"Bevacizumab","Oxaliplatin","5-Fluorouracil",{"nctId":3930,"briefTitle":3931,"status":157,"phases":4032,"primaryCompletion":3933,"completion":3933,"start":3934,"enrollment":2219,"conditions":4033,"interventions":4034},[89],[3936,3937],[3939,3940,3900,3941,3941],{"trials":4036,"activeCount":100},[],{"trials":4038,"activeCount":100},[],{"trials":4040,"activeCount":100},[],{"intervention":4042,"totalTrials":366,"cells":4043},"Exenatide",{"EARLY_PHASE1":4044,"PHASE1":4046,"PHASE2":4048,"PHASE3":4065,"PHASE4":4067,"NA":4069},{"trials":4045,"activeCount":100},[],{"trials":4047,"activeCount":100},[],{"trials":4049,"activeCount":100},[4050,4057],{"nctId":4051,"briefTitle":4052,"status":1009,"phases":4053,"primaryCompletion":420,"completion":420,"start":4054,"enrollment":1154,"conditions":4055,"interventions":4056},"NCT01174810","Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study",[89],"2010-07",[3309],[4042],{"nctId":4058,"briefTitle":4059,"status":157,"phases":4060,"primaryCompletion":421,"completion":4061,"start":4062,"enrollment":1044,"conditions":4063,"interventions":4064},"NCT01971242","Trial of Exenatide for Parkinson's Disease",[89],"2016-08","2014-06",[3309],[4042],{"trials":4066,"activeCount":100},[],{"trials":4068,"activeCount":100},[],{"trials":4070,"activeCount":100},[],{"intervention":4072,"totalTrials":366,"cells":4073},"Avelumab",{"EARLY_PHASE1":4074,"PHASE1":4076,"PHASE2":4078,"PHASE3":4101,"PHASE4":4103,"NA":4105},{"trials":4075,"activeCount":100},[],{"trials":4077,"activeCount":100},[],{"trials":4079,"activeCount":100},[4080,4091],{"nctId":4081,"briefTitle":4082,"status":157,"phases":4083,"primaryCompletion":4084,"completion":4085,"start":4086,"enrollment":25,"conditions":4087,"interventions":4089},"NCT03494322","EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer",[89],"2021-09-15","2026-04-23","2018-07-20",[413,4088],"Squamous Cell Carcinoma",[4072,4090],"Cetuximab",{"nctId":4092,"briefTitle":4093,"status":1009,"phases":4094,"primaryCompletion":4095,"completion":4096,"start":4097,"enrollment":4098,"conditions":4099,"interventions":4100},"NCT03617666","Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study",[89],"2022-07-04","2025-05-30","2019-09-27",49,[576],[4072],{"trials":4102,"activeCount":100},[],{"trials":4104,"activeCount":100},[],{"trials":4106,"activeCount":100},[],{"intervention":4090,"totalTrials":366,"cells":4108},{"EARLY_PHASE1":4109,"PHASE1":4111,"PHASE2":4113,"PHASE3":4130,"PHASE4":4132,"NA":4134},{"trials":4110,"activeCount":100},[],{"trials":4112,"activeCount":100},[],{"trials":4114,"activeCount":100},[4115,4119],{"nctId":4081,"briefTitle":4082,"status":157,"phases":4116,"primaryCompletion":4084,"completion":4085,"start":4086,"enrollment":25,"conditions":4117,"interventions":4118},[89],[413,4088],[4072,4090],{"nctId":4120,"briefTitle":4121,"status":157,"phases":4122,"primaryCompletion":1224,"completion":4123,"start":2929,"enrollment":4124,"conditions":4125,"interventions":4126},"NCT00972881","Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer",[88,89],"2016-12-31",82,[4026],[4127,4128,4129],"cetuximab","capecitabine","irinotecan hydrochloride",{"trials":4131,"activeCount":100},[],{"trials":4133,"activeCount":100},[],{"trials":4135,"activeCount":100},[],{"intervention":136,"totalTrials":366,"cells":4137},{"EARLY_PHASE1":4138,"PHASE1":4140,"PHASE2":4142,"PHASE3":4158,"PHASE4":4160,"NA":4162},{"trials":4139,"activeCount":100},[],{"trials":4141,"activeCount":100},[],{"trials":4143,"activeCount":100},[4144,4154],{"nctId":4145,"briefTitle":4146,"status":157,"phases":4147,"primaryCompletion":4148,"completion":4149,"start":4150,"enrollment":4151,"conditions":4152,"interventions":4153},"NCT01602588","A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)",[89],"2016-10","2017-11","2013-05",54,[1296],[136],{"nctId":124,"briefTitle":125,"status":126,"phases":4155,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":4156,"interventions":4157},[89],[132],[134,95,135,136],{"trials":4159,"activeCount":100},[],{"trials":4161,"activeCount":100},[],{"trials":4163,"activeCount":100},[],{"intervention":1116,"totalTrials":366,"cells":4165},{"EARLY_PHASE1":4166,"PHASE1":4168,"PHASE2":4170,"PHASE3":4184,"PHASE4":4186,"NA":4188},{"trials":4167,"activeCount":100},[],{"trials":4169,"activeCount":100},[],{"trials":4171,"activeCount":100},[4172,4176],{"nctId":1107,"briefTitle":1108,"status":157,"phases":4173,"primaryCompletion":1110,"completion":1111,"start":1112,"enrollment":1044,"conditions":4174,"interventions":4175},[89],[1114],[1116,1102,1028,1117],{"nctId":4177,"briefTitle":4178,"status":157,"phases":4179,"primaryCompletion":4180,"completion":4181,"start":3502,"enrollment":1154,"conditions":4182,"interventions":4183},"NCT01517724","Bortezomib Consolidation Trial",[89],"2014-12","2019-01-24",[1796],[1116],{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[],{"trials":4189,"activeCount":100},[],{"intervention":4191,"totalTrials":137,"cells":4192},"Phenytoin",{"EARLY_PHASE1":4193,"PHASE1":4195,"PHASE2":4197,"PHASE3":4208,"PHASE4":4210,"NA":4212},{"trials":4194,"activeCount":100},[],{"trials":4196,"activeCount":100},[],{"trials":4198,"activeCount":100},[4199],{"nctId":4200,"briefTitle":4201,"status":157,"phases":4202,"primaryCompletion":4180,"completion":1292,"start":4203,"enrollment":3503,"conditions":4204,"interventions":4207},"NCT01451593","Neuroprotection With Phenytoin in Optic Neuritis",[89],"2011-11",[4205,4206],"Optic Neuritis","Multiple Sclerosis",[4191],{"trials":4209,"activeCount":100},[],{"trials":4211,"activeCount":100},[],{"trials":4213,"activeCount":100},[],{"intervention":1298,"totalTrials":137,"cells":4215},{"EARLY_PHASE1":4216,"PHASE1":4218,"PHASE2":4220,"PHASE3":4226,"PHASE4":4228,"NA":4230},{"trials":4217,"activeCount":100},[],{"trials":4219,"activeCount":100},[],{"trials":4221,"activeCount":100},[4222],{"nctId":1289,"briefTitle":1290,"status":157,"phases":4223,"primaryCompletion":1292,"completion":1292,"start":1293,"enrollment":1294,"conditions":4224,"interventions":4225},[89],[1296],[1280,1298,1299,1300],{"trials":4227,"activeCount":100},[],{"trials":4229,"activeCount":100},[],{"trials":4231,"activeCount":100},[],{"intervention":1299,"totalTrials":137,"cells":4233},{"EARLY_PHASE1":4234,"PHASE1":4236,"PHASE2":4238,"PHASE3":4244,"PHASE4":4246,"NA":4248},{"trials":4235,"activeCount":100},[],{"trials":4237,"activeCount":100},[],{"trials":4239,"activeCount":100},[4240],{"nctId":1289,"briefTitle":1290,"status":157,"phases":4241,"primaryCompletion":1292,"completion":1292,"start":1293,"enrollment":1294,"conditions":4242,"interventions":4243},[89],[1296],[1280,1298,1299,1300],{"trials":4245,"activeCount":100},[],{"trials":4247,"activeCount":100},[],{"trials":4249,"activeCount":100},[],{"intervention":1300,"totalTrials":137,"cells":4251},{"EARLY_PHASE1":4252,"PHASE1":4254,"PHASE2":4256,"PHASE3":4262,"PHASE4":4264,"NA":4266},{"trials":4253,"activeCount":100},[],{"trials":4255,"activeCount":100},[],{"trials":4257,"activeCount":100},[4258],{"nctId":1289,"briefTitle":1290,"status":157,"phases":4259,"primaryCompletion":1292,"completion":1292,"start":1293,"enrollment":1294,"conditions":4260,"interventions":4261},[89],[1296],[1280,1298,1299,1300],{"trials":4263,"activeCount":100},[],{"trials":4265,"activeCount":100},[],{"trials":4267,"activeCount":100},[],{"intervention":4269,"totalTrials":137,"cells":4270},"[18F]Fluoropivalate",{"EARLY_PHASE1":4271,"PHASE1":4273,"PHASE2":4275,"PHASE3":4287,"PHASE4":4289,"NA":4291},{"trials":4272,"activeCount":100},[],{"trials":4274,"activeCount":100},[],{"trials":4276,"activeCount":100},[4277],{"nctId":4278,"briefTitle":4279,"status":1009,"phases":4280,"primaryCompletion":4281,"completion":1772,"start":4282,"enrollment":4283,"conditions":4284,"interventions":4286},"NCT04717674","[18F]FPIA PET\u002FCT Imaging in Patients With Solid Tumours",[89],"2024-08","2021-12-07",21,[725,4285],"Tumor, Solid",[4269],{"trials":4288,"activeCount":100},[],{"trials":4290,"activeCount":100},[],{"trials":4292,"activeCount":100},[],{"intervention":2681,"totalTrials":137,"cells":4294},{"EARLY_PHASE1":4295,"PHASE1":4297,"PHASE2":4299,"PHASE3":4305,"PHASE4":4307,"NA":4309},{"trials":4296,"activeCount":100},[],{"trials":4298,"activeCount":100},[],{"trials":4300,"activeCount":100},[4301],{"nctId":2672,"briefTitle":2673,"status":126,"phases":4302,"primaryCompletion":2675,"completion":2675,"start":1143,"enrollment":2676,"conditions":4303,"interventions":4304},[89],[2678,27,2679],[1102,2681,2682,1117],{"trials":4306,"activeCount":100},[],{"trials":4308,"activeCount":100},[],{"trials":4310,"activeCount":100},[],{"intervention":4312,"totalTrials":137,"cells":4313},"BMN 673",{"EARLY_PHASE1":4314,"PHASE1":4316,"PHASE2":4318,"PHASE3":4328,"PHASE4":4330,"NA":4332},{"trials":4315,"activeCount":100},[],{"trials":4317,"activeCount":100},[],{"trials":4319,"activeCount":100},[4320],{"nctId":4321,"briefTitle":4322,"status":434,"phases":4323,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":100,"conditions":4326,"interventions":4327},"NCT02127151","A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer",[89],"2017-05-01","2014-10-01",[1821],[4312],{"trials":4329,"activeCount":100},[],{"trials":4331,"activeCount":100},[],{"trials":4333,"activeCount":100},[],{"intervention":3910,"totalTrials":137,"cells":4335},{"EARLY_PHASE1":4336,"PHASE1":4338,"PHASE2":4340,"PHASE3":4346,"PHASE4":4348,"NA":4350},{"trials":4337,"activeCount":100},[],{"trials":4339,"activeCount":100},[],{"trials":4341,"activeCount":100},[4342],{"nctId":3902,"briefTitle":3903,"status":157,"phases":4343,"primaryCompletion":1143,"completion":1143,"start":3905,"enrollment":96,"conditions":4344,"interventions":4345},[88,89],[3907,27,1192,2712],[3909,3910,1202],{"trials":4347,"activeCount":100},[],{"trials":4349,"activeCount":100},[],{"trials":4351,"activeCount":100},[],{"intervention":4353,"totalTrials":137,"cells":4354},"cediranib maleate",{"EARLY_PHASE1":4355,"PHASE1":4357,"PHASE2":4359,"PHASE3":4368,"PHASE4":4370,"NA":4372},{"trials":4356,"activeCount":100},[],{"trials":4358,"activeCount":100},[],{"trials":4360,"activeCount":100},[4361],{"nctId":4362,"briefTitle":4363,"status":126,"phases":4364,"primaryCompletion":4150,"completion":540,"start":1293,"enrollment":2627,"conditions":4365,"interventions":4366},"NCT01310855","Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma",[89],[1296],[4353,4367],"gefitinib",{"trials":4369,"activeCount":100},[],{"trials":4371,"activeCount":100},[],{"trials":4373,"activeCount":100},[],{"intervention":4367,"totalTrials":137,"cells":4375},{"EARLY_PHASE1":4376,"PHASE1":4378,"PHASE2":4380,"PHASE3":4386,"PHASE4":4388,"NA":4390},{"trials":4377,"activeCount":100},[],{"trials":4379,"activeCount":100},[],{"trials":4381,"activeCount":100},[4382],{"nctId":4362,"briefTitle":4363,"status":126,"phases":4383,"primaryCompletion":4150,"completion":540,"start":1293,"enrollment":2627,"conditions":4384,"interventions":4385},[89],[1296],[4353,4367],{"trials":4387,"activeCount":100},[],{"trials":4389,"activeCount":100},[],{"trials":4391,"activeCount":100},[],{"intervention":4393,"totalTrials":137,"cells":4394},"pSG2.HIVconsv DNA vaccine",{"EARLY_PHASE1":4395,"PHASE1":4397,"PHASE2":4399,"PHASE3":4412,"PHASE4":4414,"NA":4416},{"trials":4396,"activeCount":100},[],{"trials":4398,"activeCount":100},[],{"trials":4400,"activeCount":100},[4401],{"nctId":4402,"briefTitle":4403,"status":157,"phases":4404,"primaryCompletion":2602,"completion":4405,"start":1097,"enrollment":4406,"conditions":4407,"interventions":4408},"NCT02425241","Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination",[88,89],"2016-09",41,[1774],[4393,4409,4410,4411],"ChAdV63.HIVconsv booster vaccine","MVA.HIVconsv booster vaccine","CPHPC",{"trials":4413,"activeCount":100},[],{"trials":4415,"activeCount":100},[],{"trials":4417,"activeCount":100},[],{"intervention":4409,"totalTrials":137,"cells":4419},{"EARLY_PHASE1":4420,"PHASE1":4422,"PHASE2":4424,"PHASE3":4430,"PHASE4":4432,"NA":4434},{"trials":4421,"activeCount":100},[],{"trials":4423,"activeCount":100},[],{"trials":4425,"activeCount":100},[4426],{"nctId":4402,"briefTitle":4403,"status":157,"phases":4427,"primaryCompletion":2602,"completion":4405,"start":1097,"enrollment":4406,"conditions":4428,"interventions":4429},[88,89],[1774],[4393,4409,4410,4411],{"trials":4431,"activeCount":100},[],{"trials":4433,"activeCount":100},[],{"trials":4435,"activeCount":100},[],{"intervention":4410,"totalTrials":137,"cells":4437},{"EARLY_PHASE1":4438,"PHASE1":4440,"PHASE2":4442,"PHASE3":4448,"PHASE4":4450,"NA":4452},{"trials":4439,"activeCount":100},[],{"trials":4441,"activeCount":100},[],{"trials":4443,"activeCount":100},[4444],{"nctId":4402,"briefTitle":4403,"status":157,"phases":4445,"primaryCompletion":2602,"completion":4405,"start":1097,"enrollment":4406,"conditions":4446,"interventions":4447},[88,89],[1774],[4393,4409,4410,4411],{"trials":4449,"activeCount":100},[],{"trials":4451,"activeCount":100},[],{"trials":4453,"activeCount":100},[],{"intervention":4411,"totalTrials":137,"cells":4455},{"EARLY_PHASE1":4456,"PHASE1":4458,"PHASE2":4460,"PHASE3":4466,"PHASE4":4468,"NA":4470},{"trials":4457,"activeCount":100},[],{"trials":4459,"activeCount":100},[],{"trials":4461,"activeCount":100},[4462],{"nctId":4402,"briefTitle":4403,"status":157,"phases":4463,"primaryCompletion":2602,"completion":4405,"start":1097,"enrollment":4406,"conditions":4464,"interventions":4465},[88,89],[1774],[4393,4409,4410,4411],{"trials":4467,"activeCount":100},[],{"trials":4469,"activeCount":100},[],{"trials":4471,"activeCount":100},[],{"intervention":4028,"totalTrials":137,"cells":4473},{"EARLY_PHASE1":4474,"PHASE1":4476,"PHASE2":4478,"PHASE3":4484,"PHASE4":4486,"NA":4488},{"trials":4475,"activeCount":100},[],{"trials":4477,"activeCount":100},[],{"trials":4479,"activeCount":100},[4480],{"nctId":4020,"briefTitle":4021,"status":157,"phases":4481,"primaryCompletion":4023,"completion":4024,"start":1223,"enrollment":995,"conditions":4482,"interventions":4483},[89],[4026],[4028,3940,4029,4030],{"trials":4485,"activeCount":100},[],{"trials":4487,"activeCount":100},[],{"trials":4489,"activeCount":100},[],{"intervention":4029,"totalTrials":137,"cells":4491},{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4502,"PHASE4":4504,"NA":4506},{"trials":4493,"activeCount":100},[],{"trials":4495,"activeCount":100},[],{"trials":4497,"activeCount":100},[4498],{"nctId":4020,"briefTitle":4021,"status":157,"phases":4499,"primaryCompletion":4023,"completion":4024,"start":1223,"enrollment":995,"conditions":4500,"interventions":4501},[89],[4026],[4028,3940,4029,4030],{"trials":4503,"activeCount":100},[],{"trials":4505,"activeCount":100},[],{"trials":4507,"activeCount":100},[],{"intervention":4030,"totalTrials":137,"cells":4509},{"EARLY_PHASE1":4510,"PHASE1":4512,"PHASE2":4514,"PHASE3":4520,"PHASE4":4522,"NA":4524},{"trials":4511,"activeCount":100},[],{"trials":4513,"activeCount":100},[],{"trials":4515,"activeCount":100},[4516],{"nctId":4020,"briefTitle":4021,"status":157,"phases":4517,"primaryCompletion":4023,"completion":4024,"start":1223,"enrollment":995,"conditions":4518,"interventions":4519},[89],[4026],[4028,3940,4029,4030],{"trials":4521,"activeCount":100},[],{"trials":4523,"activeCount":100},[],{"trials":4525,"activeCount":100},[],{"intervention":4527,"totalTrials":137,"cells":4528},"TroVax®",{"EARLY_PHASE1":4529,"PHASE1":4531,"PHASE2":4533,"PHASE3":4543,"PHASE4":4545,"NA":4547},{"trials":4530,"activeCount":100},[],{"trials":4532,"activeCount":100},[],{"trials":4534,"activeCount":100},[4535],{"nctId":4536,"briefTitle":4537,"status":157,"phases":4538,"primaryCompletion":4539,"completion":4539,"start":160,"enrollment":4540,"conditions":4541,"interventions":4542},"NCT01556841","The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer",[89],"2019-04-19",94,[115,117,118],[4527],{"trials":4544,"activeCount":100},[],{"trials":4546,"activeCount":100},[],{"trials":4548,"activeCount":100},[],{"intervention":4128,"totalTrials":137,"cells":4550},{"EARLY_PHASE1":4551,"PHASE1":4553,"PHASE2":4555,"PHASE3":4561,"PHASE4":4563,"NA":4565},{"trials":4552,"activeCount":100},[],{"trials":4554,"activeCount":100},[],{"trials":4556,"activeCount":100},[4557],{"nctId":4120,"briefTitle":4121,"status":157,"phases":4558,"primaryCompletion":1224,"completion":4123,"start":2929,"enrollment":4124,"conditions":4559,"interventions":4560},[88,89],[4026],[4127,4128,4129],{"trials":4562,"activeCount":100},[],{"trials":4564,"activeCount":100},[],{"trials":4566,"activeCount":100},[],{"intervention":4129,"totalTrials":137,"cells":4568},{"EARLY_PHASE1":4569,"PHASE1":4571,"PHASE2":4573,"PHASE3":4579,"PHASE4":4581,"NA":4583},{"trials":4570,"activeCount":100},[],{"trials":4572,"activeCount":100},[],{"trials":4574,"activeCount":100},[4575],{"nctId":4120,"briefTitle":4121,"status":157,"phases":4576,"primaryCompletion":1224,"completion":4123,"start":2929,"enrollment":4124,"conditions":4577,"interventions":4578},[88,89],[4026],[4127,4128,4129],{"trials":4580,"activeCount":100},[],{"trials":4582,"activeCount":100},[],{"trials":4584,"activeCount":100},[],{"intervention":4586,"totalTrials":137,"cells":4587},"Ondansetron 8mg or matched placebo",{"EARLY_PHASE1":4588,"PHASE1":4590,"PHASE2":4592,"PHASE3":4605,"PHASE4":4607,"NA":4609},{"trials":4589,"activeCount":100},[],{"trials":4591,"activeCount":100},[],{"trials":4593,"activeCount":100},[4594],{"nctId":4595,"briefTitle":4596,"status":1009,"phases":4597,"primaryCompletion":4598,"completion":4598,"start":4599,"enrollment":4600,"conditions":4601,"interventions":4604},"NCT04167813","Trial of Ondansetron as a Parkinson's HAllucinations Treatment",[89],"2024-08-30","2021-10-01",168,[4602,4603],"Parkinson's Hallucinations","Dementia With Lewy Bodies",[4586],{"trials":4606,"activeCount":100},[],{"trials":4608,"activeCount":100},[],{"trials":4610,"activeCount":100},[],{"intervention":4612,"totalTrials":137,"cells":4613},"Melatonin",{"EARLY_PHASE1":4614,"PHASE1":4616,"PHASE2":4618,"PHASE3":4629,"PHASE4":4631,"NA":4633},{"trials":4615,"activeCount":100},[],{"trials":4617,"activeCount":100},[],{"trials":4619,"activeCount":100},[4620],{"nctId":4621,"briefTitle":4622,"status":1009,"phases":4623,"primaryCompletion":411,"completion":4624,"start":4625,"enrollment":995,"conditions":4626,"interventions":4628},"NCT02359448","Melatonin for Nocturia in Parkinson's Disease",[89],"2015-12","2015-04",[3309,4627],"Nocturia",[4612],{"trials":4630,"activeCount":100},[],{"trials":4632,"activeCount":100},[],{"trials":4634,"activeCount":100},[],{"intervention":505,"totalTrials":137,"cells":4636},{"EARLY_PHASE1":4637,"PHASE1":4639,"PHASE2":4641,"PHASE3":4647,"PHASE4":4649,"NA":4651},{"trials":4638,"activeCount":100},[],{"trials":4640,"activeCount":100},[],{"trials":4642,"activeCount":100},[4643],{"nctId":498,"briefTitle":499,"status":126,"phases":4644,"primaryCompletion":475,"completion":475,"start":501,"enrollment":96,"conditions":4645,"interventions":4646},[88,89],[413],[504,505],{"trials":4648,"activeCount":100},[],{"trials":4650,"activeCount":100},[],{"trials":4652,"activeCount":100},[],{"intervention":4654,"totalTrials":137,"cells":4655},"Rotigotine",{"EARLY_PHASE1":4656,"PHASE1":4658,"PHASE2":4660,"PHASE3":4672,"PHASE4":4674,"NA":4676},{"trials":4657,"activeCount":100},[],{"trials":4659,"activeCount":100},[],{"trials":4661,"activeCount":100},[4662],{"nctId":4663,"briefTitle":4664,"status":157,"phases":4665,"primaryCompletion":1153,"completion":4054,"start":4666,"enrollment":995,"conditions":4667,"interventions":4671},"NCT00663338","Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post Stroke",[89],"2010-01",[4668,4669,4670],"Right Hemisphere Stroke","Hemispatial Neglect","Motor Deficit",[4654],{"trials":4673,"activeCount":100},[],{"trials":4675,"activeCount":100},[],{"trials":4677,"activeCount":100},[],{"intervention":4679,"totalTrials":137,"cells":4680},"CMV gB vaccine",{"EARLY_PHASE1":4681,"PHASE1":4683,"PHASE2":4685,"PHASE3":4697,"PHASE4":4699,"NA":4701},{"trials":4682,"activeCount":100},[],{"trials":4684,"activeCount":100},[],{"trials":4686,"activeCount":100},[4687],{"nctId":4688,"briefTitle":4689,"status":1009,"phases":4690,"primaryCompletion":4691,"completion":2774,"start":4692,"enrollment":4693,"conditions":4694,"interventions":4696},"NCT00299260","CMV Glycoprotein B Vaccine in Allograft Recipients",[89],"2009-09","2006-08",140,[4695],"Cytomegalovirus Infections",[4679],{"trials":4698,"activeCount":100},[],{"trials":4700,"activeCount":100},[],{"trials":4702,"activeCount":100},[],{"intervention":4704,"totalTrials":137,"cells":4705},"Ketamine",{"EARLY_PHASE1":4706,"PHASE1":4708,"PHASE2":4710,"PHASE3":4721,"PHASE4":4723,"NA":4725},{"trials":4707,"activeCount":100},[],{"trials":4709,"activeCount":100},[],{"trials":4711,"activeCount":100},[4712],{"nctId":4713,"briefTitle":4714,"status":157,"phases":4715,"primaryCompletion":4716,"completion":4716,"start":4148,"enrollment":4717,"conditions":4718,"interventions":4720},"NCT02649231","Ketamine for Reduction of Alcoholic Relapse",[89],"2020-02",96,[4719],"Primary Alcohol Use Disorder",[4704],{"trials":4722,"activeCount":100},[],{"trials":4724,"activeCount":100},[],{"trials":4726,"activeCount":100},[],{"intervention":4728,"totalTrials":137,"cells":4729},"Fibrogammin®P, coagulation factor XIII concentrate",{"EARLY_PHASE1":4730,"PHASE1":4732,"PHASE2":4734,"PHASE3":4746,"PHASE4":4748,"NA":4750},{"trials":4731,"activeCount":100},[],{"trials":4733,"activeCount":100},[],{"trials":4735,"activeCount":100},[4736],{"nctId":4737,"briefTitle":4738,"status":1009,"phases":4739,"primaryCompletion":4405,"completion":4740,"start":411,"enrollment":4741,"conditions":4742,"interventions":4744},"NCT02551042","CSL Behring Sclero XIII",[89],"2018-09",26,[4743],"Systemic Sclerosis",[4728,4745],"0.9% sodium chloride",{"trials":4747,"activeCount":100},[],{"trials":4749,"activeCount":100},[],{"trials":4751,"activeCount":100},[],{"intervention":4745,"totalTrials":137,"cells":4753},{"EARLY_PHASE1":4754,"PHASE1":4756,"PHASE2":4758,"PHASE3":4764,"PHASE4":4766,"NA":4768},{"trials":4755,"activeCount":100},[],{"trials":4757,"activeCount":100},[],{"trials":4759,"activeCount":100},[4760],{"nctId":4737,"briefTitle":4738,"status":1009,"phases":4761,"primaryCompletion":4405,"completion":4740,"start":411,"enrollment":4741,"conditions":4762,"interventions":4763},[89],[4743],[4728,4745],{"trials":4765,"activeCount":100},[],{"trials":4767,"activeCount":100},[],{"trials":4769,"activeCount":100},[],{"intervention":4771,"totalTrials":137,"cells":4772},"Bumetanide",{"EARLY_PHASE1":4773,"PHASE1":4775,"PHASE2":4777,"PHASE3":4787,"PHASE4":4789,"NA":4791},{"trials":4774,"activeCount":100},[],{"trials":4776,"activeCount":100},[],{"trials":4778,"activeCount":100},[4779],{"nctId":4780,"briefTitle":4781,"status":126,"phases":4782,"primaryCompletion":4783,"completion":4783,"start":2412,"enrollment":31,"conditions":4784,"interventions":4786},"NCT02582476","Bumetanide in Hypokalaemic Periodic Paralysis",[89],"2017-05-09",[4785],"Hypokalemic Periodic Paralysis",[4771],{"trials":4788,"activeCount":100},[],{"trials":4790,"activeCount":100},[],{"trials":4792,"activeCount":100},[],{"intervention":4794,"totalTrials":137,"cells":4795},"Octreotide Acetate",{"EARLY_PHASE1":4796,"PHASE1":4798,"PHASE2":4800,"PHASE3":4814,"PHASE4":4816,"NA":4818},{"trials":4797,"activeCount":100},[],{"trials":4799,"activeCount":100},[],{"trials":4801,"activeCount":100},[4802],{"nctId":4803,"briefTitle":4804,"status":1009,"phases":4805,"primaryCompletion":4806,"completion":4807,"start":4808,"enrollment":4809,"conditions":4810,"interventions":4813},"NCT04941911","A Feasibility Study of Octreotide Infusion During Liver Transplant.",[89],"2023-10-31","2024-01-31","2022-05-27",30,[4811,4812],"Liver Transplantation","Renal Failure",[4794],{"trials":4815,"activeCount":100},[],{"trials":4817,"activeCount":100},[],{"trials":4819,"activeCount":100},[],{"intervention":4821,"totalTrials":137,"cells":4822},"Pembrolizumab and CXD101",{"EARLY_PHASE1":4823,"PHASE1":4825,"PHASE2":4827,"PHASE3":4837,"PHASE4":4839,"NA":4841},{"trials":4824,"activeCount":100},[],{"trials":4826,"activeCount":100},[],{"trials":4828,"activeCount":100},[4829],{"nctId":4830,"briefTitle":4831,"status":434,"phases":4832,"primaryCompletion":4833,"completion":1011,"start":4834,"enrollment":100,"conditions":4835,"interventions":4836},"NCT03873025","A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[88,89],"2024-04","2019-10",[1100],[4821],{"trials":4838,"activeCount":100},[],{"trials":4840,"activeCount":100},[],{"trials":4842,"activeCount":100},[],{"intervention":4844,"totalTrials":137,"cells":4845},"Amiloride",{"EARLY_PHASE1":4846,"PHASE1":4848,"PHASE2":4850,"PHASE3":4863,"PHASE4":4865,"NA":4867},{"trials":4847,"activeCount":100},[],{"trials":4849,"activeCount":100},[],{"trials":4851,"activeCount":100},[4852],{"nctId":4853,"briefTitle":4854,"status":157,"phases":4855,"primaryCompletion":4856,"completion":4857,"start":4858,"enrollment":1358,"conditions":4859,"interventions":4860},"NCT01910259","MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial",[89],"2018-06-14","2018-07-04","2014-12-18",[2839],[4844,4861,4862],"Riluzole","Fluoxetine",{"trials":4864,"activeCount":100},[],{"trials":4866,"activeCount":100},[],{"trials":4868,"activeCount":100},[],{"intervention":4861,"totalTrials":137,"cells":4870},{"EARLY_PHASE1":4871,"PHASE1":4873,"PHASE2":4875,"PHASE3":4881,"PHASE4":4883,"NA":4885},{"trials":4872,"activeCount":100},[],{"trials":4874,"activeCount":100},[],{"trials":4876,"activeCount":100},[4877],{"nctId":4853,"briefTitle":4854,"status":157,"phases":4878,"primaryCompletion":4856,"completion":4857,"start":4858,"enrollment":1358,"conditions":4879,"interventions":4880},[89],[2839],[4844,4861,4862],{"trials":4882,"activeCount":100},[],{"trials":4884,"activeCount":100},[],{"trials":4886,"activeCount":100},[],{"intervention":4862,"totalTrials":137,"cells":4888},{"EARLY_PHASE1":4889,"PHASE1":4891,"PHASE2":4893,"PHASE3":4899,"PHASE4":4901,"NA":4903},{"trials":4890,"activeCount":100},[],{"trials":4892,"activeCount":100},[],{"trials":4894,"activeCount":100},[4895],{"nctId":4853,"briefTitle":4854,"status":157,"phases":4896,"primaryCompletion":4856,"completion":4857,"start":4858,"enrollment":1358,"conditions":4897,"interventions":4898},[89],[2839],[4844,4861,4862],{"trials":4900,"activeCount":100},[],{"trials":4902,"activeCount":100},[],{"trials":4904,"activeCount":100},[],{"intervention":449,"totalTrials":137,"cells":4906},{"EARLY_PHASE1":4907,"PHASE1":4909,"PHASE2":4911,"PHASE3":4917,"PHASE4":4919,"NA":4921},{"trials":4908,"activeCount":100},[],{"trials":4910,"activeCount":100},[],{"trials":4912,"activeCount":100},[4913],{"nctId":443,"briefTitle":444,"status":434,"phases":4914,"enrollment":100,"conditions":4915,"interventions":4916},[88,89],[447],[153,449,450],{"trials":4918,"activeCount":100},[],{"trials":4920,"activeCount":100},[],{"trials":4922,"activeCount":100},[],{"intervention":450,"totalTrials":137,"cells":4924},{"EARLY_PHASE1":4925,"PHASE1":4927,"PHASE2":4929,"PHASE3":4935,"PHASE4":4937,"NA":4939},{"trials":4926,"activeCount":100},[],{"trials":4928,"activeCount":100},[],{"trials":4930,"activeCount":100},[4931],{"nctId":443,"briefTitle":444,"status":434,"phases":4932,"enrollment":100,"conditions":4933,"interventions":4934},[88,89],[447],[153,449,450],{"trials":4936,"activeCount":100},[],{"trials":4938,"activeCount":100},[],{"trials":4940,"activeCount":100},[],{"intervention":2777,"totalTrials":137,"cells":4942},{"EARLY_PHASE1":4943,"PHASE1":4945,"PHASE2":4947,"PHASE3":4953,"PHASE4":4955,"NA":4957},{"trials":4944,"activeCount":100},[],{"trials":4946,"activeCount":100},[],{"trials":4948,"activeCount":100},[4949],{"nctId":2771,"briefTitle":2772,"status":157,"phases":4950,"primaryCompletion":2774,"completion":540,"start":2709,"enrollment":356,"conditions":4951,"interventions":4952},[89],[27],[2777,464],{"trials":4954,"activeCount":100},[],{"trials":4956,"activeCount":100},[],{"trials":4958,"activeCount":100},[],{"intervention":1103,"totalTrials":137,"cells":4960},{"EARLY_PHASE1":4961,"PHASE1":4963,"PHASE2":4965,"PHASE3":4971,"PHASE4":4973,"NA":4975},{"trials":4962,"activeCount":100},[],{"trials":4964,"activeCount":100},[],{"trials":4966,"activeCount":100},[4967],{"nctId":1092,"briefTitle":1093,"status":157,"phases":4968,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":1098,"conditions":4969,"interventions":4970},[89],[1100],[1102,1103,1104,1028,1105,134],{"trials":4972,"activeCount":100},[],{"trials":4974,"activeCount":100},[],{"trials":4976,"activeCount":100},[],{"intervention":1105,"totalTrials":137,"cells":4978},{"EARLY_PHASE1":4979,"PHASE1":4981,"PHASE2":4983,"PHASE3":4989,"PHASE4":4991,"NA":4993},{"trials":4980,"activeCount":100},[],{"trials":4982,"activeCount":100},[],{"trials":4984,"activeCount":100},[4985],{"nctId":1092,"briefTitle":1093,"status":157,"phases":4986,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":1098,"conditions":4987,"interventions":4988},[89],[1100],[1102,1103,1104,1028,1105,134],{"trials":4990,"activeCount":100},[],{"trials":4992,"activeCount":100},[],{"trials":4994,"activeCount":100},[],{"intervention":4996,"totalTrials":137,"cells":4997},"Exenatide Pen Injector [Bydureon]",{"EARLY_PHASE1":4998,"PHASE1":5000,"PHASE2":5002,"PHASE3":5013,"PHASE4":5015,"NA":5017},{"trials":4999,"activeCount":100},[],{"trials":5001,"activeCount":100},[],{"trials":5003,"activeCount":100},[5004],{"nctId":5005,"briefTitle":5006,"status":157,"phases":5007,"primaryCompletion":5008,"completion":5008,"start":5009,"enrollment":1124,"conditions":5010,"interventions":5012},"NCT04431713","Exenatide Once-weekly as a Treatment for Multiple System Atrophy",[89],"2024-03-22","2020-09-16",[5011],"Multiple System Atrophy",[4996],{"trials":5014,"activeCount":100},[],{"trials":5016,"activeCount":100},[],{"trials":5018,"activeCount":100},[],{"intervention":5020,"totalTrials":137,"cells":5021},"Lenalidomide & Dexamethasone",{"EARLY_PHASE1":5022,"PHASE1":5024,"PHASE2":5026,"PHASE3":5036,"PHASE4":5038,"NA":5040},{"trials":5023,"activeCount":100},[],{"trials":5025,"activeCount":100},[],{"trials":5027,"activeCount":100},[5028],{"nctId":5029,"briefTitle":5030,"status":157,"phases":5031,"primaryCompletion":2602,"completion":2602,"start":5032,"enrollment":31,"conditions":5033,"interventions":5035},"NCT01459211","Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)",[89],"2012-05",[5034],"Chronic Lymphocytic Leukemia",[5020],{"trials":5037,"activeCount":100},[],{"trials":5039,"activeCount":100},[],{"trials":5041,"activeCount":100},[],{"intervention":5043,"totalTrials":137,"cells":5044},"Ganetespib",{"EARLY_PHASE1":5045,"PHASE1":5047,"PHASE2":5049,"PHASE3":5060,"PHASE4":5062,"NA":5064},{"trials":5046,"activeCount":100},[],{"trials":5048,"activeCount":100},[],{"trials":5050,"activeCount":100},[5051],{"nctId":5052,"briefTitle":5053,"status":157,"phases":5054,"primaryCompletion":5055,"completion":5055,"start":5056,"enrollment":2245,"conditions":5057,"interventions":5059},"NCT01590160","Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma",[88,89],"2019-11-05","2013-08",[5058],"Lung Cancer - Malignant Pleural Mesothelioma",[5043],{"trials":5061,"activeCount":100},[],{"trials":5063,"activeCount":100},[],{"trials":5065,"activeCount":100},[],{"intervention":5067,"totalTrials":137,"cells":5068},"Sodium Valproate",{"EARLY_PHASE1":5069,"PHASE1":5071,"PHASE2":5073,"PHASE3":5084,"PHASE4":5086,"NA":5088},{"trials":5070,"activeCount":100},[],{"trials":5072,"activeCount":100},[],{"trials":5074,"activeCount":100},[5075],{"nctId":5076,"briefTitle":5077,"status":157,"phases":5078,"primaryCompletion":5079,"completion":5079,"start":2412,"enrollment":399,"conditions":5080,"interventions":5083},"NCT03112889","Sodium Valproate for GSDV",[89],"2017-04-05",[5081,5082],"Glycogen Storage Disease Type V","McArdle Disease",[5067],{"trials":5085,"activeCount":100},[],{"trials":5087,"activeCount":100},[],{"trials":5089,"activeCount":100},[],{"intervention":5091,"totalTrials":137,"cells":5092},"Dornase Alfa Inhalation Solution [Pulmozyme]",{"EARLY_PHASE1":5093,"PHASE1":5095,"PHASE2":5097,"PHASE3":5109,"PHASE4":5111,"NA":5113},{"trials":5094,"activeCount":100},[],{"trials":5096,"activeCount":100},[],{"trials":5098,"activeCount":100},[5099],{"nctId":5100,"briefTitle":5101,"status":157,"phases":5102,"primaryCompletion":3262,"completion":5103,"start":5104,"enrollment":4406,"conditions":5105,"interventions":5108},"NCT04359654","Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)",[89],"2021-11-05","2020-06-16",[5106,5107],"COVID-19 (Coronavirus Disease 2019)","Hypoxia",[5091],{"trials":5110,"activeCount":100},[],{"trials":5112,"activeCount":100},[],{"trials":5114,"activeCount":100},[],{"intervention":5116,"totalTrials":137,"cells":5117},"OCTAPLAS",{"EARLY_PHASE1":5118,"PHASE1":5120,"PHASE2":5122,"PHASE3":5133,"PHASE4":5135,"NA":5137},{"trials":5119,"activeCount":100},[],{"trials":5121,"activeCount":100},[],{"trials":5123,"activeCount":100},[5124],{"nctId":5125,"briefTitle":5126,"status":157,"phases":5127,"primaryCompletion":5128,"completion":5128,"start":5129,"enrollment":19,"conditions":5130,"interventions":5132},"NCT04623255","Study of Plasma Exchange in Severe COVID-19",[89],"2022-01-31","2020-10-16",[5131],"COVID19",[5116],{"trials":5134,"activeCount":100},[],{"trials":5136,"activeCount":100},[],{"trials":5138,"activeCount":100},[],{"intervention":5140,"totalTrials":137,"cells":5141},"Chemotherapy",{"EARLY_PHASE1":5142,"PHASE1":5144,"PHASE2":5146,"PHASE3":5158,"PHASE4":5160,"NA":5162},{"trials":5143,"activeCount":100},[],{"trials":5145,"activeCount":100},[],{"trials":5147,"activeCount":100},[5148],{"nctId":5149,"briefTitle":5150,"status":157,"phases":5151,"primaryCompletion":5152,"completion":5153,"start":4000,"enrollment":5154,"conditions":5155,"interventions":5157},"NCT01616238","A Study for Older Adults With Acute Lymphoblastic Leukaemia",[89],"2018-12-21","2023-02-01",126,[5156],"Acute Lymphoblastic Leukaemia",[5140],{"trials":5159,"activeCount":100},[],{"trials":5161,"activeCount":100},[],{"trials":5163,"activeCount":100},[],{"intervention":5165,"totalTrials":137,"cells":5166},"CD25\u002F71 allodepleted donor T-cells",{"EARLY_PHASE1":5167,"PHASE1":5169,"PHASE2":5171,"PHASE3":5183,"PHASE4":5185,"NA":5187},{"trials":5168,"activeCount":100},[],{"trials":5170,"activeCount":100},[],{"trials":5172,"activeCount":100},[5173],{"nctId":5174,"briefTitle":5175,"status":157,"phases":5176,"primaryCompletion":5177,"completion":5177,"start":5178,"enrollment":5179,"conditions":5180,"interventions":5182},"NCT01827579","Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)",[88,89],"2020-01","2014-07",37,[5181],"Haematological Malignancies",[5165],{"trials":5184,"activeCount":100},[],{"trials":5186,"activeCount":100},[],{"trials":5188,"activeCount":100},[],{"intervention":5190,"totalTrials":137,"cells":5191},"Ambroxol",{"EARLY_PHASE1":5192,"PHASE1":5194,"PHASE2":5196,"PHASE3":5207,"PHASE4":5209,"NA":5211},{"trials":5193,"activeCount":100},[],{"trials":5195,"activeCount":100},[],{"trials":5197,"activeCount":100},[5198],{"nctId":5199,"briefTitle":5200,"status":157,"phases":5201,"primaryCompletion":5202,"completion":5203,"start":5204,"enrollment":19,"conditions":5205,"interventions":5206},"NCT02941822","Ambroxol in Disease Modification in Parkinson Disease",[89],"2018-04","2018-05","2016-12",[628],[5190],{"trials":5208,"activeCount":100},[],{"trials":5210,"activeCount":100},[],{"trials":5212,"activeCount":100},[],{"intervention":5214,"totalTrials":137,"cells":5215},"Autologous Mesenchymal Stem Cells",{"EARLY_PHASE1":5216,"PHASE1":5218,"PHASE2":5220,"PHASE3":5235,"PHASE4":5237,"NA":5239},{"trials":5217,"activeCount":100},[],{"trials":5219,"activeCount":100},[],{"trials":5221,"activeCount":100},[5222],{"nctId":5223,"briefTitle":5224,"status":1009,"phases":5225,"primaryCompletion":5226,"start":2412,"enrollment":34,"conditions":5227,"interventions":5234},"NCT02064062","Autologous Stem Cells in Achilles Tendinopathy",[89],"2018-12",[5228,5229,5230,5231,5232,5233],"Achilles Tendinitis, Right Leg","Achilles Tendinitis","Achilles Degeneration","Achilles Tendon Thickening","Tendinopathy","Achilles Tendinitis, Left Leg",[5214],{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[],{"trials":5240,"activeCount":100},[],{"intervention":5242,"totalTrials":137,"cells":5243},"Favipiravir",{"EARLY_PHASE1":5244,"PHASE1":5246,"PHASE2":5248,"PHASE3":5262,"PHASE4":5264,"NA":5266},{"trials":5245,"activeCount":100},[],{"trials":5247,"activeCount":100},[],{"trials":5249,"activeCount":100},[5250],{"nctId":5251,"briefTitle":5252,"status":157,"phases":5253,"primaryCompletion":5254,"completion":5255,"start":5256,"enrollment":5257,"conditions":5258,"interventions":5260},"NCT04499677","FLARE: Favipiravir +\u002F- Lopinavir: A RCT of Early Antivirals",[89],"2021-12-01","2022-01-17","2020-09-24",240,[5259],"COVID-19",[5242,5261],"Lopinavir\u002F Ritonavir",{"trials":5263,"activeCount":100},[],{"trials":5265,"activeCount":100},[],{"trials":5267,"activeCount":100},[],{"intervention":5261,"totalTrials":137,"cells":5269},{"EARLY_PHASE1":5270,"PHASE1":5272,"PHASE2":5274,"PHASE3":5280,"PHASE4":5282,"NA":5284},{"trials":5271,"activeCount":100},[],{"trials":5273,"activeCount":100},[],{"trials":5275,"activeCount":100},[5276],{"nctId":5251,"briefTitle":5252,"status":157,"phases":5277,"primaryCompletion":5254,"completion":5255,"start":5256,"enrollment":5257,"conditions":5278,"interventions":5279},[89],[5259],[5242,5261],{"trials":5281,"activeCount":100},[],{"trials":5283,"activeCount":100},[],{"trials":5285,"activeCount":100},[],{"intervention":346,"totalTrials":137,"cells":5287},{"EARLY_PHASE1":5288,"PHASE1":5290,"PHASE2":5292,"PHASE3":5298,"PHASE4":5300,"NA":5302},{"trials":5289,"activeCount":100},[],{"trials":5291,"activeCount":100},[],{"trials":5293,"activeCount":100},[5294],{"nctId":337,"briefTitle":338,"status":157,"phases":5295,"primaryCompletion":340,"completion":341,"start":342,"enrollment":34,"conditions":5296,"interventions":5297},[88,89],[344],[346,347,316],{"trials":5299,"activeCount":100},[],{"trials":5301,"activeCount":100},[],{"trials":5303,"activeCount":100},[],{"intervention":347,"totalTrials":137,"cells":5305},{"EARLY_PHASE1":5306,"PHASE1":5308,"PHASE2":5310,"PHASE3":5316,"PHASE4":5318,"NA":5320},{"trials":5307,"activeCount":100},[],{"trials":5309,"activeCount":100},[],{"trials":5311,"activeCount":100},[5312],{"nctId":337,"briefTitle":338,"status":157,"phases":5313,"primaryCompletion":340,"completion":341,"start":342,"enrollment":34,"conditions":5314,"interventions":5315},[88,89],[344],[346,347,316],{"trials":5317,"activeCount":100},[],{"trials":5319,"activeCount":100},[],{"trials":5321,"activeCount":100},[],{"intervention":5323,"totalTrials":137,"cells":5324},"L-serine",{"EARLY_PHASE1":5325,"PHASE1":5327,"PHASE2":5329,"PHASE3":5340,"PHASE4":5342,"NA":5344},{"trials":5326,"activeCount":100},[],{"trials":5328,"activeCount":100},[],{"trials":5330,"activeCount":100},[5331],{"nctId":5332,"briefTitle":5333,"status":1009,"phases":5334,"primaryCompletion":5335,"completion":5335,"start":5336,"enrollment":1124,"conditions":5337,"interventions":5339},"NCT06113055","Hereditary Sensory Neuropathy Serine Trial",[89],"2025-08","2023-08-21",[5338],"Hereditary Sensory Neuropathy Type I",[5323],{"trials":5341,"activeCount":100},[],{"trials":5343,"activeCount":100},[],{"trials":5345,"activeCount":100},[],{"intervention":5347,"totalTrials":137,"cells":5348},"Mycophenolate Mofetil 500mg",{"EARLY_PHASE1":5349,"PHASE1":5351,"PHASE2":5353,"PHASE3":5365,"PHASE4":5367,"NA":5369},{"trials":5350,"activeCount":100},[],{"trials":5352,"activeCount":100},[],{"trials":5354,"activeCount":100},[5355],{"nctId":5356,"briefTitle":5357,"status":1009,"phases":5358,"primaryCompletion":1135,"completion":5359,"start":5360,"enrollment":5361,"conditions":5362,"interventions":5364},"NCT04927390","Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)",[89],"2024-04-30","2021-12-08",120,[4743,5363],"Limited Cutaneous Systemic Sclerosis",[5347],{"trials":5366,"activeCount":100},[],{"trials":5368,"activeCount":100},[],{"trials":5370,"activeCount":100},[],{"intervention":5372,"totalTrials":137,"cells":5373},"Trimetazidine",{"EARLY_PHASE1":5374,"PHASE1":5376,"PHASE2":5378,"PHASE3":5389,"PHASE4":5391,"NA":5393},{"trials":5375,"activeCount":100},[],{"trials":5377,"activeCount":100},[],{"trials":5379,"activeCount":100},[5380],{"nctId":5381,"briefTitle":5382,"status":1009,"phases":5383,"primaryCompletion":5384,"completion":5384,"start":5385,"enrollment":3552,"conditions":5386,"interventions":5388},"NCT01696370","Trimetazidine Therapy in Hypertrophic Cardiomyopathy",[89],"2014-04","2012-04",[5387],"Hypertrophic Cardiomyopathy",[5372],{"trials":5390,"activeCount":100},[],{"trials":5392,"activeCount":100},[],{"trials":5394,"activeCount":100},[],{"intervention":5396,"totalTrials":137,"cells":5397},"MSCTRAIL",{"EARLY_PHASE1":5398,"PHASE1":5400,"PHASE2":5402,"PHASE3":5413,"PHASE4":5415,"NA":5417},{"trials":5399,"activeCount":100},[],{"trials":5401,"activeCount":100},[],{"trials":5403,"activeCount":100},[5404],{"nctId":5405,"briefTitle":5406,"status":1009,"phases":5407,"primaryCompletion":51,"completion":5408,"start":5409,"enrollment":1032,"conditions":5410,"interventions":5412},"NCT03298763","Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer",[88,89],"2025-09-01","2019-03-05",[5411],"Adenocarcinoma of Lung",[5396],{"trials":5414,"activeCount":100},[],{"trials":5416,"activeCount":100},[],{"trials":5418,"activeCount":100},[],{"intervention":5420,"totalTrials":137,"cells":5421},"Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1",{"EARLY_PHASE1":5422,"PHASE1":5424,"PHASE2":5426,"PHASE3":5440,"PHASE4":5442,"NA":5444},{"trials":5423,"activeCount":100},[],{"trials":5425,"activeCount":100},[],{"trials":5427,"activeCount":100},[5428],{"nctId":5429,"briefTitle":5430,"status":157,"phases":5431,"primaryCompletion":5432,"completion":5432,"start":5433,"enrollment":5434,"conditions":5435,"interventions":5437},"NCT04356833","Nebulised Rt-PA for ARDS Due to COVID-19",[89],"2021-03-18","2020-04-22",35,[5436],"COVID",[5420,5438,5439],"Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV","Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV",{"trials":5441,"activeCount":100},[],{"trials":5443,"activeCount":100},[],{"trials":5445,"activeCount":100},[],{"intervention":5438,"totalTrials":137,"cells":5447},{"EARLY_PHASE1":5448,"PHASE1":5450,"PHASE2":5452,"PHASE3":5458,"PHASE4":5460,"NA":5462},{"trials":5449,"activeCount":100},[],{"trials":5451,"activeCount":100},[],{"trials":5453,"activeCount":100},[5454],{"nctId":5429,"briefTitle":5430,"status":157,"phases":5455,"primaryCompletion":5432,"completion":5432,"start":5433,"enrollment":5434,"conditions":5456,"interventions":5457},[89],[5436],[5420,5438,5439],{"trials":5459,"activeCount":100},[],{"trials":5461,"activeCount":100},[],{"trials":5463,"activeCount":100},[],{"intervention":5439,"totalTrials":137,"cells":5465},{"EARLY_PHASE1":5466,"PHASE1":5468,"PHASE2":5470,"PHASE3":5476,"PHASE4":5478,"NA":5480},{"trials":5467,"activeCount":100},[],{"trials":5469,"activeCount":100},[],{"trials":5471,"activeCount":100},[5472],{"nctId":5429,"briefTitle":5430,"status":157,"phases":5473,"primaryCompletion":5432,"completion":5432,"start":5433,"enrollment":5434,"conditions":5474,"interventions":5475},[89],[5436],[5420,5438,5439],{"trials":5477,"activeCount":100},[],{"trials":5479,"activeCount":100},[],{"trials":5481,"activeCount":100},[],{"intervention":5483,"totalTrials":137,"cells":5484},"MPDL3280A",{"EARLY_PHASE1":5485,"PHASE1":5487,"PHASE2":5489,"PHASE3":5502,"PHASE4":5504,"NA":5506},{"trials":5486,"activeCount":100},[],{"trials":5488,"activeCount":100},[],{"trials":5490,"activeCount":100},[5491],{"nctId":5492,"briefTitle":5493,"status":157,"phases":5494,"primaryCompletion":5495,"completion":5495,"start":5496,"enrollment":1124,"conditions":5497,"interventions":5498},"NCT02314481","Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity",[89],"2025-11-30","2017-05-12",[3992],[5483,5499,5500,5501],"Vemurafenib","Alectinib","Trastuzumab emtansine",{"trials":5503,"activeCount":100},[],{"trials":5505,"activeCount":100},[],{"trials":5507,"activeCount":100},[],{"intervention":5499,"totalTrials":137,"cells":5509},{"EARLY_PHASE1":5510,"PHASE1":5512,"PHASE2":5514,"PHASE3":5520,"PHASE4":5522,"NA":5524},{"trials":5511,"activeCount":100},[],{"trials":5513,"activeCount":100},[],{"trials":5515,"activeCount":100},[5516],{"nctId":5492,"briefTitle":5493,"status":157,"phases":5517,"primaryCompletion":5495,"completion":5495,"start":5496,"enrollment":1124,"conditions":5518,"interventions":5519},[89],[3992],[5483,5499,5500,5501],{"trials":5521,"activeCount":100},[],{"trials":5523,"activeCount":100},[],{"trials":5525,"activeCount":100},[],{"intervention":5500,"totalTrials":137,"cells":5527},{"EARLY_PHASE1":5528,"PHASE1":5530,"PHASE2":5532,"PHASE3":5538,"PHASE4":5540,"NA":5542},{"trials":5529,"activeCount":100},[],{"trials":5531,"activeCount":100},[],{"trials":5533,"activeCount":100},[5534],{"nctId":5492,"briefTitle":5493,"status":157,"phases":5535,"primaryCompletion":5495,"completion":5495,"start":5496,"enrollment":1124,"conditions":5536,"interventions":5537},[89],[3992],[5483,5499,5500,5501],{"trials":5539,"activeCount":100},[],{"trials":5541,"activeCount":100},[],{"trials":5543,"activeCount":100},[],{"intervention":5501,"totalTrials":137,"cells":5545},{"EARLY_PHASE1":5546,"PHASE1":5548,"PHASE2":5550,"PHASE3":5556,"PHASE4":5558,"NA":5560},{"trials":5547,"activeCount":100},[],{"trials":5549,"activeCount":100},[],{"trials":5551,"activeCount":100},[5552],{"nctId":5492,"briefTitle":5493,"status":157,"phases":5553,"primaryCompletion":5495,"completion":5495,"start":5496,"enrollment":1124,"conditions":5554,"interventions":5555},[89],[3992],[5483,5499,5500,5501],{"trials":5557,"activeCount":100},[],{"trials":5559,"activeCount":100},[],{"trials":5561,"activeCount":100},[],{"intervention":5563,"totalTrials":137,"cells":5564},"Cannabidiol",{"EARLY_PHASE1":5565,"PHASE1":5567,"PHASE2":5569,"PHASE3":5580,"PHASE4":5582,"NA":5584},{"trials":5566,"activeCount":100},[],{"trials":5568,"activeCount":100},[],{"trials":5570,"activeCount":100},[5571],{"nctId":5572,"briefTitle":5573,"status":157,"phases":5574,"primaryCompletion":5575,"completion":5576,"start":1174,"enrollment":4124,"conditions":5577,"interventions":5579},"NCT02044809","Cannabidiol: a Novel Intervention for Cannabis Use Problems?",[89],"2017-02-09","2017-06-05",[5578],"Cannabis Use Disorder",[5563],{"trials":5581,"activeCount":100},[],{"trials":5583,"activeCount":100},[],{"trials":5585,"activeCount":100},[],{"intervention":5587,"totalTrials":137,"cells":5588},"donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta",{"EARLY_PHASE1":5589,"PHASE1":5591,"PHASE2":5593,"PHASE3":5604,"PHASE4":5606,"NA":5608},{"trials":5590,"activeCount":100},[],{"trials":5592,"activeCount":100},[],{"trials":5594,"activeCount":100},[5595],{"nctId":5596,"briefTitle":5597,"status":126,"phases":5598,"primaryCompletion":5599,"completion":5599,"start":5032,"enrollment":5600,"conditions":5601,"interventions":5602},"NCT01195480","CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)",[88,89],"2015-11",29,[2065],[5587,5603],"Irradiated donor-derived Lymphoblastoid Cell Line",{"trials":5605,"activeCount":100},[],{"trials":5607,"activeCount":100},[],{"trials":5609,"activeCount":100},[],{"intervention":5603,"totalTrials":137,"cells":5611},{"EARLY_PHASE1":5612,"PHASE1":5614,"PHASE2":5616,"PHASE3":5622,"PHASE4":5624,"NA":5626},{"trials":5613,"activeCount":100},[],{"trials":5615,"activeCount":100},[],{"trials":5617,"activeCount":100},[5618],{"nctId":5596,"briefTitle":5597,"status":126,"phases":5619,"primaryCompletion":5599,"completion":5599,"start":5032,"enrollment":5600,"conditions":5620,"interventions":5621},[88,89],[2065],[5587,5603],{"trials":5623,"activeCount":100},[],{"trials":5625,"activeCount":100},[],{"trials":5627,"activeCount":100},[],{"intervention":5629,"totalTrials":137,"cells":5630},"Rivaroxaban",{"EARLY_PHASE1":5631,"PHASE1":5633,"PHASE2":5635,"PHASE3":5651,"PHASE4":5653,"NA":5655},{"trials":5632,"activeCount":100},[],{"trials":5634,"activeCount":100},[],{"trials":5636,"activeCount":100},[5637],{"nctId":5638,"briefTitle":5639,"status":157,"phases":5640,"primaryCompletion":5641,"completion":5641,"start":5642,"enrollment":5643,"conditions":5644,"interventions":5649},"NCT03684564","RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome",[89],"2025-07-31","2021-07-09",43,[5645,5646,15,5647,5648],"Antiphospholipid Syndrome","Systemic Lupus Erythematosus","Ischemic Stroke","Brain Ischemia",[5629,5650],"Warfarin",{"trials":5652,"activeCount":100},[],{"trials":5654,"activeCount":100},[],{"trials":5656,"activeCount":100},[],{"intervention":5650,"totalTrials":137,"cells":5658},{"EARLY_PHASE1":5659,"PHASE1":5661,"PHASE2":5663,"PHASE3":5669,"PHASE4":5671,"NA":5673},{"trials":5660,"activeCount":100},[],{"trials":5662,"activeCount":100},[],{"trials":5664,"activeCount":100},[5665],{"nctId":5638,"briefTitle":5639,"status":157,"phases":5666,"primaryCompletion":5641,"completion":5641,"start":5642,"enrollment":5643,"conditions":5667,"interventions":5668},[89],[5645,5646,15,5647,5648],[5629,5650],{"trials":5670,"activeCount":100},[],{"trials":5672,"activeCount":100},[],{"trials":5674,"activeCount":100},[],{"intervention":5676,"totalTrials":137,"cells":5677},"FLT180a",{"EARLY_PHASE1":5678,"PHASE1":5680,"PHASE2":5682,"PHASE3":5693,"PHASE4":5695,"NA":5697},{"trials":5679,"activeCount":100},[],{"trials":5681,"activeCount":100},[],{"trials":5683,"activeCount":100},[5684],{"nctId":5685,"briefTitle":5686,"status":126,"phases":5687,"primaryCompletion":5688,"completion":5688,"start":5689,"enrollment":34,"conditions":5690,"interventions":5692},"NCT03369444","A Factor IX Gene Therapy Study (FIX-GT)",[88,89],"2020-10-20","2017-12-05",[5691],"Hemophilia B",[5676],{"trials":5694,"activeCount":100},[],{"trials":5696,"activeCount":100},[],{"trials":5698,"activeCount":100},[],{"intervention":5700,"totalTrials":137,"cells":5701},"tgAAG76",{"EARLY_PHASE1":5702,"PHASE1":5704,"PHASE2":5706,"PHASE3":5715,"PHASE4":5717,"NA":5719},{"trials":5703,"activeCount":100},[],{"trials":5705,"activeCount":100},[],{"trials":5707,"activeCount":100},[5708],{"nctId":5709,"briefTitle":5710,"status":157,"phases":5711,"primaryCompletion":4180,"completion":4180,"start":161,"enrollment":31,"conditions":5712,"interventions":5714},"NCT00643747","Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis",[88,89],[5713],"Retinal Degeneration",[5700],{"trials":5716,"activeCount":100},[],{"trials":5718,"activeCount":100},[],{"trials":5720,"activeCount":100},[],{"intervention":5722,"totalTrials":137,"cells":5723},"Zibotentan",{"EARLY_PHASE1":5724,"PHASE1":5726,"PHASE2":5728,"PHASE3":5741,"PHASE4":5743,"NA":5745},{"trials":5725,"activeCount":100},[],{"trials":5727,"activeCount":100},[],{"trials":5729,"activeCount":100},[5730],{"nctId":5731,"briefTitle":5732,"status":157,"phases":5733,"primaryCompletion":5734,"completion":5734,"start":5735,"enrollment":2245,"conditions":5736,"interventions":5740},"NCT02047708","Zibotentan Better Renal Scleroderma Outcome Study",[89],"2017-10","2014-10",[5737,5738,5739],"Scleroderma","Scleroderma Renal Crisis","Chronic Kidney Disease",[5722],{"trials":5742,"activeCount":100},[],{"trials":5744,"activeCount":100},[],{"trials":5746,"activeCount":100},[],{"intervention":5748,"totalTrials":137,"cells":5749},"BIBF 1120",{"EARLY_PHASE1":5750,"PHASE1":5752,"PHASE2":5754,"PHASE3":5764,"PHASE4":5766,"NA":5768},{"trials":5751,"activeCount":100},[],{"trials":5753,"activeCount":100},[],{"trials":5755,"activeCount":100},[5756],{"nctId":5757,"briefTitle":5758,"status":157,"phases":5759,"primaryCompletion":5760,"completion":5760,"start":2603,"enrollment":5761,"conditions":5762,"interventions":5763},"NCT01610869","Low Dose Cyclophosphamide +\u002F-- Nintedanib in Advanced Ovarian Cancer",[89],"2018-01-11",117,[115,117],[5748],{"trials":5765,"activeCount":100},[],{"trials":5767,"activeCount":100},[],{"trials":5769,"activeCount":100},[],{"intervention":3939,"totalTrials":137,"cells":5771},{"EARLY_PHASE1":5772,"PHASE1":5774,"PHASE2":5776,"PHASE3":5782,"PHASE4":5784,"NA":5786},{"trials":5773,"activeCount":100},[],{"trials":5775,"activeCount":100},[],{"trials":5777,"activeCount":100},[5778],{"nctId":3930,"briefTitle":3931,"status":157,"phases":5779,"primaryCompletion":3933,"completion":3933,"start":3934,"enrollment":2219,"conditions":5780,"interventions":5781},[89],[3936,3937],[3939,3940,3900,3941,3941],{"trials":5783,"activeCount":100},[],{"trials":5785,"activeCount":100},[],{"trials":5787,"activeCount":100},[],{"intervention":3941,"totalTrials":137,"cells":5789},{"EARLY_PHASE1":5790,"PHASE1":5792,"PHASE2":5794,"PHASE3":5800,"PHASE4":5802,"NA":5804},{"trials":5791,"activeCount":100},[],{"trials":5793,"activeCount":100},[],{"trials":5795,"activeCount":100},[5796],{"nctId":3930,"briefTitle":3931,"status":157,"phases":5797,"primaryCompletion":3933,"completion":3933,"start":3934,"enrollment":2219,"conditions":5798,"interventions":5799},[89],[3936,3937],[3939,3940,3900,3941,3941],{"trials":5801,"activeCount":100},[],{"trials":5803,"activeCount":100},[],{"trials":5805,"activeCount":100},[],{"intervention":5807,"totalTrials":137,"cells":5808},"Tacrolimus",{"EARLY_PHASE1":5809,"PHASE1":5811,"PHASE2":5813,"PHASE3":5825,"PHASE4":5827,"NA":5829},{"trials":5810,"activeCount":100},[],{"trials":5812,"activeCount":100},[],{"trials":5814,"activeCount":100},[5815],{"nctId":5816,"briefTitle":5817,"status":434,"phases":5818,"primaryCompletion":5819,"completion":5819,"start":5820,"enrollment":100,"conditions":5821,"interventions":5824},"NCT05073822","NOMINATE\u002F Minimisation of Immunosuppression in Kidney Transplantation",[88,89],"2027-02-20","2023-02-20",[5822,5823],"Renal Transplant Rejection","Renal Transplant Infection",[5807],{"trials":5826,"activeCount":100},[],{"trials":5828,"activeCount":100},[],{"trials":5830,"activeCount":100},[],{"intervention":5832,"totalTrials":137,"cells":5833},"Niraparib",{"EARLY_PHASE1":5834,"PHASE1":5836,"PHASE2":5846,"PHASE3":5848,"PHASE4":5850,"NA":5852},{"trials":5835,"activeCount":100},[],{"trials":5837,"activeCount":100},[5838],{"nctId":5839,"briefTitle":5840,"status":434,"phases":5841,"primaryCompletion":5842,"completion":5842,"start":5842,"enrollment":100,"conditions":5843,"interventions":5845},"NCT05666349","Reirradiation and Niraparib in Patients With Recurrent Glioblastoma",[88],"2023-10-13",[5844],"Recurrent Glioblastoma",[5832],{"trials":5847,"activeCount":100},[],{"trials":5849,"activeCount":100},[],{"trials":5851,"activeCount":100},[],{"trials":5853,"activeCount":100},[],{"intervention":5855,"totalTrials":137,"cells":5856},"CD62L- Tem",{"EARLY_PHASE1":5857,"PHASE1":5859,"PHASE2":5874,"PHASE3":5876,"PHASE4":5878,"NA":5880},{"trials":5858,"activeCount":100},[],{"trials":5860,"activeCount":100},[5861],{"nctId":5862,"briefTitle":5863,"status":1009,"phases":5864,"primaryCompletion":5865,"completion":5866,"start":341,"enrollment":22,"conditions":5867,"interventions":5873},"NCT03836690","Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation",[88],"2022-07-01","2023-04-01",[27,1191,5868,5869,5870,5871,5872],"Myeloma","Myelodysplastic Syndromes","Severe Aplastic Anemia","Primary Immune Deficiency","Graft Vs Host Disease",[5855],{"trials":5875,"activeCount":100},[],{"trials":5877,"activeCount":100},[],{"trials":5879,"activeCount":100},[],{"trials":5881,"activeCount":100},[],{"intervention":5883,"totalTrials":137,"cells":5884},"20 mg AZD7325",{"EARLY_PHASE1":5885,"PHASE1":5887,"PHASE2":5896,"PHASE3":5898,"PHASE4":5900,"NA":5902},{"trials":5886,"activeCount":100},[],{"trials":5888,"activeCount":100},[5889],{"nctId":5890,"briefTitle":5891,"status":157,"phases":5892,"primaryCompletion":5893,"completion":5893,"start":2602,"enrollment":31,"conditions":5894,"interventions":5895},"NCT02530580","Effects of GABA Modulator AZD7325 on Cutaneous Sensation",[88],"2016-07",[2174],[5883],{"trials":5897,"activeCount":100},[],{"trials":5899,"activeCount":100},[],{"trials":5901,"activeCount":100},[],{"trials":5903,"activeCount":100},[],{"intervention":5905,"totalTrials":137,"cells":5906},"CMV-TCR transduced donor-derived T cells",{"EARLY_PHASE1":5907,"PHASE1":5909,"PHASE2":5919,"PHASE3":5921,"PHASE4":5923,"NA":5925},{"trials":5908,"activeCount":100},[],{"trials":5910,"activeCount":100},[5911],{"nctId":5912,"briefTitle":5913,"status":5914,"phases":5915,"primaryCompletion":2848,"completion":2848,"start":3525,"enrollment":34,"conditions":5916,"interventions":5918},"NCT02988258","Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT","SUSPENDED",[88],[5181,5917],"CMV Infection",[5905],{"trials":5920,"activeCount":100},[],{"trials":5922,"activeCount":100},[],{"trials":5924,"activeCount":100},[],{"trials":5926,"activeCount":100},[],{"intervention":5928,"totalTrials":137,"cells":5929},"ANX776",{"EARLY_PHASE1":5930,"PHASE1":5932,"PHASE2":5943,"PHASE3":5945,"PHASE4":5947,"NA":5949},{"trials":5931,"activeCount":100},[],{"trials":5933,"activeCount":100},[5934],{"nctId":5935,"briefTitle":5936,"status":1009,"phases":5937,"primaryCompletion":5599,"completion":4061,"start":2675,"enrollment":25,"conditions":5938,"interventions":5942},"NCT02394613","A Phase I Clinical Trial of DARC",[88],[5939,5940,5941],"Glaucoma","Ocular Hypertension","Glaucoma, Suspect",[5928],{"trials":5944,"activeCount":100},[],{"trials":5946,"activeCount":100},[],{"trials":5948,"activeCount":100},[],{"trials":5950,"activeCount":100},[],{"intervention":429,"totalTrials":137,"cells":5952},{"EARLY_PHASE1":5953,"PHASE1":5955,"PHASE2":5961,"PHASE3":5963,"PHASE4":5965,"NA":5967},{"trials":5954,"activeCount":100},[],{"trials":5956,"activeCount":100},[5957],{"nctId":417,"briefTitle":418,"status":157,"phases":5958,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":5959,"interventions":5960},[88],[425,426,427],[429,430,166],{"trials":5962,"activeCount":100},[],{"trials":5964,"activeCount":100},[],{"trials":5966,"activeCount":100},[],{"trials":5968,"activeCount":100},[],{"intervention":5970,"totalTrials":137,"cells":5971},"Infusion of modified CAR19 T-cells",{"EARLY_PHASE1":5972,"PHASE1":5974,"PHASE2":5986,"PHASE3":5988,"PHASE4":5990,"NA":5992},{"trials":5973,"activeCount":100},[],{"trials":5975,"activeCount":100},[5976],{"nctId":5977,"briefTitle":5978,"status":157,"phases":5979,"primaryCompletion":5980,"completion":5981,"start":5982,"enrollment":1025,"conditions":5983,"interventions":5985},"NCT02893189","CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation",[88],"2019-12-31","2022-12-31","2017-04-27",[5984],"CD19+ Malignancies: Relapse Post-allogeneic Transplant",[5970],{"trials":5987,"activeCount":100},[],{"trials":5989,"activeCount":100},[],{"trials":5991,"activeCount":100},[],{"trials":5993,"activeCount":100},[],{"intervention":5995,"totalTrials":137,"cells":5996},"Recombinant fragment of human surfactant protein D",{"EARLY_PHASE1":5997,"PHASE1":5999,"PHASE2":6013,"PHASE3":6015,"PHASE4":6017,"NA":6019},{"trials":5998,"activeCount":100},[],{"trials":6000,"activeCount":100},[6001],{"nctId":6002,"briefTitle":6003,"status":157,"phases":6004,"primaryCompletion":6005,"completion":6006,"start":6007,"enrollment":22,"conditions":6008,"interventions":6012},"NCT05898633","Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease",[88],"2025-12-05","2025-12-31","2024-04-06",[6009,6010,6011],"Chronic Lung Disease of Prematurity","Respiratory Distress Syndrome in Premature Infant","Bronchopulmonary Dysplasia",[5995],{"trials":6014,"activeCount":100},[],{"trials":6016,"activeCount":100},[],{"trials":6018,"activeCount":100},[],{"trials":6020,"activeCount":100},[],{"intervention":6022,"totalTrials":137,"cells":6023},"2 mg AZD7325",{"EARLY_PHASE1":6024,"PHASE1":6026,"PHASE2":6035,"PHASE3":6037,"PHASE4":6039,"NA":6041},{"trials":6025,"activeCount":100},[],{"trials":6027,"activeCount":100},[6028],{"nctId":6029,"briefTitle":6030,"status":157,"phases":6031,"primaryCompletion":3998,"completion":3998,"start":474,"enrollment":31,"conditions":6032,"interventions":6033},"NCT02135198","Effects of GABA Modulator AZD7325 on Cortical Excitability",[88],[2174],[6022,6034],"10 mg AZD7325",{"trials":6036,"activeCount":100},[],{"trials":6038,"activeCount":100},[],{"trials":6040,"activeCount":100},[],{"trials":6042,"activeCount":100},[],{"intervention":6034,"totalTrials":137,"cells":6044},{"EARLY_PHASE1":6045,"PHASE1":6047,"PHASE2":6053,"PHASE3":6055,"PHASE4":6057,"NA":6059},{"trials":6046,"activeCount":100},[],{"trials":6048,"activeCount":100},[6049],{"nctId":6029,"briefTitle":6030,"status":157,"phases":6050,"primaryCompletion":3998,"completion":3998,"start":474,"enrollment":31,"conditions":6051,"interventions":6052},[88],[2174],[6022,6034],{"trials":6054,"activeCount":100},[],{"trials":6056,"activeCount":100},[],{"trials":6058,"activeCount":100},[],{"trials":6060,"activeCount":100},[],{"intervention":2668,"totalTrials":137,"cells":6062},{"EARLY_PHASE1":6063,"PHASE1":6065,"PHASE2":6071,"PHASE3":6073,"PHASE4":6075,"NA":6077},{"trials":6064,"activeCount":100},[],{"trials":6066,"activeCount":100},[6067],{"nctId":2659,"briefTitle":2660,"status":157,"phases":6068,"primaryCompletion":2662,"completion":2663,"start":2664,"enrollment":34,"conditions":6069,"interventions":6070},[88],[2666],[1102,1117,2668],{"trials":6072,"activeCount":100},[],{"trials":6074,"activeCount":100},[],{"trials":6076,"activeCount":100},[],{"trials":6078,"activeCount":100},[],{"intervention":6080,"totalTrials":137,"cells":6081},"Vandetanib",{"EARLY_PHASE1":6082,"PHASE1":6084,"PHASE2":6094,"PHASE3":6096,"PHASE4":6098,"NA":6100},{"trials":6083,"activeCount":100},[],{"trials":6085,"activeCount":100},[6086],{"nctId":6087,"briefTitle":6088,"status":434,"phases":6089,"primaryCompletion":4624,"completion":4624,"start":5735,"enrollment":100,"conditions":6090,"interventions":6093},"NCT01941849","Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma",[88],[6091,6092],"Phaeochromocytoma","Paraganglioma",[6080],{"trials":6095,"activeCount":100},[],{"trials":6097,"activeCount":100},[],{"trials":6099,"activeCount":100},[],{"trials":6101,"activeCount":100},[],{"intervention":6103,"totalTrials":137,"cells":6104},"Arm B: A combination of pentoxifylline and tocopherol acetate in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months",{"EARLY_PHASE1":6105,"PHASE1":6107,"PHASE2":6119,"PHASE3":6121,"PHASE4":6123,"NA":6125},{"trials":6106,"activeCount":100},[],{"trials":6108,"activeCount":100},[6109],{"nctId":6110,"briefTitle":6111,"status":157,"phases":6112,"primaryCompletion":6113,"completion":6114,"start":6115,"enrollment":1124,"conditions":6116,"interventions":6118},"NCT03723291","PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients",[88],"2021-12-31","2022-06-30","2019-09-01",[6117],"Head and Neck Fibrosis",[6103],{"trials":6120,"activeCount":100},[],{"trials":6122,"activeCount":100},[],{"trials":6124,"activeCount":100},[],{"trials":6126,"activeCount":100},[],{"intervention":6128,"totalTrials":137,"cells":6129},"Autologous EBV-CTL transduced with vector SFG-CNA12",{"EARLY_PHASE1":6130,"PHASE1":6144,"PHASE2":6146,"PHASE3":6148,"PHASE4":6150,"NA":6152},{"trials":6131,"activeCount":100},[6132],{"nctId":6133,"briefTitle":6134,"status":1009,"phases":6135,"primaryCompletion":6136,"completion":6137,"start":6138,"enrollment":22,"conditions":6139,"interventions":6142},"NCT03131934","Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant",[87],"2020-06-30","2025-05-15","2019-05-31",[6140,6141],"Post-transplant Lymphoproliferative Disease","Transplant-Related Hematologic Malignancy",[6128,6143],"Autologous EBV-CTL transduced with control vector SFG-CNA8",{"trials":6145,"activeCount":100},[],{"trials":6147,"activeCount":100},[],{"trials":6149,"activeCount":100},[],{"trials":6151,"activeCount":100},[],{"trials":6153,"activeCount":100},[],{"intervention":6143,"totalTrials":137,"cells":6155},{"EARLY_PHASE1":6156,"PHASE1":6162,"PHASE2":6164,"PHASE3":6166,"PHASE4":6168,"NA":6170},{"trials":6157,"activeCount":100},[6158],{"nctId":6133,"briefTitle":6134,"status":1009,"phases":6159,"primaryCompletion":6136,"completion":6137,"start":6138,"enrollment":22,"conditions":6160,"interventions":6161},[87],[6140,6141],[6128,6143],{"trials":6163,"activeCount":100},[],{"trials":6165,"activeCount":100},[],{"trials":6167,"activeCount":100},[],{"trials":6169,"activeCount":100},[],{"trials":6171,"activeCount":100},[],{"intervention":1102,"totalTrials":6173,"cells":6174},9,{"EARLY_PHASE1":6175,"PHASE1":6177,"PHASE2":6183,"PHASE3":6205,"PHASE4":6215,"NA":6217},{"trials":6176,"activeCount":100},[],{"trials":6178,"activeCount":100},[6179],{"nctId":2659,"briefTitle":2660,"status":157,"phases":6180,"primaryCompletion":2662,"completion":2663,"start":2664,"enrollment":34,"conditions":6181,"interventions":6182},[88],[2666],[1102,1117,2668],{"trials":6184,"activeCount":100},[6185,6189,6193,6197,6201],{"nctId":2672,"briefTitle":2673,"status":126,"phases":6186,"primaryCompletion":2675,"completion":2675,"start":1143,"enrollment":2676,"conditions":6187,"interventions":6188},[89],[2678,27,2679],[1102,2681,2682,1117],{"nctId":2706,"briefTitle":2707,"status":157,"phases":6190,"primaryCompletion":473,"completion":473,"start":2709,"enrollment":2710,"conditions":6191,"interventions":6192},[89],[27,2712],[596,598,599,600,601,603],{"nctId":1092,"briefTitle":1093,"status":157,"phases":6194,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":1098,"conditions":6195,"interventions":6196},[89],[1100],[1102,1103,1104,1028,1105,134],{"nctId":1107,"briefTitle":1108,"status":157,"phases":6198,"primaryCompletion":1110,"completion":1111,"start":1112,"enrollment":1044,"conditions":6199,"interventions":6200},[89],[1114],[1116,1102,1028,1117],{"nctId":1140,"briefTitle":1141,"status":157,"phases":6202,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":1145,"conditions":6203,"interventions":6204},[89],[27],[1148,596,464,600,603],{"trials":6206,"activeCount":100},[6207,6211],{"nctId":1161,"briefTitle":1162,"status":157,"phases":6208,"primaryCompletion":1164,"completion":1165,"start":1166,"enrollment":1167,"conditions":6209,"interventions":6210},[89,90],[27],[1148,1102,1117],{"nctId":584,"briefTitle":585,"status":157,"phases":6212,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":6213,"interventions":6214},[90],[27],[593,594,595,596,597,598,599,600,601,602,603],{"trials":6216,"activeCount":100},[],{"trials":6218,"activeCount":100},[6219],{"nctId":1185,"briefTitle":1186,"status":157,"phases":6220,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":6221,"interventions":6222},[],[1191,1192,1193],[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],{"intervention":599,"totalTrials":96,"cells":6224},{"EARLY_PHASE1":6225,"PHASE1":6227,"PHASE2":6229,"PHASE3":6239,"PHASE4":6245,"NA":6247},{"trials":6226,"activeCount":100},[],{"trials":6228,"activeCount":100},[],{"trials":6230,"activeCount":100},[6231,6235],{"nctId":2706,"briefTitle":2707,"status":157,"phases":6232,"primaryCompletion":473,"completion":473,"start":2709,"enrollment":2710,"conditions":6233,"interventions":6234},[89],[27,2712],[596,598,599,600,601,603],{"nctId":124,"briefTitle":125,"status":126,"phases":6236,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":6237,"interventions":6238},[89],[132],[134,95,135,136],{"trials":6240,"activeCount":100},[6241],{"nctId":584,"briefTitle":585,"status":157,"phases":6242,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":6243,"interventions":6244},[90],[27],[593,594,595,596,597,598,599,600,601,602,603],{"trials":6246,"activeCount":100},[],{"trials":6248,"activeCount":100},[6249],{"nctId":1185,"briefTitle":1186,"status":157,"phases":6250,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":6251,"interventions":6252},[],[1191,1192,1193],[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],{"intervention":603,"totalTrials":96,"cells":6254},{"EARLY_PHASE1":6255,"PHASE1":6257,"PHASE2":6259,"PHASE3":6269,"PHASE4":6275,"NA":6277},{"trials":6256,"activeCount":100},[],{"trials":6258,"activeCount":100},[],{"trials":6260,"activeCount":100},[6261,6265],{"nctId":2706,"briefTitle":2707,"status":157,"phases":6262,"primaryCompletion":473,"completion":473,"start":2709,"enrollment":2710,"conditions":6263,"interventions":6264},[89],[27,2712],[596,598,599,600,601,603],{"nctId":1140,"briefTitle":1141,"status":157,"phases":6266,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":1145,"conditions":6267,"interventions":6268},[89],[27],[1148,596,464,600,603],{"trials":6270,"activeCount":100},[6271],{"nctId":584,"briefTitle":585,"status":157,"phases":6272,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":6273,"interventions":6274},[90],[27],[593,594,595,596,597,598,599,600,601,602,603],{"trials":6276,"activeCount":100},[],{"trials":6278,"activeCount":100},[6279],{"nctId":1185,"briefTitle":1186,"status":157,"phases":6280,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":6281,"interventions":6282},[],[1191,1192,1193],[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],{"intervention":1202,"totalTrials":175,"cells":6284},{"EARLY_PHASE1":6285,"PHASE1":6287,"PHASE2":6289,"PHASE3":6299,"PHASE4":6301,"NA":6303},{"trials":6286,"activeCount":100},[],{"trials":6288,"activeCount":100},[],{"trials":6290,"activeCount":100},[6291,6295],{"nctId":3890,"briefTitle":3891,"status":126,"phases":6292,"primaryCompletion":3893,"completion":3893,"start":3175,"enrollment":3894,"conditions":6293,"interventions":6294},[89],[3896,3897],[3881,3899,3900],{"nctId":3902,"briefTitle":3903,"status":157,"phases":6296,"primaryCompletion":1143,"completion":1143,"start":3905,"enrollment":96,"conditions":6297,"interventions":6298},[88,89],[3907,27,1192,2712],[3909,3910,1202],{"trials":6300,"activeCount":100},[],{"trials":6302,"activeCount":100},[],{"trials":6304,"activeCount":100},[6305],{"nctId":1185,"briefTitle":1186,"status":157,"phases":6306,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":6307,"interventions":6308},[],[1191,1192,1193],[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],{"intervention":2682,"totalTrials":366,"cells":6310},{"EARLY_PHASE1":6311,"PHASE1":6313,"PHASE2":6315,"PHASE3":6321,"PHASE4":6323,"NA":6325},{"trials":6312,"activeCount":100},[],{"trials":6314,"activeCount":100},[],{"trials":6316,"activeCount":100},[6317],{"nctId":2672,"briefTitle":2673,"status":126,"phases":6318,"primaryCompletion":2675,"completion":2675,"start":1143,"enrollment":2676,"conditions":6319,"interventions":6320},[89],[2678,27,2679],[1102,2681,2682,1117],{"trials":6322,"activeCount":100},[],{"trials":6324,"activeCount":100},[],{"trials":6326,"activeCount":100},[6327],{"nctId":1185,"briefTitle":1186,"status":157,"phases":6328,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":6329,"interventions":6330},[],[1191,1192,1193],[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],{"intervention":6332,"totalTrials":137,"cells":6333},"Dabigatran",{"EARLY_PHASE1":6334,"PHASE1":6336,"PHASE2":6338,"PHASE3":6340,"PHASE4":6342,"NA":6344},{"trials":6335,"activeCount":100},[],{"trials":6337,"activeCount":100},[],{"trials":6339,"activeCount":100},[],{"trials":6341,"activeCount":100},[],{"trials":6343,"activeCount":100},[],{"trials":6345,"activeCount":100},[6346],{"nctId":6347,"briefTitle":6348,"status":1009,"phases":6349,"primaryCompletion":6350,"start":4061,"enrollment":31,"conditions":6351,"interventions":6355},"NCT02885961","The Coagulation Cascade in Idiopathic Pulmonary Fibrosis",[92],"2017-08",[6352,6353,6354],"Idiopathic Pulmonary Fibrosis","IPF","Interstitial Lung Disease",[6332],{"intervention":6357,"totalTrials":137,"cells":6358},"Next generation sequencing",{"EARLY_PHASE1":6359,"PHASE1":6361,"PHASE2":6363,"PHASE3":6365,"PHASE4":6367,"NA":6369},{"trials":6360,"activeCount":100},[],{"trials":6362,"activeCount":100},[],{"trials":6364,"activeCount":100},[],{"trials":6366,"activeCount":100},[],{"trials":6368,"activeCount":100},[],{"trials":6370,"activeCount":100},[6371],{"nctId":6372,"briefTitle":6373,"status":1009,"phases":6374,"primaryCompletion":6375,"completion":6375,"start":6376,"enrollment":148,"conditions":6377,"interventions":6379},"NCT04212195","Cohort Research on Wilson's Disease",[],"2021-12-06","2018-12-06",[6378],"Wilson's Disease",[6357],{"intervention":6381,"totalTrials":137,"cells":6382},"Cannabis with delta-9-tetrahydrocannabinol",{"EARLY_PHASE1":6383,"PHASE1":6385,"PHASE2":6387,"PHASE3":6389,"PHASE4":6391,"NA":6393},{"trials":6384,"activeCount":100},[],{"trials":6386,"activeCount":100},[],{"trials":6388,"activeCount":100},[],{"trials":6390,"activeCount":100},[],{"trials":6392,"activeCount":100},[],{"trials":6394,"activeCount":100},[6395],{"nctId":6396,"briefTitle":6397,"status":157,"phases":6398,"primaryCompletion":6399,"completion":6399,"start":6400,"enrollment":1056,"conditions":6401,"interventions":6410},"NCT04851392","Do Adolescents and Adults Differ in Their Acute Response to Cannabis?",[92],"2021-06-16","2019-03-11",[6402,6403,6404,6405,6406,6407,6408,6409],"Cannabis","Cannabis Intoxication","Cannabis Use","Cannabis Dependence","Marijuana","THC","CBD","Adolescent Development",[6381,6411],"Cannabis with THC without CBD",{"intervention":6411,"totalTrials":137,"cells":6413},{"EARLY_PHASE1":6414,"PHASE1":6416,"PHASE2":6418,"PHASE3":6420,"PHASE4":6422,"NA":6424},{"trials":6415,"activeCount":100},[],{"trials":6417,"activeCount":100},[],{"trials":6419,"activeCount":100},[],{"trials":6421,"activeCount":100},[],{"trials":6423,"activeCount":100},[],{"trials":6425,"activeCount":100},[6426],{"nctId":6396,"briefTitle":6397,"status":157,"phases":6427,"primaryCompletion":6399,"completion":6399,"start":6400,"enrollment":1056,"conditions":6428,"interventions":6429},[92],[6402,6403,6404,6405,6406,6407,6408,6409],[6381,6411],{"intervention":6431,"totalTrials":137,"cells":6432},"Verteporfin",{"EARLY_PHASE1":6433,"PHASE1":6435,"PHASE2":6437,"PHASE3":6439,"PHASE4":6441,"NA":6443},{"trials":6434,"activeCount":100},[],{"trials":6436,"activeCount":100},[],{"trials":6438,"activeCount":100},[],{"trials":6440,"activeCount":100},[],{"trials":6442,"activeCount":100},[],{"trials":6444,"activeCount":100},[6445],{"nctId":6446,"briefTitle":6447,"status":157,"phases":6448,"primaryCompletion":4149,"completion":6449,"start":1112,"enrollment":31,"conditions":6450,"interventions":6452},"NCT02872064","Treatment of Primary Breast Cancer Using PDT",[92],"2017-12",[6451],"Breast Neoplasms",[6431],{"intervention":6454,"totalTrials":137,"cells":6455},"Prostaglandin analogue",{"EARLY_PHASE1":6456,"PHASE1":6458,"PHASE2":6460,"PHASE3":6462,"PHASE4":6464,"NA":6466},{"trials":6457,"activeCount":100},[],{"trials":6459,"activeCount":100},[],{"trials":6461,"activeCount":100},[],{"trials":6463,"activeCount":100},[],{"trials":6465,"activeCount":100},[],{"trials":6467,"activeCount":100},[6468],{"nctId":6469,"briefTitle":6470,"status":126,"phases":6471,"primaryCompletion":6472,"completion":6472,"start":6473,"enrollment":6474,"conditions":6475,"interventions":6476},"NCT02774811","Primary Glaucoma Treatment Trial in Kenya and South Africa - SLT vs. Medication",[92],"2019-01","2014-02",15,[5939],[6454],{"intervention":6478,"totalTrials":137,"cells":6479},"Viraferon-peg and Rebetol",{"EARLY_PHASE1":6480,"PHASE1":6482,"PHASE2":6484,"PHASE3":6486,"PHASE4":6488,"NA":6490},{"trials":6481,"activeCount":100},[],{"trials":6483,"activeCount":100},[],{"trials":6485,"activeCount":100},[],{"trials":6487,"activeCount":100},[],{"trials":6489,"activeCount":100},[],{"trials":6491,"activeCount":100},[6492],{"nctId":6493,"briefTitle":6494,"status":157,"phases":6495,"primaryCompletion":6496,"completion":6496,"start":6497,"conditions":6498,"interventions":6500},"NCT00723242","The Role of Dendritic Cells in Hepatitis C Infection",[92],"2004-12","2002-04",[6499],"Chronic Hepatitis C Infection",[6478],{"intervention":6502,"totalTrials":137,"cells":6503},"Any treatment regimen",{"EARLY_PHASE1":6504,"PHASE1":6506,"PHASE2":6508,"PHASE3":6510,"PHASE4":6512,"NA":6514},{"trials":6505,"activeCount":100},[],{"trials":6507,"activeCount":100},[],{"trials":6509,"activeCount":100},[],{"trials":6511,"activeCount":100},[],{"trials":6513,"activeCount":100},[],{"trials":6515,"activeCount":100},[6516],{"nctId":6517,"briefTitle":6518,"status":157,"phases":6519,"primaryCompletion":6449,"completion":6449,"start":6520,"enrollment":6521,"conditions":6522,"interventions":6524},"NCT02875574","Improving the Management of Drug Resistant Tuberculosis in the UK",[],"2016-11",630,[6523],"Tuberculosis",[6502],{"intervention":6526,"totalTrials":137,"cells":6527},"ACE inhibitor",{"EARLY_PHASE1":6528,"PHASE1":6530,"PHASE2":6532,"PHASE3":6534,"PHASE4":6536,"NA":6538},{"trials":6529,"activeCount":100},[],{"trials":6531,"activeCount":100},[],{"trials":6533,"activeCount":100},[],{"trials":6535,"activeCount":100},[],{"trials":6537,"activeCount":100},[],{"trials":6539,"activeCount":100},[6540],{"nctId":6541,"briefTitle":6542,"status":1009,"phases":6543,"primaryCompletion":6544,"completion":6545,"start":6546,"enrollment":6547,"conditions":6548,"interventions":6550},"NCT04322786","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?",[],"2016-05-31","2021-03-31","1998-01-01",1302508,[6549],"Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom",[6526],{"intervention":6552,"totalTrials":137,"cells":6553},"five relaxation treatments and one control",{"EARLY_PHASE1":6554,"PHASE1":6556,"PHASE2":6558,"PHASE3":6560,"PHASE4":6562,"NA":6564},{"trials":6555,"activeCount":100},[],{"trials":6557,"activeCount":100},[],{"trials":6559,"activeCount":100},[],{"trials":6561,"activeCount":100},[],{"trials":6563,"activeCount":100},[],{"trials":6565,"activeCount":100},[6566],{"nctId":6567,"briefTitle":6568,"status":157,"phases":6569,"primaryCompletion":6570,"completion":6570,"start":6571,"enrollment":995,"conditions":6572,"interventions":6577},"NCT03593551","Effects of Different Relaxation Interventions on Reducing Stress in Chinese Breastfeeding Mothers",[92],"2018-06-28","2018-06-03",[6573,6574,6575,6576],"Stress-related Problem","Breastfeeding","Relaxation Therapy","Psychological Stress",[6552],{"intervention":6579,"totalTrials":137,"cells":6580},"Mantoux test",{"EARLY_PHASE1":6581,"PHASE1":6583,"PHASE2":6585,"PHASE3":6587,"PHASE4":6589,"NA":6591},{"trials":6582,"activeCount":100},[],{"trials":6584,"activeCount":100},[],{"trials":6586,"activeCount":100},[],{"trials":6588,"activeCount":100},[],{"trials":6590,"activeCount":100},[],{"trials":6592,"activeCount":100},[6593],{"nctId":6594,"briefTitle":6595,"status":434,"phases":6596,"primaryCompletion":6597,"completion":6597,"start":3934,"enrollment":100,"conditions":6598,"interventions":6600},"NCT02102841","Investigating Immune Mechanisms in Atopic Eczema",[92],"2017-05",[6599],"Atopic Dermatitis",[6579],{"intervention":6602,"totalTrials":137,"cells":6603},"GLWL-01",{"EARLY_PHASE1":6604,"PHASE1":6606,"PHASE2":6608,"PHASE3":6610,"PHASE4":6612,"NA":6614},{"trials":6605,"activeCount":100},[],{"trials":6607,"activeCount":100},[],{"trials":6609,"activeCount":100},[],{"trials":6611,"activeCount":100},[],{"trials":6613,"activeCount":100},[],{"trials":6615,"activeCount":100},[6616],{"nctId":6617,"briefTitle":6618,"status":157,"phases":6619,"primaryCompletion":6620,"completion":6621,"start":6622,"enrollment":5434,"conditions":6623,"interventions":6626},"NCT03641417","Investigating the Role of Ghrelin in Regulating Appetite and Energy Intake in Patients Following Bariatric Surgery (BARI-INSIGHT)",[92],"2020-03-06","2020-03-13","2019-02-15",[33,6624,6625],"Bariatric Surgery Candidate","Appetitive Behavior",[6602],{"intervention":1195,"totalTrials":137,"cells":6628},{"EARLY_PHASE1":6629,"PHASE1":6631,"PHASE2":6633,"PHASE3":6635,"PHASE4":6637,"NA":6639},{"trials":6630,"activeCount":100},[],{"trials":6632,"activeCount":100},[],{"trials":6634,"activeCount":100},[],{"trials":6636,"activeCount":100},[],{"trials":6638,"activeCount":100},[],{"trials":6640,"activeCount":100},[6641],{"nctId":1185,"briefTitle":1186,"status":157,"phases":6642,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":6643,"interventions":6644},[],[1191,1192,1193],[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],{"intervention":1196,"totalTrials":137,"cells":6646},{"EARLY_PHASE1":6647,"PHASE1":6649,"PHASE2":6651,"PHASE3":6653,"PHASE4":6655,"NA":6657},{"trials":6648,"activeCount":100},[],{"trials":6650,"activeCount":100},[],{"trials":6652,"activeCount":100},[],{"trials":6654,"activeCount":100},[],{"trials":6656,"activeCount":100},[],{"trials":6658,"activeCount":100},[6659],{"nctId":1185,"briefTitle":1186,"status":157,"phases":6660,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":6661,"interventions":6662},[],[1191,1192,1193],[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],{"intervention":1197,"totalTrials":137,"cells":6664},{"EARLY_PHASE1":6665,"PHASE1":6667,"PHASE2":6669,"PHASE3":6671,"PHASE4":6673,"NA":6675},{"trials":6666,"activeCount":100},[],{"trials":6668,"activeCount":100},[],{"trials":6670,"activeCount":100},[],{"trials":6672,"activeCount":100},[],{"trials":6674,"activeCount":100},[],{"trials":6676,"activeCount":100},[6677],{"nctId":1185,"briefTitle":1186,"status":157,"phases":6678,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":6679,"interventions":6680},[],[1191,1192,1193],[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],{"intervention":1198,"totalTrials":137,"cells":6682},{"EARLY_PHASE1":6683,"PHASE1":6685,"PHASE2":6687,"PHASE3":6689,"PHASE4":6691,"NA":6693},{"trials":6684,"activeCount":100},[],{"trials":6686,"activeCount":100},[],{"trials":6688,"activeCount":100},[],{"trials":6690,"activeCount":100},[],{"trials":6692,"activeCount":100},[],{"trials":6694,"activeCount":100},[6695],{"nctId":1185,"briefTitle":1186,"status":157,"phases":6696,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":6697,"interventions":6698},[],[1191,1192,1193],[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],{"intervention":1199,"totalTrials":137,"cells":6700},{"EARLY_PHASE1":6701,"PHASE1":6703,"PHASE2":6705,"PHASE3":6707,"PHASE4":6709,"NA":6711},{"trials":6702,"activeCount":100},[],{"trials":6704,"activeCount":100},[],{"trials":6706,"activeCount":100},[],{"trials":6708,"activeCount":100},[],{"trials":6710,"activeCount":100},[],{"trials":6712,"activeCount":100},[6713],{"nctId":1185,"briefTitle":1186,"status":157,"phases":6714,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":6715,"interventions":6716},[],[1191,1192,1193],[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],{"intervention":1201,"totalTrials":137,"cells":6718},{"EARLY_PHASE1":6719,"PHASE1":6721,"PHASE2":6723,"PHASE3":6725,"PHASE4":6727,"NA":6729},{"trials":6720,"activeCount":100},[],{"trials":6722,"activeCount":100},[],{"trials":6724,"activeCount":100},[],{"trials":6726,"activeCount":100},[],{"trials":6728,"activeCount":100},[],{"trials":6730,"activeCount":100},[6731],{"nctId":1185,"briefTitle":1186,"status":157,"phases":6732,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":6733,"interventions":6734},[],[1191,1192,1193],[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],{"intervention":1203,"totalTrials":137,"cells":6736},{"EARLY_PHASE1":6737,"PHASE1":6739,"PHASE2":6741,"PHASE3":6743,"PHASE4":6745,"NA":6747},{"trials":6738,"activeCount":100},[],{"trials":6740,"activeCount":100},[],{"trials":6742,"activeCount":100},[],{"trials":6744,"activeCount":100},[],{"trials":6746,"activeCount":100},[],{"trials":6748,"activeCount":100},[6749],{"nctId":1185,"briefTitle":1186,"status":157,"phases":6750,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":6751,"interventions":6752},[],[1191,1192,1193],[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],{"intervention":1204,"totalTrials":137,"cells":6754},{"EARLY_PHASE1":6755,"PHASE1":6757,"PHASE2":6759,"PHASE3":6761,"PHASE4":6763,"NA":6765},{"trials":6756,"activeCount":100},[],{"trials":6758,"activeCount":100},[],{"trials":6760,"activeCount":100},[],{"trials":6762,"activeCount":100},[],{"trials":6764,"activeCount":100},[],{"trials":6766,"activeCount":100},[6767],{"nctId":1185,"briefTitle":1186,"status":157,"phases":6768,"primaryCompletion":1188,"completion":1188,"start":1189,"conditions":6769,"interventions":6770},[],[1191,1192,1193],[1195,1148,596,1196,1197,599,1198,1199,1200,1201,1202,1203,1204,603],{"intervention":6772,"totalTrials":137,"cells":6773},"Direct oral anticoagulant",{"EARLY_PHASE1":6774,"PHASE1":6776,"PHASE2":6778,"PHASE3":6780,"PHASE4":6782,"NA":6784},{"trials":6775,"activeCount":100},[],{"trials":6777,"activeCount":100},[],{"trials":6779,"activeCount":100},[],{"trials":6781,"activeCount":100},[],{"trials":6783,"activeCount":100},[],{"trials":6785,"activeCount":100},[6786],{"nctId":6787,"briefTitle":6788,"status":1009,"phases":6789,"primaryCompletion":6790,"completion":6791,"start":6792,"enrollment":6793,"conditions":6794,"interventions":6797},"NCT03759938","OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial",[92],"2024-05-30","2024-10-31","2019-06-18",3648,[6795,6796],"Stroke, Acute","Atrial Fibrillation",[6772],{"intervention":6799,"totalTrials":137,"cells":6800},"Oxygen",{"EARLY_PHASE1":6801,"PHASE1":6803,"PHASE2":6805,"PHASE3":6807,"PHASE4":6809,"NA":6811},{"trials":6802,"activeCount":100},[],{"trials":6804,"activeCount":100},[],{"trials":6806,"activeCount":100},[],{"trials":6808,"activeCount":100},[],{"trials":6810,"activeCount":100},[],{"trials":6812,"activeCount":100},[6813],{"nctId":6814,"briefTitle":6815,"status":157,"phases":6816,"primaryCompletion":6817,"completion":6818,"start":6819,"enrollment":3894,"conditions":6820,"interventions":6823},"NCT03287466","Targeted OXYgen Therapy in Critical Illness",[92],"2019-11-30","2020-02-15","2018-01-15",[6821,6822],"Critical Illness","Respiratory Failure",[6799],{"intervention":6825,"totalTrials":137,"cells":6826},"DNA bio-banking",{"EARLY_PHASE1":6827,"PHASE1":6829,"PHASE2":6831,"PHASE3":6833,"PHASE4":6835,"NA":6837},{"trials":6828,"activeCount":100},[],{"trials":6830,"activeCount":100},[],{"trials":6832,"activeCount":100},[],{"trials":6834,"activeCount":100},[],{"trials":6836,"activeCount":100},[],{"trials":6838,"activeCount":100},[6839],{"nctId":6840,"briefTitle":6841,"status":157,"phases":6842,"primaryCompletion":6843,"completion":6843,"start":6844,"enrollment":2676,"conditions":6845,"interventions":6851},"NCT04200664","Audiovestibular Function in Infratentorial Superficial Siderosis",[],"2021-10-19","2020-02-07",[6846,6847,6848,6849,6850],"Siderosis","Neurological Disorder","Rare Diseases","Age Related Hearing Loss","Presbycusis",[6825],{"intervention":6853,"totalTrials":137,"cells":6854},"Routine transdermal oestrogen patch",{"EARLY_PHASE1":6855,"PHASE1":6857,"PHASE2":6859,"PHASE3":6861,"PHASE4":6863,"NA":6865},{"trials":6856,"activeCount":100},[],{"trials":6858,"activeCount":100},[],{"trials":6860,"activeCount":100},[],{"trials":6862,"activeCount":100},[],{"trials":6864,"activeCount":100},[],{"trials":6866,"activeCount":100},[6867],{"nctId":6868,"briefTitle":6869,"status":1009,"phases":6870,"primaryCompletion":6871,"completion":6872,"start":4405,"enrollment":2219,"conditions":6873,"interventions":6880},"NCT02871986","Pubertal Induction in Individuals With Hypogonadism",[],"2018-03","2020-03",[6874,6875,6876,6877,6878,6879],"Primary Amenorrhoea","Hypothalamic Amenorrhoea","Hypogonadotrophic Hypogonadism","Hypopituitarism","Turner's Syndrome","Primary Ovarian Insufficiency",[6853],{"intervention":6882,"totalTrials":137,"cells":6883},"PYY (3-36) Peptide",{"EARLY_PHASE1":6884,"PHASE1":6886,"PHASE2":6888,"PHASE3":6890,"PHASE4":6892,"NA":6894},{"trials":6885,"activeCount":100},[],{"trials":6887,"activeCount":100},[],{"trials":6889,"activeCount":100},[],{"trials":6891,"activeCount":100},[],{"trials":6893,"activeCount":100},[],{"trials":6895,"activeCount":100},[6896],{"nctId":6897,"briefTitle":6898,"status":1009,"phases":6899,"primaryCompletion":6900,"completion":2122,"start":6901,"enrollment":1154,"conditions":6902,"interventions":6903},"NCT05110664","APPETITE: linguAl PYY3-36 on aPpEtite and acuTe Energy InTakE",[],"2022-08","2022-02",[33],[6882,6904],"Placibo",{"intervention":6904,"totalTrials":137,"cells":6906},{"EARLY_PHASE1":6907,"PHASE1":6909,"PHASE2":6911,"PHASE3":6913,"PHASE4":6915,"NA":6917},{"trials":6908,"activeCount":100},[],{"trials":6910,"activeCount":100},[],{"trials":6912,"activeCount":100},[],{"trials":6914,"activeCount":100},[],{"trials":6916,"activeCount":100},[],{"trials":6918,"activeCount":100},[6919],{"nctId":6897,"briefTitle":6898,"status":1009,"phases":6920,"primaryCompletion":6900,"completion":2122,"start":6901,"enrollment":1154,"conditions":6921,"interventions":6922},[],[33],[6882,6904]]